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SUMMARY 
Breast cancer very commonly metastasizes to bone, often with devastating consequences, 
including pain, pathological fractures, hypercalcaemia and nerve compression syndromes. 
Bisphosphonates are very effective in the management of bone secondaries from breast 
cancer. Recent clinical studies have also suggested that adjuvant oral clodronate in 
patients with primary breast cancer may confer a survival benefit thereby raising the 
possibility that bisphosphonates have an anti-tumour effect. The aim of this PhD was to 
determine whether bisphosphonates have an anti-tumour effect on human breast cancer 
cells. 
The potent third generation bisphosphonate, zoledronic acid, was found to reduce cell 
number and increase apoptosis, mediated by inhibition of the mevalonate pathway, in 
human breast cancer cells in vitro. The effects on cell apoptosis were shown to be 
synergistic when zoledronic acid was combined with a chemotherapeutic agent, 
paclitaxel. To extend the investigation to the in vivo setting, we developed a dual 
fluorescence labelling technique to isolate apoptotic breast cancer cells from the bone 
marrow of patients with breast cancer undergoing treatment with intravenous 
pamidronate or zoledronic acid. The technique was effective at detecting breast cancer 
cells but studies were inconclusive in determining the effect of intravenous 
bisphosphonate treatment on breast cancer cell apoptosis in vivo. These studies are 
ongoing. Bisphosphonates may also alter the bone microenvironment by inhibiting 
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osteoclast-mediated bone resorption and interfering with the release of cytokines and 
growth factors. To complete these studies, we measured the levels of a panel of cytokines 
and growth factors in patient serum and bone marrow before and three days after 
intravenous bisphosphonate treatment and also compared pretreatment levels with those 
in a baseline group with primary breast cancer. TGFj3-1 was significantly elevated in 
bone marrow plasma from patients with advanced breast cancer than in patients with 
primary breast cancer, along with serum IL-6 and sIL-6R. In the advanced breast cancer 
group, bisphosphonate treatment resulted in significantly lowered levels of serum FGF-2 
and bone marrow VEGF. 
The work presented in this thesis demonstrates that the bisphosphonate zoledronic acid 
does have anti-tumour effects on breast cancer cells in vitro, both alone and in synergy 
with paclitaxel, to induce apoptosis. This raises the possibility of in vivo anti-tumour 
effects in breast cancer. The dual fluorescence labelling technique made it possible to 
detect breast cancer cells in human bone marrow but the studies regarding the in vivo 
induction of apoptosis in breast cancer cells following intravenous bisphosphonate 
treatment were inconclusive. There were significant differences in bone-derived growth 
factors between patients with primary breast cancer and secondary bone metastases. 
There was also a significant reduction in certain cytokines and growth factors in the bone 
marrow and serum after intravenous bisphosphonate treatment, suggesting that 
bisphosphonates may also exert an indirect effect on the bone marrow microenvironment. 
Further in vivo studies in patients with breast cancer are required to confirm both the 
direct anti-tumour effects and indirect effects. 
2 
ABBREVIATIONS 
APD 
ATP 
b-FGF 
BSA 
BSP 
CL2MBP 
cm 
DMSO 
DAPI 
dATP 
dCTP 
dGTP 
dl 
DNA 
dUTP 
DCIS 
EDTA 
ELl SA 
ER 
FCS 
FGF 
FITC 
FOH 
FPP 
FTase 
G-CSF 
GGOH 
GGtase 
GM-CFU 
GTP 
H+ 
IC 
ICAM 
Ig 
IGF 
IFNy 
IL 
IPP 
kg 
I 
LCIS 
Ilg 
III 
Pamidronate, 3-amino-l-hydroxy-propylidene-l, I-bisphosphonate 
Adenosine triphosphate 
Basic Fibroblast Growth Factor (or FGF-2) 
Bovine serum albumin 
Bone Sialoprotein 
Clodronate, dichloromethylene-l, I-bisphosphonate 
Centimetre 
Dimethyl sulphoxide 
4' -6-diamidino-2-phenylindole 
Deoxyadenosine triphosphate 
Deoxycytosine triphosphate 
Deoxyguanosine triphosphate 
Decilitre 
Deoxyribonucleic acid 
Deoxyuridine triphosphate 
Ductal carcinoma in situ 
Ethylenediamine tetraacetic acid 
Enzyme-linked immunosorbant assay 
Oestrogen receptor 
Foetal calf serum 
Fibroblast growth factor 
Flouroscein isothiocyanate 
Famesol 
Famesyl pyrophosphate 
Famesyl transferase 
Granulocyte-colony stimulating factor 
Geranylgerani01 
Geranylgeranyl transferase 
Granulocyte-macrophage colony forming unit 
Guanosine triphosphate 
Hydrogen ions 
Inhibitory concentration 
Intracellular adhesion molecule 
Immunoglobulin 
Insulin-like growth factor 
Interferon gamma 
Interleukin 
Isopentenyl pyrophosphate 
Kilogram 
Litre 
Lobular carcinoma in situ 
Microgram 
Microlitre 
3 
J!m 
J!M 
M 
M-CSF 
Mev 
mg 
min 
ml 
mM 
MMP 
mRNA 
MVA 
NF-KB 
OCIF 
ON 
OPG 
OPN 
PAl 
PBS 
PCR 
PDGF 
PTH 
PTHrP 
RANK 
RANKL 
sIL-6R 
sgp-130 
SRE 
TIMPs 
TNFa. 
uPA 
uPAR 
V-CAM 
VEGF 
Micrometre 
Micromolar 
Molar 
Macrophage-colony stimulating factor 
Mevastatin 
Milligram 
Minute 
Millilitre 
Millimolar 
Matrix Metalloproteinase 
Messenger RNA 
Mevalonate 
Nuclear factor-kappa-beta 
Osteoclastogenesis inhibitory factor 
Osteonectin 
Osteoprotegerin 
Osteopontin 
Plasminogen activator inhibitor 
Phosphate buffered saline 
Polymerase Chain Reaction 
Platelet-derived Growth Factor 
Parathyroid Hormone 
Parathyroid Hormone related Peptide 
Receptor Activator for NFKb 
Receptor Activator for NFKb ligand 
Soluble IL-6 receptor 
Soluble gp-130 
Skeletal related event 
Tissue Inhibitors of Matrix Metalloproteinases 
Tumour Necrosis Factor alpha 
Urokinase-type Plasminogen Activator 
Urokinase plasminogen activator receptor 
Vascular Cell adhesion Molecule 
Vascular Endothelial Growth Factor 
4 
CHAPTERl 
INTRODUCTION 
5 
Chapter 1 Introduction 
1.1 BREAST CANCER 
1.1.1 Introduction 
Breast cancer is considered to be one of the "major killers" together with cancers of the 
intestine, lung and prostate in the industrialised world. Biologically it is a heterogeneous 
entity and much attention has been focus sed by medical researchers on all aspects of the 
disease, including the aetiology and epidemiology, the development of treatment 
modalities and the psychosocial impact on patients and carers. Modem diagnostic 
techniques, greater awareness amongst women and the widespread development of 
screening programmes have made the diagnosis of early stage breast cancer easier. 
It is estimated that during the first decade ofthe new millennium almost 1 million women 
will develop breast cancer worldwide. It is the commonest cancer of women in Europe 
and accounts for 20% of all malignancies. In the UK, it makes up around 15% of new 
cases per year (Cancer Research UK statistics, 1997). It occurs rarely before the age of20 
years. Up to 50 years of age there is a steady increase in the incidence of breast cancer 
although the rate of increase slows down in postmenopausal women. Mortality rates from 
breast cancer in Western Europe and North America are around 15-251100,000 women, 
whilst the incidence is 50-60/100, 000 women. 
1.1.2 Risk Factors for the Development of Breast Cancer 
Several risk factors have been identified as being associated with an increased risk of 
breast cancer. These include genetic and familial factors, hormonal, dietary and 
environmental factors as well as benign breast disease. However, 50% of women who 
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develop breast cancer have no identifiable risk factors other than being female and their 
age (Madigan M, 1995). 
1.1.3 Pathology 
• Non-invasive breast cancer 
Two patterns of non-invasive breast cancer are well recognised. Lobular carcinoma in 
situ (LCIS) is a proliferative lesion limited to one or more mammary lobules and is 
composed of cells which morphologically have malignant characteristics but do not 
breach the basement membrane. Many cases (50-70%) are multicentric and occur mainly 
in premenopausal women. Lobular carcinoma in situ carries with it a risk of 10-15% of 
developing invasive cancer in the same breast at 10 years if not treated with mastectomy. 
Ductal carcinoma in situ (DCIS) is characterised by the proliferation of malignant cells 
within the ducts but without invading the surrounding stroma. It is multifocal in around 
30% of cases. These lesions are divided into comedo and non-comedo types. Comedo 
DCIS is characterised by the presence of necrosis at the centre of the ducts and has a 
higher risk of recurrence, especially after breast conserving management. 
• Invasive breast cancer 
The most common type of breast cancer is invasive ductal carcmoma, comprIsmg 
approximately 70% of all cases. Invasive lobular carcinoma represents 10-20% of all 
breast cancers. The remaining 10% of cases are accounted for by several other types of 
invasive cancers, including medullary carcinoma, mucoid carcinoma, papillary carcinoma 
and inflammatory carcinoma. 
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1.1.4 Prognostic factors 
Certain histopathological and biological features of breast tumours can give some 
indication of prognosis and may predict response to anti-neoplastic therapy. Prognostic 
factors, related to the patient and disease at presentation, may also be important in 
defining the best therapy available and may aid the estimation of the costs and benefits of 
a particular treatment programme. These are outlined in Table 1 below. 
Patient and Clinical Features 
Age 
Menopausal status 
Estimated duration of tumour growth 
Clinical presentation 
Imaging presentation (multicentricity) 
Liver, renal and bone marrow function 
Baseline marker 
Tumour Related Features 
Nodal status 
Pathological tumour size 
Multicentricity 
Involvement of resection margins 
Histopathogical features (histological type, 
grade, vascular invasion, intraductal 
component) 
Oestrogen (and progesterone receptor) 
status 
Marker of proliferation (thymidine 
incorporation, Ki-67, flow cytometry) 
Growth factor receptors (epidermal growth 
factor receptor, HER2lneu, Insulin-like 
growth factor receptor) 
Table 1 Important features with prognostic relevance which influence treatment choice. 
Adapted from Goldhirsch, 1997 (Goldhirsch, 1997). 
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1.1.5 Treatment of primary breast cancer. 
There have been many changes in the management of invasive carcinoma of the breast 
confined to the mammary gland and ipsilateral axillary lymph nodes. The major 
treatment modalities and their indications are discussed briefly below. 
• Surgery 
Breast surgery is primarily indicated for tumours presenting as T -stage <4 (Le. no 
involvement of the skin or chest wall) and nodal N-stage <2 (mobile ipsilateral axillary 
nodes). In T3 tumours, i.e. that are larger than 5cm, primary systemic cytotoxic therapy 
should be considered. Multicentre randomised clinical trials have demonstrated that 
breast conservation and total mastectomy with axillary clearance produce equivalent 
survivals (Harris JR, 1992). Good surgical technique significantly influences the ultimate 
cosmetic outcome. 
• Radiotherapy 
Radiotherapy retains a central role in the management of breast cancer. In the case of 
breast conserving surgery, radiotherapy to the conserved breast has been found to 
significantly reduce the incidence of relapse in the ipsilateral breast (Scnitt, 1993). 
Several factors, including multicentricity, total tumour excision, the presence of extensive 
intraductal component and lymphatic invasion, influence how much radiotherapy will 
help to control disease in the conserved breast. 
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• Adjuvant Systemic therapy 
Many breast cancer patients who remain disease free after local and regional treatment 
eventually relapse and die as result of overt metastases. The aim of adjuvant systemic 
therapy is to treat micro metastatic disease present at the time of initial surgery and it is 
estimated that it may prevent relapse in about one third of patients who would have 
relapsed without it (Goldhirsch, 1997). Adjuvant systemic therapies include 
chemotherapy, endocrine therapy, combined chemo-endocrine therapy and ovarIan 
ablation. 
1.1.6 Treatment of metastatic breast cancer 
The development of overt metastastic breast cancer results in chronic incurable disease 
with a survival time that may vary from a few weeks to many years. Overall, the median 
duration of survival is 2 years. Thus, the treatment choice in this setting should be guided 
by the extent of the disease, its related symptoms and an estimation of survival. The aim 
of local and systemic therapies in this setting is to palliate symptoms foremost. The 
choice of systemic treatments includes chemotherapy and hormone therapy. 
In a substantial number of cases hormone therapy is considered as first line treatment due 
to its relatively Iow toxicity. Certain clinical features, such as long disease-free interval 
and non-visceral disease (Brufman, 1993), along with high expression of oestrogen or 
progesterone receptors (Brooks S, 1980; Dao T, 1980; Degenshein Q, 1980) are 
predictive of higher rate of response. Endocrine therapies can be classified as ablative (eg 
oophorectomy, radiotherapy ablation or chemical suppression with eg gosereIin) or 
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additive (eg megesterol acetate/ aromatase inhibitors). Ablative therapies are aimed at 
ovarian suppression in pre-menopausal women whereas additive therapies are aimed at 
antagonising the production or peripheral effects of oestrogens, ie; the anti-oestrogens. 
Pure anti-oestrogens are steroidal analogues of oestradiol and bind to the oestrogen 
receptor leading to disruption of transcriptional activity. These include tamoxifen, which 
has been in use for the management of breast cancer since the 1970s and is well 
established in the adjuvant and metastatic settings. Newer steroidal anti-oestrogen agents 
include toremifene and faslodex. The other class of anti-oestrogens are the aromatase 
inhibitors. In postmenopausal women, the major source of oestrogen is from the 
conversion of adrenal and ovarian androgens (androstenedione and testosterone) to 
oestrogens in peripheral tissues, including breast, bone, peripheral vasculature and brain. 
Aromatase is the enzyme involved in the conversion of androgens to oestrogen and this is 
the target of the aromatase inhibitors. First generation agents, such as aminoglutethemide, 
had relatively low efficacy and a poor side effect profile. Second generation agents 
overcame the side effect problems somewhat but it is the third generation aromatase 
inhibitors, such as anstrazole, letrozole and exemestane, that have real benefits in terms 
of potency and reduced toxicity. Randomised controlled trials in advanced breast cancer 
have demonstrated the benefits of aromatase inhibitors over tamoxifen (Bonneterre J, 
2000; Nabholtz JM, 2000; Mouridsen H, 2001) and, for post-menopausal women who are 
eligible for hormone therapy, these agents are becoming widely used for first line 
metastatic therapy. 
11 
Chapter 1 Introduction 
Chemotherapy interventions are generally more toxic and are often used in hormone-
refractory disease. However, these may be offered as first line therapy if the patient has 
rapidly progressive disease or extensive visceral metastases. As chemotherapy is not a 
curative measure, a careful balance must be struck between optimum palliation of 
symptoms, disease response and the patient's quality of life. The toxicity may be 
considerable. Chemotherapeutic agents are often given in combination and the optimum 
duration is unclear. There is little evidence to suggest that continuing treatment beyond a 
partial or complete response is beneficial. Indeed, there is clinical evidence suggesting 
that discontinuing treatment at response and restarting at further progression gives an 
equivalent survival to continuous therapy but with less toxicity (Muss H, 1991). Once 
progression occurs, the patient may be treated successfully with other regimens but the 
chances of response are diminished with each subsequent regimen. New biological 
therapies, such as monoclonal antibodies to the growth factor receptor Her 2, have also 
emerged as effective agents in combination with chemotherapy. 
Local treatments for symptomatic metastases include radiotherapy and surgery. The 
management of bone metastases in particular is discussed below. 
1.2 BONE METASTASES IN BREAST CANCER 
1.2.1 Clinical features 
Bone metastases are extraordinarily common in patients with breast cancer. Breast 
cancer, together with prostate cancer, comprises over 80% of cases of metastatic bone 
disease (Rubens, 1991). A study of 587 women dying of breast cancer revealed that 69% 
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had radiological evidence of skeletal disease before death compared with 27% with lung 
and liver metastases (Coleman RE, 1987). Interestingly, the site of first recurrence of 
breast cancer appears to significantly impact on subsequent survival. Patients with first 
relapse of breast cancer confined to the skeleton had a median survival of 20 months 
compared with 3 months for those with first recurrence in the liver (Coleman RE, 1987). 
The disease in bone therefore follows a protracted course and the associated morbidity 
forms a significant clinical problem. A study of 367 patients with metastatic breast cancer 
revealed that the development of secondaries at extraskeletal sites also influences the 
probability of surv,ival from bone metastases (Coleman RE, 1988a). Patients with bone 
metastases and additional soft tissue secondaries had a median survival time of 1.6 years 
compared with 2.1 years for those with bone only disease. Other factors predicting 
prognosis included tumour histological grade and type, oestrogen receptor status and 
menopausal status. 
• Morbidity 
Bone metastases from breast cancer cause significant morbidity and form a sizeable 
clinical problem because of the protracted nature of the disease when confined to the 
skeleton. The problems encountered include bone pain, impaired mobility, 
hypercalcaemia, pathological fractures, nerve root and spinal cord compression 
syndromes and bone marrow infiltration. In one study, patients with breast cancer bone 
metastases experienced a skeletal related event, such as a pathological fracture, every 3-4 
months (Hortobagyi GN et al., 1996). Col em an et al found in a study of 498 patients with 
first recurrence from breast cancer in bone that 29% (145) developed one or more major 
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complications of bone destruction. 17% (86) developed hypercalcaemia, whilst 
pathological long bone fractures occurred in 16% (78) and spinal cord compression in 3% 
(13) (Coleman RE, 1987). 
Hypercalcaemia is a common complication of malignancy and is often associated with 
squamous cell carcinomas of the lung, renal cell carcinoma and adenocarcinomas of the 
breast (Guise T, 1998). It results in a number of symptoms involving the kidneys, 
gastrointestinal tract and central nervous system. If left untreated, it may result alterations 
in conscious level along with potentially fatal acute renal failure and cardiac arrythmias. 
Hypercalcaemia is very often an indication of advanced disease. 
The bone destruction caused by metastatic disease results in disruption of the bone 
architecture. This, in turn, may compromise its weight-bearing capacity and ultimately 
lead to loss of bone integrity and pathological fracture. Pathological fractures commonly 
occur in the axial skeleton, although fractures of the long bones may cause the most 
disability. Radiographic assessment of the size of lesions and the extent of bone 
destruction provides valuable information on which patients may benefit from 
prophylactic surgery (Coleman, 1998). The presence of back pain along with an 
abnormality on plain radiograph of the spine may herald impending spinal cord 
compression. Prompt management and early referral for radiotherapy or decompression 
and spinal stabilisation are crucial to ensure maximum recovery of neurological function. 
Bone pain is a significant problem and often difficult to control. It may be associated with 
pathological fractures or nerve entrapment syndromes and treatment modalities include 
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analgesic medication, radiotherapy, nerve blocks, surgical stabilisation and 
bisphosphonates. 
Radiologically, breast cancer is commonly characterised by the development of 
predominantly osteolytic skeletal lesions, although osteosclerotic and mixed 
lytic/sclerotic lesions are also seen. The development of bone disease is associated with 
an increase in osteoclast activity leading to an uncoupling of bone resorption and 
formation which results in excessive bone destruction. In order to understand the 
development of bone metastases in breast cancer, it is necessary first to review the 
process of normal bone remodelling. 
1.2.2 Bone Remodelling 
• Cells involved in bone remodelling 
Osteoclasts are the cells responsible for bone breakdown or resorption. They are large 
multinucleated cells which are derived from the granulocyte-macrophage colony forming 
unit (GM-CFU) of the haemopoietic lineage (Mundy, 1996). They are located either on 
the surface of bone or in resorption pits termed Howship's lacunae. The osteoclast has 
several specialist features to enable it to resorb bone. A peripheral actin ring forms a 
sealed environment mediated by integrins on the cell membrane which recognise certain 
proteins in the bone matrix. In this zone, a specialised part of the cell membrane, the 
ruffled border, secretes two products which will lead to bone breakdown. The first step is 
dissolution of the bone mineral by H+ ions (secreted via a proton ATPase) under the 
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action of carbonic anhydrase. Lyososomal enzymes, such as cathepsin K and 
collagenases, are then secreted via the ruffled border to degrade the matrix components. 
Bone matrix is synthesised by osteoblasts, cells which derive from mesenchymal 
progenitors (Fleisch, 2000). They secrete the osseous organic matrix, or osteoid, which 
forms a layer under the cuboidal osteoblast cells. This osteoid is subsequently mineralised 
to form the calcified bone matrix. The osteoid layer is widened in pathological conditions 
which result in absence of mineralization, such as osteomalacia. When osteoblasts are not 
involved in bone formation they lie flat and are termed resting osteoblasts or lining cells. 
Eventually osteoblasts become embedded in bone and are located in lacunae. They are 
then termed osteocytes (Puzas, 1996). These cells are connected to each other and 
osteoblasts and lining cells by long cytoplasmic processes contained in canaliculi. These 
also contain extracellular fluid and osteocytes may influence calcium homeostasis by 
altering its composition. Osteocytes may also be involved in the response and adaptation 
of bone to mechanical stimuli. 
• The remodelling process 
The skeleton is a dynamic structure, undergoing constant structural remodelling to 
maintain its integrity. This process occurs in discreet units termed "bone remodelling 
units" by Frost (Frost, 1964) who initially described the sequence of events involved. The 
sequence begins with bone resorption by osteoclasts followed by new bone formation by 
osteoblasts to produce a "bone structural unit". The process of bone remodelling is 
outlined in Figure 1.1 below. 
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Figure 1.1 Bone Remodelling. Biochemical and mechanical stimuli result in the retraction of bone lining cells 
and exposure of the bone surface to begin bone remodelling. Multinucleated osteoclasts form by fusion of their 
precursors and are activated to commence the formation of a resorption cavity. Once the cavity is smoothed by 
mononuclear cells, osteoblasts are recruited and a highly mineralised cement line is laid at the base of the 
resorption cavity. This is the reversal phase. Osteoblasts are then recruited to this site and produce an 
uncalcified osteoid matrix which subsequently undergoes mineralization. During the final step, quiescence, 
osteoblastic activity ceases. The newly formed bone is termed a bone structural unit. Adapted from Compston, 
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Foci of remodelling occur throughout the skeleton, in both cortical and cancellous or 
trabecular bone, each focus being independent of activity at other sites. This suggests 
that, as well being influenced by systemic factors, the remodelling process is also being 
regulated at a local level. 
1.2.3 Control of bone remodelling 
• Systemic hormonal regulation 
A number of hormones regulate bone remodelling that including parathyroid hormone 
(PTH), 1,25(OH)2 vitamin D (calcitriol), and calcitonin. Parathyroid hormone has been 
shown to stimulate bone resorption in vitro, in addition to having anabolic effects on bone 
which are mediated by insulin-like growth factors (IGFs). Vitamin D increases bone 
resorption as well as playing an important role in the mineralisation of bone via action on 
osteoblasts. Calcitonin directly results in reduction of bone resorption. Other hormones 
that are vital for normal growth also play a part in the regulation of bone remodelling. 
Both insulin and growth hormone act via IGFs to increase mineralisation and bone mass, 
respectively. Thyroid hormone is involved in the growth and differentiation of bone cells 
and oestrogen and testosterone both inhibit bone resorption. Glucocorticoids are also 
known to directly inhibit osteoblast activity, resulting in decreased bone formation, as 
well as stimulating increased bone turnover. 
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• Local Regulation 
Factors local to the bone microenvironment also modulate the rate of bone turnover. The 
bone matrix is a storehouse of growth factors, such as TGFj3 and IGFs, that are known to 
stimulate bone formation and reduce bone resorption. Other factors, including fibroblast 
growth factors (FGFs) and platelet-derived growth factors (PDGFs) influence both bone 
resorption and formation to increase bone turnover. Certain cytokines that are produced 
by bone cells and stromal cells are also known to be important. Il-l and IL-6 stimulate 
osteoclast formation and bone resorption (de la Mata J, 1995; Ishimi Y, 1990; 
Pfeilschifter J, 1989) as well as macrophage colony-stimulating factor (M-CSF) and 
prostoglandins amongst others (Fleisch, 2000). 
A recently discovered factor which inhibits osteoclast formation and activity is 
osteoprotogerin (OPG, also known as osteoclastogenesis inhibitory factor, OCIF) 
(Anderson DM, 1997; Simonet WS, 1997). This is a glycoprotein of the TNF receptor 
family, which is produced by stromal cells, osteoblast lineage cells and pre-B cells. It acts 
as a decoy receptor and binds to an osteoclastic differentiation factor called receptor 
activator of NF-KB ligand (RANKL) which is located on the membrane of osteoblast 
lineage cells. RANKL binds to its transmembrane receptor RANK (Nakagawa N, 1998) 
on osteoclast precursors to stimulate osteoclast recruitment, differentiation and activation 
(Fuller K, 1998; Lacey DL, 1998; Yasuda H, 1998) [Burgess TL, 1999 May 3; #308]. 
Therefore the action of OPG as a decoy receptor is to inhibit osteoclast maturation and 
activation, thereby inhibiting bone resorption (Yasuda H, 1998). Studies in mice bearing 
a defective RANKL gene show that these animals suffer severe osteopetrosis as 
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osteoblasts are unable to stimulate osteoclastgenesis (Kong YY, 1999) suggesting that the 
RANK, via the actions of RANKL, is a key receptor for the activation and survival of 
osteoclasts. 
1.2.4 Pathogenesis of bone metastases 
• General mechanisms of metastasis 
Once tumour cells at the primary site have established, there are multiple steps involved 
in the growth and spread of the tumour to bone (Figure 1.2). In order to invade the host 
tissue and metastasise, the tumour cells must possess an aggressive phenotype, which 
enables them to promote angiogenesis and cell migration, adhere selectively to other 
cells, basement membranes and extracellular matrices and produce proteolytic enzymes 
to complete the invasive process (Aslakson C, 1992; Folkman, 1984; Mundy, 1997). 
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Figure 1.2 The pathogenesis of cancer metastases. Tumour cells must detach from the primary tumour, 
invade the tumour vasculature and enter in the circulation. Those that survive immune surveillance 
arrest in the capillary bed of distant organs, including bone and must extravasate to invade the host 
organ parenchyma. Tumour cells then respond to paracrine stimuli in the microenvironment to induce 
proliferation and promote angiogenesis to allow the metastasis to establish. 
21 
Chapter 1 Introduction 
The metastatic process to bone appears to be selective and there are several theories as to 
the mechanisms behind this. The anatomical theory (Batson, 1940) suggests that the sites 
of metastasis might be significantly influenced by the blood flow from the primary site, 
particularly the vertebral vein system, although this has since been challenged in later 
studies (Dodds PR, 1981). The concept that has influenced most of the recent work in this 
field is the "seed and soil" hypothesis first postulated by Paget (Paget, 1889). He noted 
the extraordinary predilection of breast cancer to metastasise to the skeleton and 
suggested that breast cancer cells, the "seed", may possess properties that enable them to 
establish preferentially in bone which is rich in growth factors and provides a fertile 
"soil" for the metastasis to establish. The factors involved in the general metastatic 
process and those specific to cancer metastatic to bone are discussed below. 
• Angiogenesis 
To grow above 2mm in size a tumour must possess a blood supply (Folkman, 1984) and 
this is an important step in the metastatic process as it allows contact with the host's 
circulation (Van Der Pluijm G, 2000). Endothelial growth factors, such as vascular 
endothelial growth factors (VEGF), platelet-derived growth factor (pDGF) and fibroblast 
growth factors (FGF), and endogenous anti angiogenic factors, such as angiostatin, 
regulate tumour neovascularisation. Of particular importance is VEGF which has been 
shown to be over-expressed by many tumours types. It has been shown to promote 
endothelial cell growth and chemotaxis (Ferrara N, 1997; Neufeld G, 1999) as well as the 
induction of the expression of proteases in endothelial cells (Pepper MS, 1991; Unemori 
-
EN, 1992). It may enhance the migration of tumour cells by increasing vascular 
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permeability (Chaplin DJ, 1997; Dvorak HF, 1995) and has also been implicated in 
lymphatic spread (Mandriota S, 2001). Tumour angiogenesis and growth can be inhibited 
by blocking the activity of VEGF using neutralising antibodies in tumour-bearing mice 
(Kim KJ, 1993) indicating that this factor plays a central role in tumour progression. 
• Adhesion molecules 
Once neovascularisation has occurred, the next step in the metastatic process is the 
detachment of tumour cells from the primary site and subsequent attachment to 
endothelial cells and extracellular matrices. Cellular adhesion molecules such as 
integrins, cadherins, especially E-cadherin, and selectins mediate tumour cell interactions 
with substrata and can be differentially expressed to allow escape from the primary site, 
tumour cell migration and attachment to basement membranes at the target organ. 
The cadherin family of cell adhesion molecules, particularly E-cadherin, plays an 
important role in epithelial cell-cell adhesion. Loss of E-cadherin expression in epithelial 
tumours is associated with the development of a highly invasive phenotype (Behrens, 
1993; Behrens J, 1989). Invasive breast cancer cell lines, such as MDA-MB-231, express 
low levels ofE-cadherin whereas non-metastatic cell lines are associated with high levels 
of expression (Sommers CL, 1991). Indeed, the de novo expression of E-cadherin in 
MDA-MB-231 cells reduces the ability of these cells to form osteolytic metastases in the 
bone of nude mice (Mbalaviele G, 1996). As well as changes in cadherin expression, cell-
cell attachment may also be disrupted by the deletion of the cytoplasmic tail of the 
cadherin molecule or by alterations in catenin proteins which mediate interactions with 
the cytoskeleton. Hence complex alterations may occur to alter cell-cell adhesion. 
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The integrins are a diverse family of receptors that mediate adhesion between the cell 
membrane and the extracellular matrix or other cell adhesion molecules. They are 
composed of distinct a. and ~ subunits, each of which has further subtypes, and the 
specificity with which ligands are bound is determined by the combination of subunits. 
Moreover, certain integrins may be activated or inactivated in response to other signals 
and hence modulate cell adhesion (Meyer T, 1998). Indeed, the function of integrins is 
not restricted to cell-substrata adhesion alone. Recent studies have suggested that these 
receptors may play a role in signal transduction and may influence cell motility and 
invasion (Hynes, 1992). 
Members of the immunoglobulin superfamily, such as ICAM-l, ICAM-2, V-CAM and 
PE CAM, have been implicated in the extravasation process (as reviewed by Meyer and 
Hart,) (Meyer T, 1998). The expression of these adhesion molecules, which contain one 
or more Ig-like domains, is upregulated by cytokines such as TNFa. and interleukin-l 
during the inflammatory process. Leucocytes recruited to the sites may interact with these 
adhesion molecules to arrest prior to extravasation. They may thus mediate interaction 
between the endothelium and tumour cells to enhance their migration through the vessel 
walls at metastastic sites. Similarly, expression of members of the selectin family of 
adhesion molecules is triggered during inflammation. The resultant low affinity binding 
initiates leucocyte rolling and this is followed by arrest and extravasation as described 
above. Similar processes may be implicated in tumour cell arrest and extravasation. 
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• Proteolytic enzymes 
Breast cancer cells must have a means of penetrating the basement membrane and 
invading the surrounding tissue and a host of proteolytic enzymes are vital to this process. 
The key groups of proteolytic enzymes implicated in tumour invasion are the serine 
proteases, including urokinase-type plasminogen activator (uP A) and plasmin, the matrix 
metalloproteinases and the cysteine proteases, cathepsin B and L (MacDougall JR, 1995). 
The uPAI urokinase plasminogen activator receptor (uPAR) system is involved in many 
physiological processes, including wound healing and angiogenesis, and is also 
implicated in tumour metastasis. Members involved in this system have been shown by 
immunohistochemistry to be located at the invasive edge of cancers and surrounding 
stromal cells, (Pyke C, 1991) suggesting that multifaceted interactions are occurring 
between tumour cells and the tissue environment to degrade the stroma. uP A, uP AR and 
PAl (plasminogen activator inhibitor) have recently been recognised as important 
prognostic factors in breast cancer. High breast tumour levels of uP A have been 
associated with higher relapse rates (Janicke F, 1990) and a worse prognosis (Duffy MJ, 
1990). There is also evidence to suggest that this system may influence the metastatic 
potential of cancer cells. In one study, the in vitro invasive potential of rat breast 
carcinoma cells was enhanced by upregulating the expression of uP A and, in vivo, these 
resulted in larger mammary tumour growth with increased metastases (King RH, 1996). 
Interestingly, in a mouse syngeneic tumour model, mono clonal antibodies against uP A 
significantly reduced the development of lung metastases (Hearing VJ, 1998). Another 
~ 
important group of proteolytic enzymes are the matrix metalloproteinases. These are a 
25 
Chapter 1 Introduction 
family of zinc-dependant endopeptidases which are divided into the gelatinases, 
collagenases and stromelysins according to the substrate upon which they act. Increased 
plasma levels of MMPs have been associated with higher levels of invasion and 
metastases in breast tumours (MacDougall JR, 1995). In bone in particular, Yoneda et al 
have reported that human breast cancer cells express the gelatinases MMP-2 and MMP-9 
in their latent forms but that expression of the activated forms can be induced when 
cultured on extracellular matrix derived from osteoblasts (Yoneda T, 1997). In addition, 
MMP-9 has recently been shown to stimulate osteoclast-mediated bone resorption 
(Okada Y, 1995; Witty JP, 1996) and influence the differentiation of osteoclast 
precursors (Blavier L, 1995). It is possible, therefore, that MMPs produced by breast 
cancer cells may influence osteoclast differentiation and stimulate bone resorption to 
enhance the progression of bone secondaries. Another factor is the influence of 
ubiquitously occurring inhibitors of metalloproteinases, the tissue inhibitors of matrix 
metalloproteinases (TIMPs). These closely regulate the activity of MMPs and their over-
expression in breast cancer cells markedly inhibits the formation of bone metastases in 
experimental studies (Yoneda T, 1997). 
• Bone-specific proteins expressed by breast cancer cells 
The properties of metastastic cancer cells discussed so far are common to all metastastic 
tumours. There may be additional factors unique to osteotrophic cancers which aid their 
spread to bone in particular. Several proteins originally identified as bone matrix proteins 
are also expressed by certain cancers which have a predilection for bone such as breast 
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cancer and prostate cancer. These proteins include osteopontin (OPN), osteonectin (ON) 
and bone sialoprotein (BSP) (Koeneman KS, 1999; Rosol, 2000) (Jacob K, 1999). 
o Osteopontin 
OPN is a protein secreted by osteoblasts and placental trophoblasts and contains a 
conserved RDG (Arg-Gly-Asp) amino acid sequence. This allows binding to integrins 
and the ubiquitous CD44 cell adhesion protein (Weber GF, 1996; Xuan JW, 1995). 
Osteopontin expressed on breast cancer cells may mediate cell-cell or cell-matrix 
interaction and aid chemotaxis, thereby enhancing metastasis to bone. 
o Bone Sialoprotein 
Another bone matrix protein which is expressed by breast cancer cells, as well as other 
osteotrophic tumours, is bone sialoprotein (BSP) (Mundy G, 1996; Quinn JE, 1998) 
(Rubens, 1999). BSP is a glycoprotein which is secreted by osteoblasts and contains an 
integrin-binding RDG sequence which acts as a ligand for osteoclasts to potentiate bone 
resorption. It may facilitate interaction between breast cancer cells and osteoclasts as well 
as promoting cancer cell migration and proliferation (Sung V, 1998). BSP can be 
measured in the serum and may serve as a marker for osteotrophic cancers (Fedarco NS, 
1999). Recent clinical studies have suggested that serum levels of BSP may be a reliable 
predictor of the development of subsequent bone metastases in patients with breast cancer 
(Bellahcene A, 1998). In addition, the expression of BSP in primary breast and prostate 
cancer has been associated with disease progression and a poorer prognosis (Bellahcene 
A, 1998; Mundy G, 1996) Yoneda T, 1997). Waltregny et al recently demonstrated a 
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differential increase in expression of BSP in bone metastases compared with visceral 
metastases from patients with breast and prostate cancer (Waltregny D, 2000). Therefore 
this protein may play a key role in the homing and proliferation of breast cancer cells in 
bone and in the development of bone metastases. 
o Osteonectin 
Osteonectin (ON) is a multifunctional glycoprotein which is involved in mineralization, 
cell-cell interactions and angiogenesis (Rosol, 2000). In addition to its production by 
osteoblasts, it is secreted by prostate and breast carcinoma cells. It has been shown to 
enhance MMP activity in both breast and prostate cancer thereby aiding invasion and 
metastasis (Jacob K, 1999). 
• Breast cancer-bone interaction 
Bone is unique amongst metastastic sites as it is continually being renewed and 
remodelled. It is a storehouse for growth factors and these are constantly being released 
into the microenvironment as bone turnover occurs. Growth factors and cytokines are 
also released from bone marrow stromal cells and immune cells. TGF~ and IGFs 1 and 2 
make up the majority of bone derived growth factors. Once released into the bone 
marrow milieu, these growth factors may have effects on breast cancer cells to aid the 
development of metastases. The tumour cell-bone interaction is complex and not fully 
understood but forms the focus of much research activity. Recent evidence suggests that 
metastastic breast cancer cells in bone may secrete soluble factors, for example PTHrP, 
which stimulate osteoclast activity and promote bone resorption (Figure 1.3) Recent 
28 
Chapter 1 Introduction 
studies have suggested that RANKL may also play a role in this system (Thomas RJ, 
1999). This, in turn, results in the release of growth factors into the bone marrow 
microenvironment which may act on breast cancer cells to promote further bone 
destruction and development of the metastasis. Thus, a spiral of events is triggered in 
which tumour derived mediators accelerate osteoclastic bone breakdown and the 
subsequently released growth factors act on breast cancer cells to stimulate the further 
production of soluble factors and promote further tumour cell chemotaxis. Evidence for 
the specific roles of cytokines and growth factors, such as PTHrP, in this process are 
discussed in the section below. 
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Figure 1.3 Interaction between breast cancer cells and the bone microenvironment. Tumour cells 
produce soluble mediators, such as PTHrP, which stimulate osteoclast activity and promote 
osteoclast-mediated bone resorption. This in turn results in the release of growth factors, such as 
TGF-~ and IGFs, from the bone matrix which may promote further breast cancer cell chemotaxis 
and the release of cytokines from the tumour cells to further increase osteoclast activity. The net 
effect is to set up a cycle of bone destruction fueled by tumour-derived osteoclast activating 
cytokines and bone derived growth factors. In this environment, metastastic cells can establish and 
proliferate. 
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PTHrP 
Parathyroid hormone-related peptide or PTHrP is a protein with similar biological 
activity to parathyroid hormone (PTH) and is a mediator for humoral hypercalcaemia of 
malignancy. It was Fuller and Albright who first proposed a syndrome of "ectopic PTH" 
secretion (Fuller, 1941). Much later than their original hypotheses, a factor was purified 
from several cancers (Burtis Wl, 1987; Mosely lM, 1987; Strewler Gl, 1987) which had 
similar biological activity to parathyroid hormone (PTH) but was a distinct entity. This 
factor, PTHrP, was shown to have 70% homology in the first 13 amino acids of the n-
terminal to PTH (Horiuchi N, 1987). It binds to the PTH receptor (Abou-Samra AB, 
1992) to stimulate hypercalcaemia by several means including the enhancement of 
osteoclast-mediated bone resorption and increased renal tubular reabsorption of calcium. 
In addition to mediating hypercalcaemia and influencing the development and 
progression of osteolytic bone metastases in breast cancer, PTHrP may also be involved 
in regulation of cancer cell growth and may even act as a cell survival factor. 
Clinically, the expression of PTHrP by primary breast cancers correlates positively with 
the development of subsequent bone metastases and hypercalcaemia (Bundred Nl, 1991). 
PTHrP has been detected by immunohistochemistry in a higher proportion of patients 
with bone metastases from breast cancer compared to those with lung metastases or no 
metastastic disease (Kohno N, 1994). In animal studies, mice bearing MDA-MB-231 
breast cancer cells that over-expressed PTHrP developed a significantly higher number of 
osteolytic bone metastases (Guise T, 1996). Treatment with monoclonal antibodies 
against PTHrP before injection of the tumour cells resulted in a dramatic reduction in the 
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number and size of bony metastases indicating that PTHrP has a central role in breast 
cancer bone metastasis. 
• IL-6. 
Interleukin 6 (IL-6) is a multi functional regulator of immune response, haematopoesis 
and acute phase responses [Hirano, 1998 #193]. It has also been shown to influence the 
proliferation of both normal and tumour-derived cells. Several studies have demonstrated 
the secretion of IL-6 by mammary carcinoma cells (Chiu J, 1996; Pederson L, 1999) as 
well as other tumour types, particularly multiple myeloma (reviewed by Guise and 
Mundy (Guise T, 1998)and Klein et al (Klein B, 1995)and normal bone marrow stromal 
cells (Boyce B, 1999; Mohan S, 1991). In multiple myeloma, this cytokine acts as 
important growth regulator and survival factor in its ability to support myeloma cell 
proliferation (Kawano M, 1988) and indeed the stage of advancement of the disease has 
been shown to correlate with patient serum and bone marrow IL-6 concentrations 
(Bataille R et al., 1992; Bataille R, 1989; Zhang GJ, 1999). In contrast, IL-6 has been 
shown to result in growth inhibition in mammary carcinoma cells (Novick D, 1992) and it 
has also been suggested that it may regulate the growth of normal and transformed human 
mammary epithelial cells differentially (Chiu J, 1996; Lai L, 1994). Chiu et al found that 
higher levels of IL-6 were secreted by ER negative breast cancer cells than ER positive 
cells and that this acted on ER positive cells to suppress growth in a paracrine fashion 
(Chiu J, 1996). Recent observations that IL-6 may disrupt breast cancer cell adhesion 
(Tamm I, 1994) and increase tumour cell migration (Badache A, 2001) together with the 
paracrine effects described above suggest that expression of this cytokine may signify the 
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development of a more aggressive and metastatic breast cancer cell phenotype. Indeed, 
elevated serum levels of IL-6 and sIL-6R have been observed in breast cancer patients 
compared with normal controls (Jablonska, 1998) and appear to correlate with more 
aggressive disease (Haverty A, 1997; Jiang X, 2000; Yokoe T, 1997). Interestingly,IL-6 
has been implicated in the stimulation of osteoclast precursors, possibly through the 
activity of other factors such as PTHrP, which in turn would accelerate bone re sorption 
(de la Mata J, 1995). The soluble form of the 11-6 receptor (sIL-6R) binds IL-6 and the 
complex interacts with the membrane-bound receptor, gp130, to stimulate signalling and 
enhance IL-6 effects . 
• TGFp. 
TGFp is an important regulatory protein for the differentiation and proliferation of many 
human cells including bone cells (Centrella M, 1994). The TGFp-l isoform is highly 
expressed by mature osteoblasts and osteoclasts, stored in bone matrix and released into 
the microenvironment when bone resorption takes place (Pfeilschifter J, 1987). TGFp 
signals via a series of receptors which interact with the Smad family of proteins to 
mediate signalling (Massague, 1998). The effects of TGFp are cell specific, in some 
cases stimulating proliferation (mesenchymal cells) and in others inhibiting growth 
(epithelial cells) (Derynk, 1994). It also facilitates cell adhesion and the production of 
extracellular matrix protein. 
Breast cancer cells, as well as cancer associated stromal cells, have been shown to 
express TGFp (Van Roozendaal CEP, 1995). It may influence the production of other 
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important proteins, such as MMPs from breast cancer cells (Diudenvoorden W, 1999). In 
particular, TGF13 has been shown to stimulate the production of PTHrP from human 
breast cancer cells (Firek A, 1994). Using an in vivo model of osteolytic metastases, Yin 
et af elegantly demonstrated the relationship between TGF13 and PTHrP (Yin J, 1999). 
They inoculated mice with MDA-MB-231 breast cancer cells that had been transfected 
with genes encoding an inactive TGF13 receptor and found that these animals developed 
significantly fewer and smaller osteolytic lesions compared with controls or those bearing 
empty vectors. Taken together, these data suggest that TGF13 enhances the development 
of breast cancer bone metastases by stimulating the production of PTHrP and thereby 
increasing osteoclast differentiation and activity. The resulting bone re sorption leads to 
the release of further growth factors from the bone matrix and the proliferation and 
chemotaxis of breast cancer cells. 
• Insulin-like Growth Factors 
The insulin-like growth factors are important proteins in bone formation. The system 
comprises two proteins which act as ligands, IGF-l and IGF-II, two receptors and six 
binding proteins (Jones JI, 1995). IGFs I and 11 have a stimulatory effect on the functions 
of mature osteoblasts, as well as decreasing the rate of collagen degradation, indicating 
that they have a central role in the preservation of bone matrix integrity and in bone 
formation. There is evidence to suggest that they are involved in the development of the 
normal mammary gland, as well as being potentially mitogenic for breast cancer cells, as 
reviewed by Sachdev et al (Sachdev D, 2001). 
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1.2.5 Treatment of bone metastases 
The current treatment strategies for metastastic bone disease in breast cancer focus 
mainly on symptom palliation although newer agents may help to prevent the occurrence 
or slow the progression of bone disease. Bone pain is managed with the use of analgesics, 
as well as local radiotherapy and bisphosphonates to slow down the progression of bone 
disease. Surgical intervention may be required if fracture is imminent or for spinal 
instability. Radiopharmaceuticals that target radiation to the sites ofmetastases are also in 
development. As discussed previously, many patients with bone only disease will have 
hormone receptor-positive tumours, therefore systemic endocrine therapy is widely used 
in these patients. Systemic chemotherapy is often reserved for those women with 
receptor-negative disease. Bisphosphonates, as discussed below in section 1.3, are the 
treatment of choice for hypercalcaemia of malignancy. 
1.3 BISPHOSPHONATES 
1.3.1 Introduction 
Bisphosphonates are stable analogues of pyrophosphate and act as potent inhibitors of 
osteoclast-mediated bone resorption. They have been in clinical use for some time and 
have recently been established for the management of hypercalcaemia of malignancy and 
tumour induced bone disease. The structure of pyrophosphate and a generic 
bisphosphonate is shown below. Bisphosphonates are characterised by the replacement of 
the central oxygen atom by a carbon atom. This forms a central P-C-P bond (Figure 1.4). 
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Inorganic pyrophosphate Bisphosphonate 
The P-C-P group acts as a 
"bone hook" and is essential 
for hydroxyapatite binding 
and for biological activity 
o 
11 
OH-P-OH 
I 
o 
I 
OH-P-OH 
11 
o 
o 
11 .................... .... 
........ OH-P-OH ............ I
k 
................ 
r--'RI-C-R2 I It, 
OH-P-OH " 
11 '" 
Binding to hydroxyapatite is 
enhanced when RI is an OH 
group 
o " ~----~------------~ 
Anti-resorptive potency is 
determined by the R2 side 
chain 
Figure 1.4 The structure of pyrophosphate and a generic bisphosphonate. Bisphosphonates are 
analogues of inorganic pyrophosphate where the central oxygen atom has been replaced with a 
carbon atom. The resulting P-C-P structure has a high affinity for hydroxyapatite. The affinit(' for 
bone and the anti-resorptive potency of bisphosphonates can be enhanced by altering the Rand 
R2 side chains respectively. 
1.3.2 Structure of bisphosphonates 
A characteristic that both bisphosphonates and pyrophosphate have in common is a high 
affinity for bone mineral along with the dissolution of hydroxyapatite in vitro (lung A, 
1972; Russell RGG, 1970). The phosphonate groups, through the chelation of calcium by 
the oxygen atoms, form the basis for this affinity. Placing a hydroxyl group (-OH) in the 
R I side chain increases the affinity of bisphosphonates for bone mineral even further 
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(lung A, 1972). Pyrophosphate, in contrast to bisphosphonates, does not inhibit bone 
resorption and its relative instability when faced with enzymatic or chemical hydrolysis 
has been suggested as an explanation (Fleisch H, 1969; Russell RGG, 1970). 
Bisphosphonates, on the other hand, are more stable compounds. Interestingly, the 
affinity of bisphosphonates for bone mineral does not correlate with their anti-resorptive 
potency, either in vitro or in vivo (Shinoda H, 1983). The development of differing anti-
resorptive potency depends on modification of the R2 side chain (Geddes AD, 1994; 
Sietsema WK., 1989) (Figure 1.5). 
The anti-resorptive potency of bisphosphonates can be increased by the addition of a 
nitrogen group to the R2 side chain. Compounds with this modification, such as in 
pamidronate and alendronate, show an increased potency in vivo by 1-3 orders of 
magnitude compared to the low potency bisphosphonate etidronate (Sietsema WK., 1989). 
Newer compounds have been developed to include the nitrogen group within a 
heterocyclic ring to further enhance the anti-resorptive potency. Both risedronate and 
zoledronic acid, which include this structure, have been found to be more potent in vivo 
than etidronate and pamidronate (Green JR, 1994; Sietsema WK., 1989) (figure 1.5). 
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Figurel.5 The relationship between bisphosphonate structure and anti-resorptive potency. The 
relative in vivo anti-resorptive potencies are shown in brackets (Fleisch. 1991; Green JR. 1994). 
The introduction of an amino group in the R2 side chain. as in pamidronate and alendronate. 
increases the anti-resorptive potency. This is further enhanced by methylation of the amino grouP. 
as in ibandronate. or by inclusion of a heterocyclic ring in the R2 side chain. The most potent 
bisphosphonates. including risedronate and zoledronic acid. contain nitrogen atoms within the 
heterocyclic ring. 
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1.3.3 Cellular effects of bisphosphonates 
Bisphosphonates have a high affinity for mineralised bone and adsorb to the bone 
surface. During the resorption process the bisphosphonate is released from the bone 
surface, exposing the osteoclast to high concentrations of the drug (Sato M et al., 1991) 
with subsequent anti-resorptive effects (Figure 1.6). As well as effects on osteoclasts, 
however, bisphosphonates have also been shown to influence osteoclast precursors and 
osteoblasts, effects that may serve to augment their anti-resorptive action. 
€){.") 
€)cb 
Inhibit osteoclast 
formation 
Loss of resorptive 
function 
Apoptosis 
Intracellular uptake 
of bisphosphonate by 
osteoclasts during 
resorption 
Production of 
resorption-inhibiting 
factor by osteoblasts 
Figure 1.6 The effects of bisphosphonates on osteoclasts. Bisphosphonates inhibit osteoclast 
activity in several ways, including inhibiting the maturation of osteoclast precursors to mature 
osteoclasts, disrupting the osteoclast ruffled border and causing loss of resorptive function, and 
inducing osteoclast apoptosis. They also stimulate the production of a resorption-inhibiting factor by 
osteoclasts. 
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• Mature osteoclasts 
During the re sorption process, the osteoclast appears to internalise bone degradation 
products by endocytosis at the ruffled border, transport them in vesicles into the cell 
cytoplasm and clear them from the anti-resorptive surface by exocytosis (Salo J, 1997). 
As acidification of the environment below the osteoclast occurs, bisphosphonates are 
released from the bone surface and relatively high concentrations accumulate below the 
osteoclast (Sato M et al., 1991). In vivo studies suggest that radiolabeled alendronate is 
internalised in a similar way to bone degradation products therefore an intracellular 
mechanism of action is likely (Sato M et al., 1991). This is supported by the observation 
that preventing the release of bisphosphonate from bone by the addition of calcitonin 
protects osteoclasts from the effects of clodronate and pamidronate (Flanagan AM, 1989; 
Flanagan AM, 1991; Rowe DJ, 1980). 
Internalisation of bisphosphonate by the osteoclast results in disturbance of function in 
several ways. The effects include disruption of the cytoskeleton and eventual 
programmed cell death or apoptosis leading to a loss of resorptive function (Hughes DE 
et al., 1995; Miller SC, 1979; Murakami H, 1995; Plasmans CMT, 1980; Sato M et al., 
1991; Selander K, 1996). In vitro and in vivo studies have shown that osteoclast 
cytoskeletal disruption and loss of the ruffled border at the osteoclast-bone interface 
occurs after bisphosphonate treatment (Plasmans CMT, 1980; Sato M et al., 1991). In 
support of this, Murakami et al reported that tiludronate was selectively incorporated into 
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osteoclasts that were actively resorbing bone, i.e. those with a ruffled border, and 
disrupted the actin ring essential for osteoclast function (Murakami H, 1995). 
The apoptotic effects of bisphosphonates on osteoclasts have recognised for some time. 
Early studies observed that degenerative changes in osteoclast nuclear morphology 
occurred following bisphosphonate treatment (Rowe DJ, 1976; Rowe DJ, 1980; Rowe 
DJ, 1983; Schenk R, 1973). Studies with clodronate and pamidronate confirmed that 
bisphosphonate treatment was associated with a reduction in osteoclast number on the 
bone surface and injury-associated changes in nuclear morphology (Flanagan AM, 1989; 
Flanagan AM, 1991; Marshall MJ, 1990) that were later to be confirmed as characteristic 
features of programmed cell death or apoptosis. (Wyllie R, 1980) The induction of 
osteoclast apoptosis by bisphosphonates, such as clodronate, pamidronate and 
risedronate, has recently been verified both in vitro and in vivo (Hughes DE et al., 1995; 
Selander K, 1996). 
• Osteoclast precursors 
Mature osteoclasts are necessary for bone resorption therefore interference with the 
maturation of osteoclasts from their precursors inevitably inhibits this process. There is 
evidence to suggest that, as well as altering mature osteoclast function, bisphosphonates 
may have effects on osteoclast precursors. In vitro studies of the effects of 
bisphosphonates on a human bone marrow culture system have demonstrated a 
concentration-dependent inhibition of formation of osteoclast-like cells, with the order of 
-
potency of bisphosphonates correlating closely with their in vivo anti-resorptive potency 
41 
Chapter 1 Introduction 
(Hughes DE, 1989). Two mechanisms of action have been postulated. Low 
concentrations of nitrogen-containing bisphosphonates, such as pamidronate, have been 
reported to inhibit bone resorption by interfering with attachment and transformation of 
osteoclast precursors (Boonekamp P, 1986; Lowik C, 1988). A postulated mechanism for 
this is that bisphosphonates may interfere with the recognition of a bone matrix factor 
required for stimulation of osteoclast maturation. Higher concentrations of both amino-
bisphosphonates and non-nitrogen-containing bisphosphonates have been found to affect 
mature osteoclast function and hence inhibit bone resorption. Certainly, the potent 
bisphosphonate alendronate has been found to inhibit osteoclast formation in vitro (Van 
Beek ER, 1997; (Fisher JE, 1999) although no effect has been demonstrated on the 
osteoclast genesis potential of murine bone marrow in vivo (Van Beek ER, 1997). 
• Osteoblasts 
Complex interactions occur between osteoclasts and osteoblasts to influence bone 
resorption. Bisphosphonates may also interfere with bone resorption by having effects on 
osteoblasts. In vitro studies have suggested that bisphosphonate treatment of osteoblasts 
may stimulate the production of a factor that inhibits osteoclast maturation or function. 
Pre-treatment of osteoblast-like cells CRPlO/30 with either ibandronate or clodronate for 
short periods has been shown to reduce bone resorption when these cells were 
subsequently cultured with osteoclasts in vitro (Sahni M, 1993). Conditioned media from 
osteoblast-like cells treated with bisphosphonates also inhibited bone resorption by 
osteoclasts suggesting that this was a soluble factor releases by osteoblasts. Vitte et al 
-
suggested that this factor acted on osteoclast precursors to prevent maturation (Vitte C, 
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1996). Confirmatory studies with UMRI06 osteoblast-like cells (Yu X, 1996) and mouse 
calvarial osteoclasts (Nikishawa M, 1996) have suggested that bisphosphonate treatment 
stimulates the production of a soluble osteoclast-inhibitory factor from these cells also. 
1.3.4 Mechanisms of action 
The mechanisms by which bisphosphonates elicit their anti-resorptive activity are only 
now becoming clear. There appear to be differences in mechanisms of action on 
osteoclast activity depending on the structure of the bisphosphonate. These fall into two 
distinct groups; those that are similar in structure to pyrophosphate, such as clodronate 
and etidronate, and those that contain nitrogen in their R2 side chain. 
• Metabolism of bisphosphonates 
Studies looking at the effects of bisphosphonates on Dictyostelium discoideum slime 
mould demonstrated that growth was inhibited with a similar order of potency to that of 
the anti-resorptive potency of the bisphosphonate (Rogers MJ, 1994b). Bisphosphonates 
that were very similar in their structure to pyrophosphate, such as clodronate, were 
metabolised intracellularly into non-hydrolysable analogues of ATP containing 
methylene (Rogers MJ, 1994a; Rogers MJ, 1992) compared to those which contained 
nitrogen in the R2 side chain that were not metabolised. Aminoacyl tRNA synthetase 
enzymes were involved in incorporating the bisphosphonates into A TP analogues and it 
was postulated that inhibition of these enzymes by the bisphosphonate metabolites might 
be responsible for the cellular effects (Rogers MJ, 1994a). Similar observations have 
-
been made using human aminoacyl tRNA synthetase enzymes (Rogers MJ, 1996a). Frith 
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et al compared the actions of clodronate and alendronate on macrophages in vitro and 
found that clodronate, but not alendronate, is metabolised to non-hydrolysable toxic 
analogues of ATP (Frith lC et al., 1997). Follow-up studies have confirmed that 
clodronate is also metabolised in the same way in osteoclasts in vitro and results in 
osteoclast apoptosis (Frith lC, 1998). 
• Inhibition of the mevalonate pathway 
The mevalonate pathway is a biosynthetic pathway which is important· for the 
biosynthesis of cholesterol and isoprenoid groups (Figure 1.7). Recently, evidence has 
suggested that bisphosphonates can inhibit the mevalonate pathway (Amin D, 1992; 
Amin D, 1996) causing loss of prenylated proteins such as Ras. Luckman et al (Luckman 
SP et al., 1998) suggested that this mechanism may be responsible for apoptosis of 
macrophages after bisphosphonate treatment. This evidence raised the possibility that this 
pathway may also be targeted by bisphosphonates in osteoclasts. 
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Figure 1.7 Outline of the mevalonate pathway involved in the synthesis of cholesterol, 
famesyl diphosphate (FOP) and geranylgeranyl diphosphate (GGDP). FOP and GGDP act 
as substrates for the post-translation modification, or prenylation, of GTP-binding proteins 
such as Ras, Rho and Rac that are important in regulating cellular processes. Adapted from 
Russell and Rogers, 1999. 
The initial step in the pathway is the production of mevalonate, which is regulated by the 
rate limiting enzyme HMG-CoA reductase (Zhang FL, 1996). Mevalonate is converted 
via intermediate steps to isopentyl pyrophosphate (IPP) and dimethylallyl pyrophosphate, 
which are subsequently converted through geranyl pyrophosphate to famesyl 
pyrophosphate (FPP). FPP can be incorporated into a number of end products, including 
cholesterol (via squalene), ubiquinone and dolichol. FPP can also be metabolised to 
geranylgeranyl pyrophosphate (GGPP) by geranylgeranyl synthase. FPP and GGPP are 
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isoprenyl- pyrophosphate intermediates which are used for protein famesylation and 
geranylgeranylation respectively. 
During protein isoprenylation, the covalent transfer of either IS-carbon famesyl or 20-
carbon geranylgeranyl groups (from FPP and GGPP respectively) to conserved cysteine 
residues found at or near the carboxy terminus. This is a post-translational form of 
modification of the protein which is facilitated by famesyl transferase (FTase) and 
geranylgeranyl transferase (GGTase) respectively. 
The precise role of protein prenylation is still being investigated. However it is clear that 
this process may be important for the membrane localisation of certain proteins as the 
lipid prenyl group acts to anchor the protein in the cell membrane (Zhang FL, 1996). It 
has also been found to be important for protein-protein interactions (Marshall, 1993). 
Proteins which undergo prenylation include Ras, Rho and Rac (Gibbs JF, 1997; Zhang 
FL, 1996). These are small GTP binding proteins which regulate a variety of processes 
including cell proliferation, apoptosis, alterations in cytoskeletal organisation and 
membrane ruffling (Zhang FL, 1996). Interestingly, the inhibition of the activity of Rho 
results in disrupted actin ring formation and inhibited bone re sorption by osteoclasts in 
vitro. Hence the characteristic features of bisphosphonate-treated osteoclasts described 
earlier may occur as a result of inhibition of protein prenylation. 
The first evidence that bisphosphonates may inhibit the mevalonate pathway was 
provided by Amin et al in 1992, who found that bisphosphonates inhibited both squalene 
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synthase and cholesterol biosynthesis (Amin D, 1992). The potent bisphosphonates 
incadronate and ibandronate were also found to inhibit cholesterol biosynthesis in J774 
macrophages (Amin D, 1992). However, alendronate and pamidronate were less potent 
inhibitors of squalene synthase, but could still inhibit sterol biosynthesis in a cell-free 
system (Amin D, 1992) and therefore must inhibit enzymes of the mevalonate pathway 
other than squalene synthase. No inhibition of squalene synthase or cholesterol 
biosynthesis was found following treatment with etidronate or clodronate. These 
observations raised the possibility that the more potent nitrogen-containing 
bisphosphonates can inhibit not only squalene synthase but other enzymes of the 
mevalonate pathway also. As well as this, these data suggested that clodronate and 
etidronate had a different mechanism of action. Recent studies have confirmed that 
nitrogen-containing bisphosphonates inhibit enzymes of the mevalonate pathway with 
potencies corresponding to their anti-resorptive potencies, both in vitro and in vivo (Van 
Beek E, 1999b). In addition, van Beek et al have also demonstrated that the molecular 
target for nitrogen-containing bisphosphonates is the enzyme farnesyl pyrophosphate 
synthase (Van Beek E, 1999a). 
• Effects on protein tyrosine phosphatases 
Protein tyrosine phosphatases form part of the signalling cascades that are essential for 
regulation of osteoclast differentiation and signalling. Inhibition of these pathways may 
therefore interfere with osteoclast function and hamper osteoclastic bone resorption 
(Endo N, 1996). The enzymatic activity of osteoclast protein tyrosine phosphatases 
(PTPE) has been shown to be inhibited by alendronate. Both alendronate and known PTP 
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inhibitors inhibited osteoclast differentiation and bone resorption in vitro, suggesting that 
the inhibition of PTPs is one of the mechanisms whereby alendronate may inhibit bone 
resorption (Schmidt A, 1996; Skory K, 1997) although this may not be the predominant 
mechanism. 
• Inhibition o/Osteoc/ast It" ATPase 
The osteoclast proton ATPase pump, located in the ruffled border, is important in the 
acidification of the resorption cavity during bone resorption (Baron, 1989). There is 
evidence to suggest that bisphosphonates may have an inhibitory affect on the activity of 
this pump. David et al showed that tiludronate directly inhibited the activity of the proton 
H+ ATPase in vesicles derived from osteoclast plasma membranes (David P, 1996). 
Earlier studies by Carano et al suggested that the bisphosphonates etidronate, clodronate 
and pamidronate inhibited intracellular acidification by this pump by indirectly acting as 
metabolic inhibitors (Carano A, 1990). Zimolo et al similarly showed that etidronate and 
alendronate inhibit intracellular acidification, although this could be attributed to the 
prevention of insertion of H+ ATPase into the osteoclast membrane by the 
bisphosphonates (Zimolo Z, 1995). 
1.3.5 Clinical uses 
• Hypercalcaemia 0/ malignancy 
Hypercalcaemia is a common complication of malignancy and often occurs in the late 
stages of disease. Approximately 30-40% if patients with breast cancer and 20% of 
patients with lung cancer experience hypercalcaemia. The median survival of patients 
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with solid tumours is 1 or 2 months and 70-80% have died within 1 year if left untreated 
(Kanis J, 1994). Several factors may contribute to tumour-induced hypercalcaemia, 
including the release of humoral factors from tumours which stimulate excessive bone 
resorption, local tumour-induced bone re sorption and renal factors such as increased 
tubular reabsorption of calcium and impaired function of the glomeruli. Bisphosphonates, 
along with intravenous fluid replacement, have become the treatment of choice for 
hypercalcaemia of malignancy. Other treatments include calcitonin, phosphate and 
mithramycin (Ralston, 1992). 
Bisphosphonates have proved to be effective in the treatment of hypercalcaemia of 
malignancy and the efficacy appears to be related to the relative anti-resorptive potencies. 
The least potent bisphosphonate in anti-resorptive terms, etidronate, is useful in inducing 
normocalcaemia in hypercalcaemic patients but the time to maximal response is 7 days 
and the effects are short-lived (Ralston S, 1989). Purohit et at showed that intravenous 
treatment with clodronate 1500mg resulted in more rapid achievement of 
normocalcaemia (within 3 days) with a longer duration of action (14 days) than had 
previously been seen with etidronate (Purohit 0, 1995). A comparison between 
clodronate and pamidronate in this study, however, demonstrated the superiority of 
pamidronate over clodronate in the time to, and the duration of, normocalcaemia. All 
three of the agents discussed are licensed for the treatment of hypercalcaemia of 
malignancy. Other, bisphosphonates have also been investigated for this indication. 
Clinical studies with ibandronate (Ralston S, 1997) showed similar efficacy in 
hypercalcaemia of ~alignancy to that of pamidronate in earlier trials. Interestingly, two 
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large randomised trials comparing the potent third generation bisphosphonate zoledronic 
acid with pamidronate in patients with tumour-induced hypercalcaemia have shown that a 
single dose of 4mg or 8mg of zoledronic acid was significantly more effective in 
normalising serum calcium than 90mg ofpamidronate (Major P, 2001). The newer, more 
potent agents may well become more clinically important as their potency allows lower 
doses to be given and also for their administration as short intravenous infusions over 15 
minutes rather than 90 minutes or longer. 
• Multiple Myeloma 
There has been much clinical and laboratory research interest in the role of 
bisphosphonates in multiple myeloma. It is a plasma cell malignancy which is 
characterised clinically by the development of osteolytic bone lesions, renal 
insufficiency, anaemia and a compromised immune system. Increased osteoclast 
formation and activity is a key feature. The osteolytic bone disease remains a major cause 
of morbidity in these patients and bisphosphonates have played a large part in the 
management multiple myeloma. Of the oral bisphosphonates studied in this context, 
etidronate was found to be the least beneficial (Belch AR, 1991). In contrast, Lahtinen et 
al reported that patients with newly diagnosed, untreated myeloma bone disease receiving 
oral clodronate 2.4g/day for 24 months showed a reduction in the rates of radiological 
osteolytic progression and vertebral fracture compared with placebo (Lahtinen R, 1992). 
A more recent study conducted by the MRC compared 1.6g/day of clodronate alongside 
standard chemotherapy to placebo (McCloskey et al., 1998). This trial found a significant 
reduction in proporti~n of patients suffering new vertebral and non-vertebral fractures, as 
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well as a reduction in hypercalcaemia, bone pain and height loss. Interestingly, when the 
data was analysed retrospectively, a significant increase in survival was found in those 
patients who entered the trial without vertebral fractures and received clodronate. The 
question of the effects of bisphosphonates on survival in patients with multiple myeloma 
was addressed prospectively by Berenson et al (Berenson J et al., 1996; Berenson JR et 
al., 1998). This study randomised patients with Durie-Salmon stage III myeloma and at 
least one lytic lesion to receive either first-line chemotherapy or subsequent 
chemotherapy along with pamidronate 90mg or placebo. The proportions of patients 
experiencing SREs were significantly less in the bisphosphonate group than the placebo 
group. There was a significant improvement in pain and quality of life scores and the 
time to first skeletal event was significantly increased in the pamidronate group. 
Interestingly, median survival duration in the pamidronate group was 28 months vs 23 
months in the placebo group (not statistically significant). Both oral clodronate and 
intravenous pamidronate are now used as part of the standard care of patients with 
multiple myeloma and bone disease. 
• Bone metastases secondary to breast cancer 
In recent years bisphosphonates have become important in the management of cancer-
induced bone disease and are now well established in the management of patients with 
bone metastases secondary to breast cancer (Paterson AHO, 1993; Hortobagyi ON, 1996; 
Berenson J, 1996; McCloskey, 1998; Diel IJ, 1998; Theriault RL, 1999, Powles T, 2002). 
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Clinical studies have confirmed that bisphosphonate treatment can result in re-
calcification of lytic bone lesions secondary to breast cancer in a significant number of 
patients (Body n, 1995; Coleman RE, 1988b; Morton AR, 1988; Thiebaud D, 1991) and 
both oral and intravenous bisphosphonates have been investigated for their effects in the 
metastastic setting. 
Oral bisphosphonates have been in use for some time and the majority of data on their 
clinical benefits in breast cancer come from trials using either pamidronate or clodronate, 
although newer compounds are also emerging. In a large, unblinded study, Van Holten et 
al suggested that the daily use of oral pamidronate 600mg resulted in an approximately 
50% reduction in total skeletal complications initially (Van Holten-Verzantvoort A, 
1987) and 38% reduction on update of the data (van Holten-Verzantvoort AT et al., 
1993). There was also a significant reduction in the requirements for a change in 
systemic therapy or radiotherapy although no significant changes were seen in time to 
further skeletal events, survival or radiological appearance of the lesions. 300mg 
pamidronate dose was also investigated in this study but was not found to be of benefit, in 
contrast to 600mg pamidronate. The drawback, however, was that 600mg of pamidronate 
was poorly tolerated due to increased gastrointestinal side effects therefore this dose 
could not be maintained. More, recently, Coleman et al observed that both 150mg and 
300mg of oral pamidronate resulted in symptomatic improvement in 32% and 25% 
respectively of patients treated for metastatic breast cancer (Coleman RE, 1998). This 
was associated with a reduction in bone resorption and radiological stabilization or 
sclerosis of metastastic lesions. 
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A large, randomized, placebo controlled, double-blind trial has also been carried out with 
clodronate (Paterson AHG et al., 1993). Patients randomized to receive 1600mg 
clodronate daily experienced a significant reduction in skeletal complications, including 
incidence ofhypercaicaemia, rate of vertebral fracture and vertebral deformity. There was 
a trend towards a reduction in radiotherapy requirements for patients in the clodronate 
arm and the rate of skeletal events was significantly lower in the clodronate- treated 
group (219 skeletal events per 100 patient years) compared with placebo (305 skeletal 
events per 100 patient years) (p<O.OOl). Interestingly, there was no significant difference 
in survival between the two groups in this study. The issues of poor absorption and 
bioavailability of orally administered bisphosphonates, as well as patient compliance and 
gastrointestinal side effects, remain problematic. Recently, ibandronate, a potent 
nitrogen-containing bisphosphonate, has been shown to be well tolerated in oral 
formulation at doses that inhibit bone resorption (Coleman RE, 1999) and may prove to 
be a useful addition to the range of oral bisphosphonates available. 
Several studies have been conducted with intravenous bisphosphonates in the context of 
breast cancer metastatic to bone. Two studies addressed the role of intravenous 
pamidronate along with chemotherapy and compared this to chemotherapy alone (Conte. 
PF, 1996; Hultbom R, 1996). These studies used doses of 45mg 3 weekly and 60mg 3-4 
weekly, respectively. Both found a significant increase in the time to progression of bone 
metastases in the bisphosphonate arm. Two further randomized placebo-controlled 
studies were carried out in which pamidronate 90mg iv alongside systemic chemotherapy 
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or endocrine therapy was compared to systemic therapy plus placebo (Hortobagyi ON et 
al., 1996; Theriault RL et al., 1999). Hortobagyi et al found a delay of 13.1 months in 
first skeletal related event (SRE) in the pamidronate group compared to 7.0 months in the 
placebo group (Hortobagyi ON et al., 1996). They also found a reduction in the 
proportion of patients experiencing SREs in the bisphosphonate group (46%) compared 
with placebo (65%). There was no difference in overall survival. Theriault et al reported 
a similar reduction in the proportion of patients suffering SREs in the pamidronate-
treated group (56%) compared with placebo (67%). The timing of first SRE in patients 
receiving pamidronate was delayed (10.4 months) compared with the placebo group (6.9 
months) (Theriault RL et al., 1999). Patients receiving pamidronate experienced 
additional benefits in quality of life and improved analgesic control compared with the 
placebo groups. A recent study comparing the potent third generation bisphosphonate 
zoledronic acid (4mg or 8mg iv) with 90mg iv pamidronate in patients with lytic bone 
lesions due to breast cancer or multiple myeloma reported that zoledronic acid was 
equivalent to pamidronate in terms of skeletal related events and tolerability. Intravenous 
bisphosphonates now have an established role in the management of skeletal 
complications of breast cancer and multiple myeloma. 
• Adjuvant use of bisphosphonates in breast cancer 
Furthermore, in the adjuvant situation, studies with oral clodronate suggest that the use of 
bisphosphonates in combination with chemotherapy or endocrine therapy may delay first 
recurrence in bone (Diel 11, 1998). In addition, Diel et al have shown that treatment with 
oral clodronate may be associated with reduced rates of visceral metastases and improved 
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survival compared with those receiving standard anti-neoplastic therapy alone (Diel IJ, 
1998). Powles et al (Powles T, 2002) conducted a larger study of 1069 women with early 
breast cancer who were randomized to receive either clodronate 1600mg daily or placebo 
for 2 years. The incidence of bone metastases during the treatment period was 
significantly lower in the patients on clodronate treatment compared to those on placebo, 
although on longer follow-up this difference became non-significant statistically. 
Interestingly, there was a significant reduction in mortality in the clodronate group over 
the follow-up period. However, the role of bisphosphonates in the adjuvant setting 
remains to be clarified as Saarto et al reported an increase in the frequency of bone and 
visceral metastases with poorer survival in clodronate treated patients when compared 
with control (Saarto T, 2001). Large scale studies investigating the adjuvant use of both 
clodronate and the potent third generation bisphosphonate, zoledronic acid, are currently 
underway. 
1.4 ANTI-TUMOUR EFFECTS OF BISPHOSPHONATES 
Several studies have been done to investigate the anti-tumour effects of bisphosphonates 
in breast cancer. The clinical evidence for possible survival benefits in breast cancer and 
multiple myeloma has stimulated investigation into the direct effects of bisphosphonates 
on tumour cells, in addition to osteoclast effects. 
• In vitro 
Shipman et al have demonstrated that the nitrogen-containing bisphosphonates, 
-
Incadronate and pamidronate, could induce apoptosis of human multiple myeloma cells 
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in vitro, (Shipman CM, 1997) an effect that was mediated by inhibition of the mevalonate 
pathway (Shipman CM, 1998). This has recently been confirmed by Aparicio et al 
(Aparicio A et al., 1998). Pamidronate has very recently been shown to induce apoptosis 
in human melanoma cells (RiebeIing C, 2002) and inhibit growth in human osteosarcoma 
cells (Sonnemann J, 2001). Studies have also suggested that bisphosphonates can inhibit 
the adhesion and invasion of breast cancer cells to bone matrices (Van der Pluijm G, 
1996; Magnetto S, 1999; Boissier, 1997) and can enhance the ability of anti-neoplastic 
agents to inhibit breast cancer cell invasion (Magnetto S, 1999). 
• In vivo 
Although bisphosphonates have effects on osteoclasts, macrophages and tumour cells in 
vitro, the direct anti-tumour activity of these compounds in vivo remains uncertain. 
Interestingly, there have been several in vivo studies that suggest that anti-tumour effects 
may occur with bisphosphonate treatment. Wingen et al observed a reduction in tumour 
growth in bone in a rat model of mammary carcinoma after treatment with pamidronate 
(Wingen F, 1988). Furthermore, when pamidronate was combined with melphalan, a 
chemotherapeutic agent, there was a greater reduction in tumour burden than with either 
agent alone. Studies with risedronate in a murine model of osteolytic bone disease show a 
selective reduction in the burden of MDA-MB-231 breast carcinoma cells in bone after 
bisphosphonate treatment (Sasaki A, 1995). Interestingly, the animals treated with 
risedronate had a significant improvement in survival compared with control animals. 
However, these effects were attributed to indirect effects on tumour cells due to inhibition 
of bone resorption as no inhibition of tumour cell proliferation was observed with 
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risedronate treatment in vitro. Subsequent studies with a potent third generation 
bisphosphonate YH529 in the same in vivo model showed that treatment resulted in fewer 
new bone and non-osseous metastases and inhibition of progression of established bone 
lesions (Sasaki A, 1998). Similar effects, inhibition of new bone metastases and slowed 
progression of established lesions, have been observed with ibandronate in vivo and the 
effects were enhanced when ibandronate was combined with tissue inhibitor of matrix 
metalloproteinase-2 (TIMP-2) (Yoneda T, 1997). 
1.5 AIMS OF THIS WORK 
It has long been recognized that bisphosphonates inhibit osteoclast activity and 
osteoclast-mediated bone resorption. However, the demonstration that these compounds 
can induce apoptosis in cells other than osteoclasts, and that the treatment of breast 
cancer patients with bisphosphonates may improve survival, raises the intriguing 
possibility that bisphosphonates may have direct anti-tumour effects in breast cancer 
cells. The aims of the work presented in this thesis are described below: 
• The first aim of this work was to determine whether the third generation 
bisphosphonate zoledronic acid had a direct anti-tumour effect on breast cancer 
cells in vitro. 
• Since bisphosphonates are often used in conjunction with anti-neoplastic agents in 
the clinical setting, and may influence patient survival, the second aim was to 
investigate zoledronic acid had additive or synergistic effects with anti-neoplastic 
agents, such a~ paclitaxel, at clinically relevant concentrations. 
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• The third aim was to relate these data to the in vivo situation and investigate 
whether intravenous bisphosphonate treatment in patients with breast cancer and 
bone metastases resulted in anti-tumour effects in vivo. 
• It is possible that by inhibiting bone resorption, bisphosphonates prevent the 
release of local factors from osteoclasts and bone which could affect the behavior 
of tumour cells. Therefore, our final aim was to determine the in vivo effects of 
intravenous bisphosphonate treatment, in the same group of patients, on cytokines 
and growth factors present in the local bone marrow environment. 
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2.1 CHEMICALS 
2.1.1 Zoledronic Acid 
Zoledronic acid 1- Hydroxy-2-[(1 H-imidazol-l-yl) ethylidene] bisphosphonic acid 
monohydrate was supplied as the hydrated disodium salt by Novartis Pharma AG (Basel, 
Switzerland) (Green JR, 1994). A stock solution was prepared in phosphate buffered 
saline (PBS) (PH7.4) and filter-sterilised using a 0.22-IlM filter (Gelman Sciences, 
Northampton, UK). 
2.1.2 Mevalonate Pathway Reagents 
Famesol (FOH) (mixed isomers) and geranylgeraniol (GGOH) were purchased from 
Sigma Chemical Co. (Poole, UK) and American Radiolabeled Chemicals Inc. (St Louis, 
MO), respectively. Stock solutions were prepared in 100% ethanol. 
All other chemicals, unless otherwise stated, were obtained from Sigma Chemical Co. 
2.2 CELL CULTURE 
2.2.1 Phosphate-buffered saline and tissue culture media 
Cells were cultured in single strength RPMI 1640 media purchased from Life 
Technologies (Paisley, UK). 10x concentrate of phosphate-buffered saline (PBS) from 
Life Technologies (Paisley, UK) was diluted with dd.H20 to prepare single strength 
solutions under sterile conditions. 
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2.2.2 Foetal Calf Serum 
Foetal calf serum (FCS) was purchased from Life Technologies (Paisley, UK) and was 
heat inactivated by placing in a water bath at 56°C for at least 30 minutes. Every new 
batch ofFCS was routinely tested to ensure that cell growth was adequately supported 
and that there were no alterations in cell behaviour. 
2.2.3 Human breast carcinoma cell lines 
The human breast carcinoma cell line MCF-7 was obtained from the European Collection 
of Animal Cell Cultures (Salisbury, UK). Professor R. Nicholson (University of Cardiff, 
Wales, UK) kindly provided the MDA-MB-231 human breast carcinoma cell line. The 
MCF-7 cell line was derived from the pleural effusion of a patient with metastatic breast 
carcinoma (Soule HD et al., 1973) as was the MDA-MB-231 cell line (Cailleau R et al., 
1974). 
Cells were cultured in RPMI 1640 (Life Technologies, Paisley, UK) supplemented with 
10% FCS, ImM glutamine, ImM sodium pyruvate and Ix MEM nonessential amino 
acids (Life Technologies) (tissue culture media). They were maintained at 37°C in a 
humidified atmosphere of 95% air and 5% CO2• Cells were harvested using trypsin!. 
ETDA 0.5%/ 0.2% (Life Technologies) and passaged twice a week. 
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2.3 DETERMINATION OF CELL NUMBER 
2.3.1 Haemocytometer. 
The haemocytometer (Improved Neubauer) was used to determine cell number and 
density by counting the number of cells in a chamber of known depth. The coverslip was 
adhered to the haemocytometer, signified by the appearance of "Newtons Rings". Breast 
cancer cells were harvested and resuspended in a known volume of fresh tissue culture 
media. 7.5~1 was taken from this cell suspension and introduced into the haemocytometer 
chamber. The number of cells in four Imm areas was determined and the mean of this 
value was taken. This signified the cell number x 104/ml and was used to calculate initial 
cell densities for each experiment. 
2.4 ANALYSIS OF NUCLEAR MORPHOLOGY 
2.4.1 Introduction 
Programmed cell death or apoptosis is a phenomenon that can be readily distinguished 
from other forms of cell death due the characteristic nuclear morphology displayed. In the 
initial stages condensation of the nuclear chromatin occurs to form distinct granular 
masses against the nuclear membrane (Kerr JFR, 1994; Wyllie R, 1980). During this 
stage, condensation of the cytoplasm can also be seen along with convolution of the cell 
and nuclear membrane. In solid tissues, separation of the apoptotic cells from the adjacent 
healthy cells now occurs. Once the nuclear and cell membranes have become convoluted, 
the nucleus breaks up into discrete fragments consisting either entirely of condensed 
chromatin or of chromatin forming crescent shapes around the nuclear periphery. 
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Membrane-bound apoptotic bodies are also formed by budding of the cell. Apoptosis 
primarily affects single cells whereas necrosis characteristically affects groups of cells, 
resulting in inflammation of the adjacent viable tissue. Necrosis is associated with 
irregular clumping of chromatin, swelling of the nucleus and organelles such as 
mitochondria and swelling of the cytoplasm, which results in rupture of both the plasma 
and organelle membranes (Wyllie R, 1980). Apoptotic cells are therefore clearly 
identifiable on the basis of changes in nuclear morphology, and can easily be 
distinguished from both normal and necrotic cells. 
2.4.2 Method of analysis of nuclear morphology 
Breast cancer cells were cultured in the presence or absence of zoledronic acid and also in 
the presence or absence of paclitaxel for up to 96 hours. After harvesting, the cells were 
fixed in 4% (v/v) formaldehyde in PBS for 10 minutes at room temperature and cytospun 
onto glass slides using a Shandon cytospin 3 at 500rpm for 5 minutes. These were then 
stained with 2J..lg/ml 4' -6-diamidino-2-phenyl-indole (DAPI) 4' -6-diamidino-2-phenyl-
indole (DAPI) in PBS and mounted in Citifluor (Agar Scientific, Stanstead, UK). To 
prevent evaporation the coverslip edges were sealed with nail varnish and the cell were 
examined with either a 40x objective or a 100x objective (oil immersion) using a DMRB 
fluorescence microscope (Leica) with a Photometrics CCD camera and SmartCapturerR 
image analysis system (Vysis (UK) Ltd, Richmond, UK). 
Apoptotic cells were identified on the basis of characteristic changes in nuclear 
morphology (Wyllie R, 1980). 5 random fields were counted per slide (four replicates per 
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treatment unless otherwise stated) and the percentage of apoptotic cells was calculated. 
Each experiment, unless otherwise stated, was performed on a minimum of two separate 
occaSIOns. 
2.5 DETECTION OF DNA FRAGMENTATION. 
2.5.1 In situ nick translation assay. 
Apoptotic cells were also identified by using an in situ fluorescence nick translation 
assay, which detects DNA strand breaks in apoptotic nuclei. Intemucleosomal DNA 
fragmentation is thought to arise due to activation of endogenous endonuclease and is 
characteristic of apoptosis (Arends MJ et al., 1990). The in situ nick translation assay 
detects endonuclease-mediated DNA strand breaks by the addition of dATP, dCTP, 
dGTP and biotinylated dUTP to free 3' hydroxyl ends of the DNA strands (Gorczyca W, 
1993). This reaction is catalysed by DNA polymerase. The biotinylated dUTP is then 
detected by R-phycoerythrin (R-PE), directly conjugated to streptavidin, which binds to 
biotin. The level of R-PE incorporation in the cells is measured by flow cytometry. This 
technique has been shown to detect cells that also demonstrate the characteristic nuclear 
morphology of apoptosis (Rogers, 1996; Shipman CM, 1997). 
Flow cytometry is a technique where the cells are passed as a single cell suspension 
through a sensing point allowing measurements to be made on each individual cell rather 
than the population as a whole. The cells are excited by a light source, usually a laser, and 
the cells can be labeled with single or multiple fluorescent probes that are excited by a 
given wavelength of light. When excited, different fluorescent probes will emit light 
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(fluoresce) at different wavelengths, enabling several parameters to be measured. The 
scattered and fluorescent light emitted by cells following excitation is collected by 
photo detectors and converted into electronic signals that enable graphical and statistical 
analysis. The in situ nick translation assay involves the incorporation of R-PE-Iabeled 
dUTP into DNA strand breaks in apoptotic cells. R-PE is excited at 495nm-564nm of 
light and emits light at approximately 576nm. The levels of R-PE fluorescence act as a 
measure of apoptosis, with apoptotic cells having higher levels ofR-PE fluorescence than 
non-apoptotic cells (figure 2.1). 
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Figure 2.1 The in situ nick translation assay allows the detection of apoptotic breast 
cancer cells. MCF-7 cells were treated with vehicle control (A) and lOOIlM zoledronic . 
acid (B). Healthy cells appear in the control as a peak below the first log decade (A). A 
small additional peak of apoptotic cells appears between the first and second log decades 
after treatment with zoledronic acid (B). 
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Cells were harvested following bisphosphonate treatment, washed once with sterile PBS, 
and then fixed in 4% formaldehyde in PBS for 15 minutes on ice. Cells were then washed 
again in PBS, re suspended in 0.5ml ice-cold ethanol and stored at -20°C until analysis. 
To label DNA strand breaks in apoptotic cells, the cells were again washed in PBS and 
incubated at room temperature with a buffer containing 50mM tris, 2.5 mM magnesium 
chloride, 10)lglml bovine serum albumen, 10 mM /3-mercaptoethanol, O.2nM of 
unlabeled dATP, dGTP and dCTP and O.2nM biotin-16-dUTP in the presence of 1 unit 
DNA polymerase for 4 hours with intermittent gentle agitation (Gorczyca W, 1993) 
(Rogers MJ, 1996b). The cells were then washed in sterile PBS and incubated with a 
second buffer containing 4x saline-sodium citrate buffer (SSC), 0.1 % Triton-X 100, 5% 
(w/v) fat free powdered milk and 1% (v/v) R-phycoerythrin (R-PE) - conjugated 
streptavidin (DAKO) for 30 minutes at room temperature in the dark. After washing with 
PBS, cells were resuspended in 300)l1 of PBS and analysed on a Becton Dickinson 
FACSort using the FL2 detector with a 585nm bandpass filter (42nm bandwidth). 3,000 
events were counted for each sample run and the proportion of cells positively labelled 
with R-PE was determined. This proportion represented the proportion of cells with DNA 
fragmentation. All experiments were repeated on a minimum of two occasions. 
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2.6 PRIMARY CELLS 
2.6.1 Isolation of primary cells from the bone marrow by erythrocyte lysis. 
The erythrocyte lysis method makes use of a buffer containing 10mM potassium 
bicarbonate, O.I55M ammonium chloride and O.ImM ethylenediamine tetraacetic acid 
(EDT A) in distilled water to lyse red cells whilst preserving the mononuclear cells 
present in a peripheral blood or bone marrow sample. 1.25ml blood or bone marrow in 
EDTA was centrifuged at 300g (I200rpm, 5min) and the plasma removed carefully with 
a Pasteur pipette (leaving buffy layer). The pellet of cells was resuspended in 4.5mllysis 
buffer in a 15ml polypropylene tube (Coming, High Wycombe, UK) and incubated at 
room temperature for 10 minutes (spinning tubes using a blood rotator whilst incubating). 
The sample was then mixed with 20ml RPMI tissue culture media, overlaid onto IOml 
5% (w/v) albumin solution in RPMI, and centrifuged at 300g for IOminutes without 
braking. The pellet was washed twice in media and resuspended in Iml sterile PBS to 
allow determination of cell number using the haemocytometer as previously described. 
2.6.2 Fixation and permeabilisation 
Following erythrocyte lysis as described above, the cells were fixed in 1% (v/v) 
formaldehyde for 15 minutes on ice and stored in 70% (v/v) ethanol at -20°C until later 
flow cytometry analysis. 
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2.7 STATISICAL ANALYSIS 
Results were expressed as the mean ± SEM. The relationship between the concentration 
of zoledronic acid, time of incubation with zoledronic acid, and effects on cell number 
and apoptosis were analysed using the non-parametric Kruskal-Wallis Analysis by Rank 
test. Experiments using the in situ nick translation assay were performed with a single 
sample per treatment. These data were therefore not analysed for statistical significance. 
All other data were analysed using non-parametric Mann Whitney U test unless otherwise 
specified. All experiments were repeated on at least two separate occasions. 
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3.1 SUMMARY 
Bisphosphonates are well established in the management of breast-cancer induced bone 
disease. Recent studies have suggested that these compounds are effective in preventing 
the development of bone metastases. However, it is unclear whether this reflects an 
indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The aim 
of the work presented in this chapter was to investigate whether bisphosphonates have 
direct effects on breast cancer cells in vitro by investigating the effects of the potent 
bisphosphonate zoledronic acid on cell number and apoptosis in human breast carcinoma 
cell lines. 
Zoledronic acid caused a dose- and time-dependent decrease in cell number and a 
concomitant increase in tumour cell apoptosis in MCF-7 and MDA-MB-231 human 
breast carcinoma cells. Short-term exposure to zoledronic acid was sufficient to cause a 
significant reduction in cell number and an increase in apoptosis in MCF-7 cells. These 
effects could be prevented by incubation with geranylgeraniol, suggesting that zoledronic 
acid-induced apoptosis is mediated by inhibiting enzymes of the mevalonate pathway. 
The data presented here demonstrate that, in addition to inhibiting bone resorption, 
zoledronic acid can induce breast cancer cell apoptosis in vitro, indicating that further 
investigation into the direct effects of bisphosphonates on tumour cells in vivo is 
warranted. 
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3.2 INTRODUCTION 
Bisphosphonates are now well established in the management of patients with multiple 
myeloma and bone metastases secondary to breast cancer and have been shown to reduce 
skeletal morbidity and improve quality oflife (Berenson J et al., 1996; Diel IJ et al., 
1998; Hortobagyi GN et al., 1996) McCloskey, 1998, Paterson AHG et al., 1993; 
Theriault RL et al., 1999). In addition, there is evidence that treatment of primary breast 
cancer patients with oral clodronate alongside chemotherapy and hormonal therapy may 
delay first skeletal recurrence (Diel IJ et al., 1998, Powles et aI, 2002). Furthermore, Diel 
et al suggested that adjuvant clodronate treatment might also confer a survival benefit 
when compared with standard anti-neoplastic therapy alone. Interestingly, another similar 
study with oral clodronate did not reveal any benefit on skeletal or extra-skeletal disease, 
(Saarto T et al., 2001) indicating that the role ofbisphosphonates in the adjuvant setting 
remains to be clarified. 
The mechanisms by which bisphosphonates elicit their anti-resorptive activity are only 
now becoming clear. Recent data suggest that bisphosphonates may have different 
mechanisms of action depending on their structure. Bisphosphonates that are similar to 
pyrophosphate in structure, such as clodronate and etidronate, are metabolised to 
cytotoxic analogues of ATP which, in turn, are responsible for inhibiting osteoclast 
activity (Frith JC et al., 1997). However nitrogen-containing bisphosphonates induce 
apoptosis in osteoclasts and other cells, such as macrophages and myeloma cells, by 
interfering with the mevalonate pathway (Hughes DE et al., 1995; Luckman SP et al., 
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1998; Shipman CM et al., 1998). Bisphosphonates have also been shown to have other, 
more subtle, effects on tumour cells in particular. In some studies, bisphosphonate 
treatment has resulted in the inhibition of breast cancer cell adhesion to substrates (Van 
der Pluijm G, 1996; Boissier, 1997; Magnetto S, 1999) and subsequent invasion (Boissier 
S, 2000). Thus, the demonstration that these compounds can induce apoptosis in cells 
other than osteoclasts, and that the treatment of patients with bisphosphonates may 
improve survival, raises the intriguing possibility that bisphosphonates may also have 
direct anti-tumour effects in breast cancer cells. The aim of the work presented in this 
chapter was to determine whether the third generation bisphosphonate zoledronic acid has 
direct effects on human breast carcinoma cells in vitro. 
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3.3 METHODS 
3.3.1 Chemicals 
Chemicals were obtained and prepared as described in Chapter 2, Material and Methods. 
3.3.2 Measurement of cell number. 
MCF-7 and MDA-MB-231 breast cancer cells were plated at a density of 5xl 04 cells/ml 
in 24-well plates in replicates of four wells per treatment and allowed to adhere and 
proliferate for 72 hours. Cells were then incubated with fresh media containing increasing 
concentrations of zoledronic acid (0.1-1001lM) for 72 hours. In some studies, MCF-7 
cells were seeded as described above and incubated with lOOIlM zoledronic acid for 24, 
48, 72 and 96 hours. MCF-7 cells were also incubated with 100llM EDTA for 72 hours to 
determine the effects of calcium chelation on cell number. In some experiments, MCF-7 
cells were treated with lOOIlM zoledronic acid in the presence or absence of lOOIlM 
mevalonate, 50llM famesol or 50llM geranylgeraniol, for 72 hours, in order to determine 
the effects of intermediates of the mevalonate pathway on zoledronic acid-induced 
apoptosis. To assess the effects of acute exposure to zoledronic acid, MCF-7 cells were 
prepared as described above and incubated with or without zoledronic acid for 2, 6, or 24 
hours. The media was then replaced with fresh media without zoledronic acid and the 
cells incubated for a total of 72 hours. In each experiment, following incubation, cells 
were harvested, suspended in PBS and cell number determined using a haemocytometer 
(Improved Neubauer) (Materials and Methods). 
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3.3.3 Identification of apoptotic cells by examination of nuclear morphology. 
MCF-7 and MDA-MB-231 breast cancer cells were cultured as described above for 
assessment of nuclear morphology with four replicates per treatment. Cells were 
incubated with zoledronic acid or vehicle as above. Both cells that were still adherent and 
those in the supernatant were then harvested, fixed with 4% formaldehyde (v/v) in PBS 
and cytospun onto glass slides. Following bisphosphonate treatment, cells were stained 
with DAPI as described in Materials and Methods. 
3.3.4 Identification of apoptotic cells by the in situ nick translation assay. 
MCF-7 and MDA-MB-231 breast cancer cells were seeded at Ix 105 cells/ml in 6-well 
plates, allowed to adhere and proliferate for 72 hours and then treated as described in the 
previous section. Cells were harvested, washed in sterile PBS, fixed in 4% formaldehyde 
for 15 minutes on ice and permeablised by incubation with 100% ethanol overnight. This 
was followed by analysis of DNA fragmentation by fluorescence in situ nick translation 
assay as described in the Materials and Methods, section 2.5.1. 
3.3.5 Statistical analysis 
Stastistical analysis was carried out as described in the Materials and Methods section. 
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3.4 RESULTS 
3.4.1 Zoledronic acid causes a reduction in breast cancer cell number. 
Treatment of MCF-7 breast cancer cells with increasing concentrations ofzoledronic acid 
for 72 hours caused a dose-dependant decrease in cell number (Figure 3.1A) (p<0.001). 
0.1-1IlM zoledronic acid had little effect on the number of MCF-7 cells. In contrast, 
zoledronic acid at 10 and 100llM caused a significant reduction in the proportions of 
MCF-7 cells (49.54 ± 5.43% and 23.55 ± 5.43% of control, respectively) (p<0.05). 
Zoledronic acid had little effect on MDA-MB-231 cells at concentrations of 0.1-10IlM, 
whereas the 100llM concentration resulted in a significant reduction in cell number 
(25.33 ± 6.0% of control) (p<0.05). Treatment of breast cancer cells with lOOIlM 
zoledronic acid for increasing periods of time resulted in a 63.5% reduction in MCF-7 
cell number at 72 hours (6.8± 5.3 x 104 vs18.6± 3.2 x 104) and an 87.1% reduction at 96 
hours (3.81± 1.9 x 104 Vs 29.6 ± 4.5 x 104) (p<0.05 in each case) (Figure 3.1B). 
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Figure 3.1. Effect of (A) increasing concentrations ofzoledronic acid (O.l-lOOIlM) on MCF-7 
and MDA-MB-231 cell number after incubation for 72 hours and (B) increasing time of 
incubation of MCF-7 cells (24-96 hours) with lOOIlM zoledronic acid. Results are expressed as 
percent of control or absolute cell numbers. Data are the mean and SEM (n=4). * p<0.05 
compared with control. 
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Incubation of MCF-7 cells with 100~M EDTA resulted in a small but significant 
reduction in cell number when compared with control (16.08 X 104 ± 4.2 vs. 24.S2 X 104 ± 
4.3). However, treatment with zoledronic acid caused a greater reduction in cell number 
(7.00 xl 04 ± 1.S vs. 24.S2 xl 04 ± 4.3) and this was significantly lower than that caused by 
EDTA (p<O.OS when zoledronic acid was compared to EDTA) (Table 3.1). 
Table 3.1. Comparison of the effect ofzoledronic acid and EDTA on MCF-7 cell number 
and apoptosis 
Treatmenta Cell Number (x 104l 
Control 24.S2 ± 4.3 
EDTA (lOO~M) 16.08 ± 4.2* 
Zoledronic acid (100~M) 7.00 ± 1.S*t 
Apoptosis (%) 
1.09 ± O.S 
1.30 ± O.S 
8.60 ± 1.2* 
a Cells were incubated with control, zoledronic acid or EDT A for a total of 72 hours. 
b Results are expressed as mean ± SEM (n=4). 
* p<O.OS compared with control. t p<O.OS compared with EDT A. 
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3.4.2 Zoledronic acid induces apoptosis of breast cancer cells. 
Treatment of MCF-7 and MDA-MB-231 cells with zoledronic acid caused an increase in 
the proportion of cells with nuclear morphology characteristic of apoptosis. These 
characteristics included nuclear fragmentation, chromatin condensation and the formation 
of dense, rounded apoptotic bodies (Figure 3.2). Treatment of cells with increasing 
concentrations of zoledronic acid (0.1-100flM) resulted in a dose-dependant increase in 
the proportion of cells undergoing apoptosis (p<0.005). Concentrations of 0.1 and IflM 
zoledronic acid had little effect on MCF-7 cell apoptosis. In contrast, treatment with 
lOflM zoledronic acid resulted in a greater than four-fold increase in MCF-7 cell 
apoptosis (431.26 ± 32.21 % of control) whereas the IOOflM concentration induced a six-
fold increase in the proportion of apoptotic cells (652.54 ± 71.49% of control) (Figure 
3.3A). Treatment of MDA-MB-23 1 cells with concentrations ofO.lflM, IflM and lOflM 
bisphosphonate had little effect on apoptosis. However, MDA-MB-231 cells showed a 
fifteen-fold increase in apoptosis (1515.24 ± 139.33% of control) after treatment with 
100flM zoledronic acid (p<0.05). Treatment of MCF-7 cells with 100flM zoledronic acid 
for 24-96 hours caused a significant time-dependant increase in apoptosis (p<0.005) 
(figure 3.3B). In contrast, treatment of cells with IOOflM EDT A had no effect on tumour 
cell apoptosis when compared to control (1.3 ± 0.5% vs. 1.09 ± 0.5% respectively) 
(Table3.1 ). 
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A 
B 
Figure 3.2.Effect of zoledronic acid on apoptosis of MCF-7 and MDA-MB-23I breast cancer 
cells. Fluorescence micrographs of MCF-7 cells incubated with (A) vehicle control and (B) 
100J..lM zoledronic acid for 72 hours demonstrating characteristic changes in nuclear 
morphological. Cells were cytospun, stained with 4' -6-diamidino-2-phenyl-indole (DAPI) and 
examined with a x I 00 oil immersion objective. Apoptotic nuclei are identified with an 
asterisk. 
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Figure 3.3. The effect of increasing concentrations of zoledronic acid (0.1-100JlM) on MCF-7 and 
MDA-MB-231 cell apoptosis after 72 hours treatment with 100llM zoledronic acid (A). The effect 
of increasing time of incubation (24-96 hours) with 100JlM zoledronic acid on MCF-7 apoptosis 
(B). Results are expressed as percent of the appropriate control or as absolute percentages. Data are 
the mean ± SE (n=4). * p<0.05 compared with control. 
80 
Chapter 3 Zoledronic acid induces apoptosis in breast cancer cells 
The induction ofapoptosis in MCF-7 and MDA-MB-231 cells by zoledronic acid was 
confirmed using a fluorescence in situ nick translation assay. Treatment of MCF-7 cells 
with a range ofzoledronic acid concentrations had little effect on apoptosis at 0.1 and 
1.0IlM, however, an increase in the proportion of apoptotic cells was observed with 
10IlM and IOOIlM zoledronic acid compared with control (28.7% and 70.7% vs. 22.57%, 
respectively). Treatment ofMDA-MB-231 cells with 0.1-1IlM zoledronic acid did not 
cause an increase in apoptosis although treatment with the 10 and IOOIlM zoledronic acid 
resulted in an increase in the proportions of apoptotic cells (126.6% and 126.6% of 
control) (Table 3.2). A time-dependant increase in MCF7 cell apoptosis was confirmed 
when cells were incubated with lOOIlM zoledronic acid for 24-96 hours (Table 3.3). 
Table 3.2. The effects of increasing concentrations of zoledronic acid on MCF-7 and 
MDA-MB-231 cell apoptosis (in situ nick translation assay) 
Zoledronic acid (IlM)a 
Control 
0.1 
1.0 
10.0 
100.0 
Apoptosis b (% of control) 
MDA-MB-231 
100 
98.98 
82.53 
126.63 
126.63 
MCF-7 
100 
96.89 
115.06 
127.02 
314.26 
a Cells were incubated with control and zoledronic acid for a total of72 hours. 
b Apoptosis was assessed by in situ nick translation assay and results expressed as percent 
of control. 
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Table 3.3. The effects of IOOIlM zoledronic acid on MCF-7 cell apoptosis after 24,48, 
72 and 96 hours of incubation (in situ nick translation assay) 
Time (hours) 
24 
48 
72 
96 
Zoledronic acid (% of 
controlt 
120.9 
126.8 
215.8 
226.9 
a Apoptosis was assessed by the in situ nick translation assay and results were expressed 
as percent of control. 
3.4.3 Induction of apoptosis of breast cancer cells by zoledronic acid occurs via 
inhibition of enzymes of the mevalonate pathway. 
The effects of the addition of intermediates of the mevalonate pathway on zoledronic 
acid-induced MCF-7 cell number and apoptosis were determined. MCF-7 cell number 
was reduced compared with control on treatment with IOOIlM zoledronic acid (28.09 ± 
2.1 % of control) (figure 3.4). This was not affected greatly after addition of 100llM 
mevalonate (24.24% of control) or 50llM famesol (19.21 ± 1.98% of control). However, 
the addition of 50llM geranylgerniol significantly protected against the effect of 
zoledronic acid on cell number (51.94 ± 5.57% of control) (p<0.05). 
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Figure 3.4. Effect of intermediates ofthe mevalonate pathway on zoledronic acid-induced 
reduction in breast cancer cell number. MCF7 cells were treated with 1 OO~M zoledronic 
acid in the presence or absence of 1 OO~M mevalonate (MV A), 50~M famesol (FOH) and 
50~M geranyl geraniol (GGOH) for 72 hours. Cells were then harvested, resuspended in 
PBS, and the cell number determined using a haemocytometer. Results are expressed as 
percent of control. Data are mean ± SEM (n=4). * p<0.05 when compared with zoledronic 
acid. 
Analysis of nuclear morphology demonstrated that treatment of MCF-7 cells with 100~M 
zoledronic acid resulted in a significant increase in apoptosis (18.68 ± 2.5%) compared 
with control (0.26 ± 0.1 %). The addition of 50~M famesol resulted in a partial inhibition 
of apoptosis (14.31 ± 0.3%), whereas the addition of 50~M geranylgeraniol inhibited 
apoptosis to levels close to control (2.27 ± 0.2%) (p<0.05 compared to zoledronic acid 
100J-lM) (figure 3.5A). These effects were confirmed using the in situ nick translation 
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assay (figure 3.5B). Treatment of MCF-7 cells with 100/lM zoledronic acid resulted in a 
significant increase in apoptosis compared to control (60.57% and 16.6% apoptosis, 
respectively). The addition of 100/lM mevalonate or 50/lM farnesol to zoledronic acid 
had little effect on zoledronic acid-induced apoptosis (54.83% and 49.17% respectively). 
In contrast, the addition of 50/lM geranylgeraniol inhibited zoledronic acid-induced 
apoptosis to levels below that of control (12.11%). 
84 
Chapter 3 Zoledronic acid induces apoptosis in breast cancer cells 
A 25 
Ct! +MV A +FOH +GGOH 
~ Zoledronic acid 100~ -I 
Ct! +MV A +FOH +GGOH 
~ Zoledronic acid 1 OO~ -/ 
Figure 3.5. Effect of intermediates of the mevalonate pathway on zoledronic acid-induced breast 
cancer cell apoptosis. MCF7 cells were treated with lOOIlM zoledronic acid in the presence or 
absence of lOOIlM mevalonate (MV A), 50llM famesol (FOH) and 50llM geranyl geraniol (GGOH) 
for 72 hours. Apoptosis was determined by analysis of nuclear morphology after staining cells with 
DAPI (A) and by the in situ nick translation assay (B). Results are expressed as absolute percentages. 
Data for nuclear morphology experiments are mean ± SEM (n=4). * p<O.05 when compared with 
zoledronic acid. 
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3.4.4 Acute exposure to zoledronic acid causes a reduction in breast cancer cell 
number and an increase in apoptosis. 
Zoledronic acid inhibits breast cancer cell proliferation and induces apoptosis in vitro in a 
dose- and time-dependent fashion. However in vivo, breast cancer cells are probably 
exposed to micromolar concentrations of bisphosphonates for only a few hours. 
Therefore, in order to look at conditions that may more accurately reflect the situation in 
vivo, we examined the effects of acute exposure to 100JlM zoledronic acid on MCF-7 cell 
number and apoptosis (figure 3.4). Two hours of exposure to zoledronic acid resulted in 
reduction in cell number to 77.1 ± 19% of control (p<O.OS). This was associated with an 
increase in the proportions of apoptotic cells from 1.23 ± O.S% in the control samples to 
8.0S ± 0.6% in zoledronic acid-treated cells (p<O.OS). Six and twenty-four hours of 
exposure resulted in a reduction in cell number of 44.7S ± 7.9% and 30.04 ± 9.8% of 
control, respectively (p<O.OS). The proportions of apoptotic cells at the six and twenty-
four hour time points were similar to that at two hours (8.24 ± 0.7% and 8.24 ± 1.1% 
respectively) (p<O.OS) indicating that acute exposure to zoledronic acid results in 
significant induction of apoptosis. The induction of apoptosis by zoledronic acid at 2, 6, 
and 24 hours was confirmed using the in situ nick translation assay. Two hours of 
exposure to 100flM zoledronic acid showed an increase in apoptosis of 236.03% of 
control. This proportion increased to 289.1S% after 6 hours of exposure and 643.62% 
after 24 hours (values expressed as percent of appropriate controls). 
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Figure 3.4. Effect of short-term exposure ofMCF-7 cells to IOOflM zoledronic acid. MCF-7 cells 
were incubated with zoledronic acid for 2, 6, 24, and 72 hours. The media was then replaced and 
the cells were maintained for a total of 72 hours. The effects on cell number (n=4) and apoptosis as 
assessed by in situ nick translation assay (NT) and changes in nuclear morphology (DAPI, n=4) 
are shown. Results are expressed as percent of control and are the mean ± SE. * p< 0.05 compared 
with control. 
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3.5 DISCUSSION 
In the present study we have shown that zoledronic acid has a dose- and time-dependant 
effect on breast cancer cell number in vitro. These observations are consistent with 
previous studies that have demonstrated that bisphosphonates cause a significant 
reduction in osteoclast number (Hughes DE, 1995; Fisher lE, 1999). Importantly, studies 
in human myeloma cells have shown that nitrogen-containing bisphosphonates, including 
zoledronic acid, also inhibit cell proliferation (Shipman CM, 1997; Shipman CM, 1998; 
Aparicio A, 1998; Derenne S, 1999). The effects ofzoledronic acid on MCF-7 and MDA-
MB-231 cell number were associated with concomitant dose- and time-dependant 
changes in nuclear morphology that were characteristic of apoptosis (Wyllie, 1980). 
These effects on tumour cell apoptosis are consistent with previous reports that have 
demonstrated the induction of apoptosis, in macrophages, osteoclasts and myeloma cells, 
by bisphosphonates such as pamidronate, alendronate, incadronate, and zoledronic acid 
(Hughes DE, 1995; Rogers, 1996; Shipman CM, 1997; Shipman CM, 1998; Aparicio A, 
1998; Fisher lE, 1999). Similarly, Senaratne et al have recently reported that a panel of 
bisphosphonates, including zoledronic acid, induces caspase activity and apoptosis in 
human breast cancer cells in vitro (Senaratne sa, 2000). The fluorescence in situ nick 
translation technique has been shown to detect cells that also demonstrate the 
characteristic nuclear morphology of apoptosis (Rogers, 1996; Shipman CM, 1997). 
Although there were differences between the levels of apoptosis detected by the two 
different techniques, the relative changes induced by bisphosphonate treatment were 
similar. The reasons for the discrepancy between methods are unclear but may reflect the 
conservative assessment of nuclear morphology as only cells displaying definitive 
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morphological characteristics were counted as apoptotic. Alternatively, the fluorescence 
in situ nick translation assay may be identifying cells in an earlier stage of apoptosis. 
In the present study concentrations of 10-1 OOJlM zoledronic acid for 72 hours were 
required to induce apoptosis of breast cancer cells. However, bisphosphonates have a 
high affinity for mineralised bone and localise to bone rapidly, thus in a clinical setting it 
is likely that primary breast cancer cells or those in visceral metastases may be exposed to 
these compounds for shorter periods. Indeed, peak serum concentrations are likely to be 
in the range of 1-3JlM and maintained for only a few hours (Berenson JR, 2000). In bone 
metastases, where osteoclasts are resorbing bone loaded with bisphosphonate, and 
thereby releasing it, prolonged exposure to high local concentrations of the compound 
would be predicted (Sato M, 1991). However, exposure times of 2, 6 and 12 hours may 
more accurately reflect those seen by cells other than osteoclasts in vivo. Incubation of 
MCF-7 cells with 100JlM zoledronic acid for these periods resulted in a similar reduction 
in cell number and increase in apoptosis, suggesting that acute exposure is sufficient to 
have an anti-tumour effect in these cells. This is consistent with observations from a 
study in J774 macrophages which demonstrated a time-dependant increase in caspase-3-
like enzyme activity, associated with apoptosis, when acutely exposed to nitrogen-
containing bisphosphonates (Coxon FP, 1998). 
Although zoledronic acid clearly has cytotoxic effects on breast cancer cells, these may 
be mediated by their ability to chelate calcium. However, studies with EDTA, which will 
also chelate calcium: demonstrated that this has only a small effect on the reduction in 
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cell number and remained significantly different from the effect observed following 
zoledronic acid treatment. Unlike the effect on cell number, EDT A treatment did not 
result in a significant increase in apoptosis compared to control suggesting that the 
apoptosis induced by zoledronic acid is not mediated by chelation of calcium. The 
reasons for the differences in these effects on cell number and apoptosis are unclear; 
however, calcium chelation with EDT A may have cytostatic effect on breast cancer cells 
rather than a cytotoxic effect. Interestingly, MCF-7 and MDA-MB-231 cells showed 
different levels of sensitivity to zoledronic acid, the reasons for which remain unclear. 
However, this may reflect the differing expression of p53 as MCF-7 cells express wild 
type p53 whilst MDA-MB-231 cells express a mutant p53 sequence, which may confer 
increased resistance to apoptotic stimuli (O'Connor PM, 1997). Alternatively, MDA-MB-
231 cells may produce a number of cytokines or local growth factors that could act as 
survival factors and inhibit zoledronic acid-induced apoptosis (Fromigue, 2000). There 
may also be differences, between the cell lines, in the way in which zoledronic acid is 
taken up. 
We have also demonstrated that zoledronic acid-induced apoptosis of MCF-7 breast 
cancer cells can be inhibited by addition of intermediates of the mevalonate pathway, 
which is consistent with observations in osteoclasts, macrophages and myeloma cells 
(Fisher JE, 1999; Luckman SP, 1998; Shipman CM, 1998). This pathway has been shown 
to be important in the post-translational modification of small GTP-binding proteins 
including Ras, by the process of farneslyation, and Rho and Rac by geranylgeranylation. 
These proteins are -involved in a range of important cellular processes including 
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proliferation (Ras), membrane trafficking and cytoskeletal organisation (Rho and Rac). In 
the present study, the addition of geranylgeraniol, rescued MCF-7 cells from zoledronic 
acid-induced apoptosis, whereas the addition of famesol only partially inhibited tumour 
cell death. Recent observations by Fisher et al suggest that this may also be the case in 
osteoclasts where disruption of the cytoskeleton and loss of the osteoclast ruffled border, 
as well as apoptosis, are seen with bisphosphonate treatment (Fisher JE, 1999). However, 
this contrasts with previous studies in J774 macrophages and the JJN3 myeloma cells in 
which bisphosphonate-induced apoptosis could be prevented by the addition of both 
geranylgeraniol and famesol. Our findings also contrast with the results of a recent study 
by Senaratne et al (Senaratne SG 2002) who demonstrated that the addition of famesol to 
zoledronic acid-treated MDA-MB-231 cells protected the against loss of viability and 
loss of membrane localization of Ras, as well as protecting MCF-7 cells from the 
apoptotoc effects of zoledronic acid. The reasons for the differences between these 
studies are unclear; however, famesylated proteins such as Ras may be less important in 
breast cancer cell and osteoclast function than in macrophages and myeloma cells. The 
effects of intermediates of the mevalonate pathway on zoledronic acid-induced reduction 
in cell number are less clear. The addition of geranylgeraniol to the system partially 
negates this effect but there is still a marked reduction compared with control. The 
reasons for this are unclear but it is possible that the addition of geranylgeraniol is 
insufficient to prevent zoledronic acid-induced inhibition of adhesion to the substratum 
and subsequent cell growth. In addition, the calcium chelating action of zoledronic acid, 
which would not be altered by intermediates of the mevalonate pathway, may affect cell 
number as suggested earlier. 
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In summary, the data presented in this chapter strongly suggest that zoledronic acid can 
have an important anti-tumour effect in breast cancer cells in vitro by promoting tumour 
cell apoptosis. It is therefore possible that the beneficial effects seen in patients receiving 
bisphosphonate therapy may be due to anti-tumour effects as well as inhibition of 
osteoclast-mediated bone resorption. These observations warrant further investigation in 
vitro and in vivo in patients receiving bisphosphonates. 
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ZOLEDRONIC ACID AND PACLITAXEL HAVE 
SYNERGISTIC EFFECTS ON HUMAN BREAST CANCER 
CELLS. 
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4.1 SUMMARY 
Bisphosphonates are commonly used alongside chemotherapy and endocrine agents in 
the clinical arena. Recent clinical data suggests that bisphosphonate treatment may 
influence non-skeletal as well as skeletal metastases and may also confer a survival 
advantage. This raises the possibility that bisphosphonates may act on breast cancer cells 
in synergy with anti-neoplastic agents. In the previous chapter we have demonstrated that 
the potent bisphosphonate zoledronic acid can have direct anti-tumour effects on breast 
cancer cells in vitro. The aim of the work presented in this chapter was to investigate the 
effects of combining zoledronic acid and paclitaxel, a commonly used chemotherapy 
agent on breast cancer cell number and apoptosis. 
Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel 
resulted in a four to five-fold increase in MCF-7 cell apoptosis. Isobologram analysis 
revealed synergistic effects on MCF-7 cell number and apoptosis when zoledronic acid 
and paclitaxel were combined. The synergistic effects on apoptosis were confirmed using 
the MDA-MB-231 cell line. 
These data suggest that zoledronic acid can act in synergy with paclitaxel on breast 
cancer cells in vitro and this may provide one explanation for the beneficial effects of 
bisphosphonates experienced by breast cancer patients. These effects require further in 
vivo study. 
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4.2 INTRODUCTION 
Bisphosphonates are effective in the management of bone metastases from breast cancer 
and multiple myeloma and are often used in conjunction with standard anti-neoplastic 
therapies in the clinic. Several large clinical studies investigating the effects of 
bisphosphonates on skeletal related events in both breast cancer and multiple myeloma 
have demonstrated benefits in quality of life and reduction of skeletal morbidity 
(Berenson J et al., 1996; Diel IJ et al., 1998; Hortobagyi GN et al., 1996; McCloskey et 
al., 1998; Paterson AHG et al., 1993; Theriault RL et al., 1999, Powles T et aI, 2002). 
Importantly, recent data from randomised controlled trials have indicated that the use of 
bisphosphonates in patients with breast cancer, in addition to anti-cancer treaments, may 
confer a survival advantage as well as skeletal benefits (Diel IJ et al., 1998). This raises 
the intriguing possibility that bisphosphonates may somehow act synergistically with 
cancer therapies to affect tumour burden. 
The investigation of synergistic effects between two compounds requires detailed and 
rigorous analysis. The isobologram method makes use of combined drug dose-response 
data to demonstrate the presence of synergy regardless of the mechanism of action of the 
drugs under investigation (Gessner, 1988). The simple comparison of the sum of the 
individual drug effects with the observed combined effect does not give an accurate 
indication of the interaction between the two drugs. The reason for this is that the dose-
response curves for most drugs are non-linear (Berenbaum, 1989). The isobologram 
method concisely evaluates drug interactions independent of the shape of the dose-
response curves and hence alleviates this problem. This method has been utilised for both 
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in vitro (Leonessa F, 1994; Voigt W, 2000) and in vivo (Church MW, 1988) studies. The 
quantification of the interactions identified by the isobolgram method requires further 
rigorous analysis of the dose-response data (Greco WR, 1995) and this can be done using 
a mathematical model (Appendix 1). The degree of synergy or antagonism between two 
compounds can thus be determined and can be used to compare the effects of different 
drug combinations. The aim of the work presented in this chapter, therefore, was to 
determine whether the combination of zoledronic acid with the commonly used 
chemotherapeutic agent paclitaxel synergistically enhanced the anti-tumour effects 
observed in Chapter 3. 
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. 4.3 METHODS 
4.3.1 Chemicals 
Zoledronic acid was prepared as described previously in Materials and Methods 
(section 2.1.3). Paclitaxel was purchased from Sigma Chemical Co (Poole, UK) and a 
stock solution of a.lmM (w/v) was made by dissolving paclitaxel in dimethyl 
sulphoxide (DMSO) and then filter-sterilised using a a.22/lm filter. All other 
chemicals were purchased from Sigma Chemical Co unless otherwise stated. 
4.3.2 Identification of apoptotic cells 
In preliminary studies to identify possible synergistic effects between zoledronic acid 
and paclitaxel MCF7 cells were seeded at a density of 5xl a4 cells/ml in 24-well plates 
(Costar) in replicates of four wells per treatment and allowed to adhere and proliferate 
for 72 hours. Cells were incubated with fresh media in the presence or absence of . 
I a~M zoledronic acid and/or 2nM paclitaxel acid for a total of 72 hours. 
Some preliminary studies to assess the proportion of apoptotic cells were also carried 
out using the in situ nick translation assay. MCF -7 cells were plated at a density of 
Ixlas/ml in 6 well plates (Costar) with one replicate per treatment and allowed to 
proliferate for 72 hours. The cells were then treated with 1 a/lM zoledronic acid and 
2nM paclitaxel as above. The proportion of apoptotic cells was determined by flow 
cytometric analysis following the incorporation of fluorescently-Iabelled dUTP into 
DNA strand breaks, as described previously (Materials and Methods). 
For more detailed characterisation of synergistic effects and to enable the construction 
of dose-response curves and isobolograms, MCF-7 and MDA-l\1B-231 cells were 
seeded as above (n=8). They were subsequently incubated with increasing 
concentrations of zoledronic acid (a.l-l aa~M) in the presence or absence of 
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increasing concentrations of paclitaxel (0.01-10nM) for 72 hours. Following 
treatment, the cells were harvested, fixed in 4% formaldehyde (v/v) in PBS and 
cytospun onto glass slides. Once this was done, cells were stained with the nuclear 
stain DAPI as described earlier (Materials and Methods, section 2.4.2). 
4.3.3 Analysis of cell number 
MCF-7 and MDA-MB-231 breast cancer cells were plated at a density of 5x104 
cells/ml in 24-well plates (Costar) (n=8) and allowed to adhere and proliferate for 72 
hours. Cells were incubated as above with fresh media contained with increasing 
concentrations of zoledronic acid (0.1-100IlM) in the presence or absence of 
increasing concentrations of paclitaxel (0.01-10nM) for 72 hours. After harvesting, 
cells were resuspended in PBS and cell number was determined using a 
haemocytometer. Dose response curves and isobolograms were constructed using this 
data. 
4.3.4 Isobologram analysis 
The isobologram method of analysis was used to assess whether synergistic effects 
were seen when paclitaxel and zoledronic acid were combined. This method allows 
the identification of interactions between two drugs, regardless of mechanism of 
action of the individual drug (Berenbaum, 1989; Greco WR, 1995). Dose response 
curves were plotted for the effects of paclitaxel and the effects of zoledronic acid on 
MCF7 cell number. From these, the combined drug IC75 (inhibitory concentration) 
values (75% of maximum effect, 25% remaining) were determined for each curve. 
The ratio of the combined drug IC75 to the IC75 value of each drug alone was calculated 
and plotted as an isobologram (DID75). The analysis was repeated for the effect of 
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paclitaxel and zoledronic acid on :MDA-231 cell number and again the IC75 values 
were used to plot the isobologram. The data obtained from experiments determining 
the effect of paclitaxel and zoledronic acid on apoptosis were also analysed in the 
same way. In this case, IClO values for MCF-7 and :MDA-:MB-231 cells and the 
corresponding ratios were calculated from the dose response curves. The analysis was 
kindly carried out by Dr Amin Rostami, Dept of Pharmacology, University of 
Sheffield Medical School. 
4.3.5 Further Isobologram analysis 
As discussed above, the isobolgram analysis makes use of the ratio of the IC values of 
paclitaxel and zoledronic acid to generate a curve which indicates the presence of 
synergy, additivity or antagonism between the two drugs. The presence, or otherwise, 
of a synergistic effect determined using this method should not depend on which 
particular IC value was chosen as it is the ratio that is important. We tested this on a 
sample of our data looking at the effect of both drugs in combination on :MDA-:MB-
231 cell apoptosis. We identified the points on the dose-response curves that 
corresponded to ICs and IClO and plotted two separate isobolograms with each of 
these IC values respectively. 
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4.3.6 GraFit Analysis 
The model shown in Appendix 1 (Equation 1) was used for analysis of synergy using the 
GraFit Version 3.00 software (Erithacus Software Ltd, Surrey, UK). This software allows 
3-dimensional analysis so that the data for the zoledronic acid and paclitaxel effects can 
be analysed simultaneously. This general model for non-additivity assumed an interaction 
term u. If u=O then the effect of the combining the two drugs could be considered 
additive only. In contrast, negative values indicated antagonism and positive values 
demonstrated synergy. The sigmoidicity function y indicates the shape of the curve. This 
analysis was also kindly carried out by Dr Amin Rostami. 
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4.4 RESULTS 
4.4.1 Combined treatment with zoledronic acid and paclitaxel, at pharmacologically 
achievable concentrations, results in apparent synergistic effects on breast cancer 
cell apoptosis. 
In preliminary studies, we investigated the effect of zoledronic acid in combination with 
paclitaxel on apoptosis of MCF-7 cells. Analysis of nuclear morphology demonstrated 
that combining zoledronic acid and paclitaxel caused a greater than two-fold increase in 
the proportion of apoptotic MCF-7 cells when compared with either drug alone (p<O.02) 
(data not shown). Treatment with IOIlM zoledronic acid and 2nM paclitaxel resulted in a 
fivefold increase in apoptosis (774.8% of control) compared to zoledronic acid alone 
(155.71 %) and a fourfold increase compared to paclitaxel alone (189.68%) (figure 4.1) on 
analysis with the in situ nick translation assay. 
CtI Zoled 
lO/!M 
Pac 
2nM 
Treatment 
Zoled 
+Pac 
Figure 4.1 Effect of combined treatment of MCF-7 cells with IOIlM zoledronic acid and 
2nM paclitaxel. Cells were incubated with IOIlM zoledronic acid in the presence or 
absence of 2nM paclitaxel for a total of 72 hours. Apoptosis was assessed using the in situ 
nick translation assay. Results are expressed as percent of control. 
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4.4.2 Isobologram analysis of combined effects of zoledronic acid and paclitaxel 
on breast cancer cell number demonstrated synergy. 
Since the above data suggested that these compounds might have synergistic effects, a 
more detailed isobologram analysis was undertaken. The combination of paclitaxel 
and zoledronic acid was shown to result in synergistic effects on MCF-7 cell number 
(figure 4.2). Dose response curves were plotted for the effect ofpaclitaxel (4.2A) and 
zoledronic acid (4.2B) on cell number and the IC75 values calculated. The resulting 
data points were plotted on an isobologram (4.2C). The DID75 ratios for paclitaxel 
alone (1) and zoledronic acid alone (1) are shown and connected by a diagonal line. 
Points lying on this line indicate a purely additive effect. Data points forming a curve 
lying above this line indicate antagonism between the two drugs whereas a curve 
lying below this line suggest a synergistic interaction. The combined DID75 ratios 
derived from the dose-response data clearly formed a curve which lay below the 
additive effect line, indicating synergistic effects between paclitaxel and zoledronate 
on tumour cell number. 
These experiments were repeated with the MDA-MB-231 cell line. As shown in 
figure 4.3A and 4.3B, and dose response curves were plotted for the effects of 
increasing concentrations of paclitaxel and increasing concentrations of zoledronic 
acid. The IC7s values for effect on cell number were calculated and were plotted as an 
isobologram, figure 4.3C. Isobologram analysis demonstrated that there was also a 
synergistic effect on MDA-MB-231 cell number when paclitaxel and zoledronic acid 
are combined. 
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Figure 4.2 Dose response curves and isobologram plot for the interaction between paclitaxel and 
zoledronic acid on MCF7 cell number. Cells were incubated with increasing concentrations of 
zoledronic acid (0.01-1001lM) in combination with increasing concentrations of paclitaxel (0.01-
10nM) for a total of 72 hours. Cells were harvested to determine cell number (n=8) and dose 
response curves were plotted for effect of paclitaxel (A) and zoledronic acid (B) on cell number. 
Combined drug IC7s values were determined from these data and used to construct an isobologram 
(LC) for the interaction between paclitaxel (e) and zoledronic acid (0). Dose response results 
expressed as percent of control and are means ± SD. 
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Figure 4.3 Dose response curves and isobologram plot for the interaction between paclitaxel and 
zoledronic acid on MDA-MB-231 cell number. Cells were incubated with increasing concentrations of 
zoledronic acid (O.Ol-lOOJ.lM) in combination with increasing concentrations ofpaclitaxel (0.01-10nM) 
for a total of 72 hours. Cells were harvested to determine cell number (n=8) and dose response curves 
were plotted for effect of pac1itaxel (A) and zoledronic acid (B) on cell number. Combined drug IC7s 
values were determined from these data and used to construct an isobologram (C) for the interaction 
between pac1itaxel (e) and zoledronic acid (0). Dose response results expressed as percent of control 
and are means ± SD. 
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4.4.3 Isobologram analysis of the combined effects of zoledronic acid and paclitaxel 
on breast cancer cell apoptosis demonstrated synergy. 
Combined treatment of MCF-7 cells with paclitaxel and zoledronic acid resulted in a 
synergistic increase in tumour cell apoptosis (figure 4.4). Combined drug ICIO values 
were determined from dose response curves plotted for paclitaxel (4.4A) and zoledronate 
(4.4B). These were then used to construct an isobologram (4.4C) as described above. 
Again, the combined DID I 0 ratios, when plotted on the isobologram, formed a curve that 
lay below the additive effect line indicating a synergistic effect on tumour cell apoptosis. 
The analysis of the combined effect ofpaclitaxel and zoledronic acid on MDA-MB-23I 
cell apoptosis also demonstrated the presence of synergy (figure 4.5). In this case, ICs and 
ICIO values were calculated from the dose response curves 4.5A and 4.5B. These were 
then used to construct two isobolgrams as before (4.5C and 4.50). Again the isobologram 
curve confirmed that paclitaxel and zoledronic acid had synergistic effects on MOA-MB-
231 cell apoptosis. In addition, the synergistic effects were present in both ICs and ICIO 
isobolograms, indicating that qualitative assessment of synergy using this method is not 
dependent on the IC value used. 
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Figure 4.4 Dose response curves and isobologram plot for the interaction between paclitaxel and 
zoledronic acid on MCF-7 cell apoptosis. Cells were incubated with increasing concentrations of 
zoledronic acid (0.01-1 OOIlM) in combination with increasing concentrations of paclitaxel (0.0 I-
t OnM) for a total of 72 hours. Cells were harvested to determine cell number (n=8) and dose response 
curves were plotted for effect of paclitaxel (A) and zoledronic acid (B) on apoptosis. Combined drug 
JCIO values were determined from these data and used to construct an isobologram (LC) for the 
interaction between paclitaxel (e) and zoledronic acid (0). Dose response results expressed as percent 
of control and are means ± SEM. 
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Figure 4.5 Dose response curves and isobologram plot for the interaction between paclitaxel and 
zoledronic acid on MDA-MB-231 cell apoptosis. Cells were incubated with increasing concentrations 
of zoledronic acid (0.0 1-1 OO~M) in combination with increasing concentrations of paclitaxel (0.01-
10nM) for a total of 72 hours. Cells were harvested to determine cell number (n=8) and dose response 
curves were plotted for effect of paclitaxel (A) and zoledronic acid (B) on apoptosis. Combined drug 
ICs and ICIQ values were determined from these data and used to construct an isobolograms (C) and 
(D) for the interaction between paclitaxel (e) and zoledronic acid (0). Dose response results expressed 
as percent of control and are means ± SEM. Isobolograms at both IC values indicated the presence of 
synergy. 
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4.4.4 Analysis of the combined effects of zoledronic acid and paclitaxel on breast 
cancer cell number and apoptosis using the GraFit software. 
The use of the model, Equation 1, suggested a synergistic effect on MCF -7 cell 
number when pac1itaxel and zoledronic acid were combined (Table 4.1). The 
calculated value of a indicated a threefold synergistic effect of the combined drugs on 
MCF-7 cell number. This combination of drugs also appeared to have a synergistic 
effect on MDA-l\1B-231 cell number. However, neither of these values were 
statistically significant (a = 3.31 ± 2.33 and 5.42 ± 5.08 for MCF-7 and MDA-MB-
231 cells respectively). There was also no significant difference between the two cell 
lines in terms of the effect on cell number. 
Table 4.1 Synergy analysis for the effect ofpac1itaxel and zoledronic acid on cell 
number 
Cell line 
MCF-7 
MDA-l\1B-231 
a value (± SE) 
3.31±2.3 
5.42 ± 5.08 
When the dose response data for breast cancer cell apoptosis was analysed using the 
model, the combination of paclitaxel and zoledronic acid clearly had a synergistic 
effect on cell death (Table 4.2). The calculated a values were 67.29 ± 25.9 for MCF-7 
cell apoptosis and 295.68 ± 90.6 for MDA-MB-231 cells. 
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Table 4.2 Synergy analysis for the effect of paclitaxel and zoledronic acid on 
apoptosis 
Cell line 
MCF-7 
MDA-MB-231 
4.5 DISCUSSION 
a value (± SE) 
67.29 ± 25.9 
295.68 ± 90.6 
In the clinical arena, bisphosphonates are often used in combination with 
chemotherapy or endocrine therapy. Randomised controlled studies in multiple 
myeloma and breast cancer patients have suggested that bisphosphonates may confer 
a survival benefit as well as influencing skeletal morbidity when combined with 
chemotherapeutic agents (Berenson JR et aI., 1998; Diel IJ et aI., 1998; McCloskey 
EV & MacLennan ICM, 1996). This raises the intriguing possibility that 
bisphosphonates may have synergistic effects on tumour cells when combined with 
anti-neoplastic agents. 
The present study has shown that treatment of MCF-7 cells with zoledronic acid and 
2nM paclitaxel, a concentration readily achievable in the serum of patients (Wilson 
WH, 1994) results in an increase in apoptosis above the expected additive effect. To 
investigate this more fully and to demonstrate synergy, the isobologram method was 
used in our studies. This method allows for the analysis of the interaction between 
two drugs independent of their mechanism of action (Berenbaum, 1989; Greco WR, 
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1995). It provides a qualitative measure of synergy and has been used both in vitro 
and in vivo (Gessner, 1988; Leonessa F, 1994). The mathematical model in Equation 
1 (Appendix 1) describes the relationship between the effect of each drug alone and 
that of the two combined. An interactivity term a can be determined by entering the 
IC values obtained from the dose response curves for each drug. If a is positive, there 
is a synergistic interaction between the two drug. Conversely, a negative value for 
a indicates antagonism. This model can also be used to compare the degrees of 
synergy between different agents, for example, the synergistic interaction between 
paclitaxel and zoledronic acid can be compared to the interaction between zoledronic 
acid and tamoxifen although this is beyond the scope of this thesis. 
The analysis of the combined effects of paclitaxel and zoledronic acid on MCF -7 cell 
number suggested the presence of synergy by the isobologram method. However, 
although there was at least an additive effect on cell number, the mathematical 
modelling data did not confirm synergy. However, paclitaxel has been shown to 
inhibit breast cancer cell proliferation by blocking mitosis (Blagosklonny MV, 1999; 
McCloskey DE, 1996; Yeung TK, 1999). This, in combination with the effects of 
bisphosphonates on tumour cell number demonstrated by ourselves, (Chapter 3,) 
(Jagdev SP, 2001) and others, (Shipman CM, 1997; Shipman CM, 1998; Aparicio A, 
1998; Derenne S, 1999) may result in a possible additive effect on cell number. A 
similar synergistic effect on MDA-MB-231 cell number was suggested on 
isobologram analysis when the cells were treated with this combination. The 
mathematical modelling data also hinted at a synergistic effect although, again, the 
results for the l\1DA-MB-231 cells were not statistically significant. 
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In our earlier studies we showed that the bisphosphonate zoledronic acid clearly 
induced apoptosis in breast cancer cells in vitro (Chapter 3). The present studies 
demonstrate that the combination of paclitaxel and zoledronic acid results in 
synergistic increases in MCF-7 and MDA-MB-231 cell apoptosis. Dose response 
studies showed increasing proportions of apoptotic cells as the combined 
concentrations of pac1itaxel and bisphosphonate went up. Isobologram analysis for 
both cell lines indicated that the effects on breast cancer cell apoptosis were indeed 
synergistic. The mathematical modelling data confirmed this. Bisphosphonates have 
been shown to act in synergy with certain agents including taxanes. Tassone et al 
demonstrated that the combination of zoledronic acid and dexamethasone inhibited 
human myeloma cell growth and resulted in synergistic induction of apoptosis 
(Tassone P, 2000). In addition, Magnetto et al investigated the effects of a 
combination of ibandronate and taxanes on breast cancer cells and suggested that the 
combination synergistically inhibited breast cancer cell adhesion and invasion 
(Magnetto S et aI., 1999). In contrast to our studies, they did not demonstrate any 
synergistic activity on breast cancer cell apoptosis. However, investigations in animal 
models also appear to confirm the possibility of synergistic interactions between 
bisphosphonates and anti-neoplastic agents. Steams and Wang found that the 
combination of alendronate and taxol inhibited the formation of bone metastases 
induced by prostate cancer cells in SCID mice (Steams ME, 1996). Similarly, the use 
of both incadronate and zoledronic acid with oral UFT (a combination of uracil and a 
fluorouracil prodrug) inhibited the formation of bone metastases and visceral 
metastases in nude mice inoculated with MDA-MB-231 cells (Yoneda T, 1999; 
Yoneda T, 2000). The mechanism by which paclitaxel and zoledronic acid 
synergistically induced apoptosis in our studies was not determined but inhibition of 
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the mevalonate pathway due to zoledronic acid treatment and the prevention of 
chromosome segregation and cell division by paclitaxel may result in a cumulative 
apoptotic insult. As the data discussed above suggest, it is possible that they may also 
act together to affect other aspects of tumour cell function such as invasion and 
adhesion. These mechanisms require further study both in vitro and in vivo. It would 
also be important to investigate possible synergy with other anti-neoplastic agents, as 
well as to explore temporal relationships, in future studies. 
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INVESTIGATION OF THE IN VIVO ANTITUMOUR EFFECTS OF 
BISPHOSPHONATES USING THE DUAL FLUORESCENCE LABELLING 
TECHNIQUE 
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5.1 SUMMARY 
The work presented in the chapters 3 and 4 demonstrates that zoledronic acid clearly has anti-
tumour effects on breast cancer cells in vitro. The important question is whether these effects are 
observed in patients with breast cancer-induced bone metastases who are receiving 
bisphosphonate treatment. To address this issue, it is important to identify the levels of apoptosis 
in tumour cells that are part of or in contact with secondary bone lesions and this can be done 
using bone marrow aspirate samples. The aim of the work presented in this chapter, therefore, 
was to develop a technique to identify apoptotic breast cancer cells in the mixed cell population 
present in bone marrow. This technique was then used to investigate the changes in bone marrow 
tumour cell apoptosis before and after intravenous bisphosphonate treatment in samples from 
breast cancer patients. 
A fluorescence dual labelling method was developed by combining an epithelial tumour marker 
(BerEP4) with a marker for apoptosis, the fluorescence in situ nick translation assay. Samples of 
peripheral blood were mixed with MCF-7 cells and used to test and optimise the assay. Having 
established a technique capable of detecting apoptotic breast cancer cells in a mixed cell 
population, 5 patient bone marrow samples were analysed before and 3 days after treatment with 
intravenous pamidronate or zoledronic acid. No tumour cells were detected in these patients 
therefore the assay was modified by replacing the BerEP4 antibody with a fluorescence-labelled 
anti-cytokeratin antibody, MNF116. Three of the initial 5 patients and a further 9 patients were 
analysed using the new antibody and 33% of patient samples were positive for tumour cells. 
However, there did not appear to be an increase in bone marrow tumour cell apoptosis after 
bisphosphonate treatment although the number of patients with paired samples that could be 
examined successfully was very small. 
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The data presented in this chapter indicated that the dual labelling assay was able to successfully 
identify and quantify the levels of apoptosis in bone marrow breast cancer cells. In these few 
patients, treatment with intravenous bisphosphonates does not appear to promote apoptosis of 
bone marrow tumour cells although a larger study is warranted to establish definitively the effect 
ofbisphosphonates on breast cancer cell apoptosis in vivo. 
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5.2 INTRODUCTION 
The use of bisphosphonates in breast cancer and multiple myeloma patients has been shown to 
have a beneficial effect on skeletal morbidity (Berenson J, 1996; Diel IJ, 1998; Hortobagyi GN, 
1996; Kanis JA, 1996; McCloskey, 1998; Theriault RL, 1999; Paterson AHG, 1993, Powles T, 
2002). In addition, recent data in patients with multiple myeloma suggest that treatment with 
bisphosphonates confers a survival benefit (Berenson J, 1996). Similar survival effects may also 
be apparent in breast cancer as Diel et al have recently reported that adjuvant bisphosphonate 
treatment influences extra-skeletal as well as skeletal metastases and may increase survival (Diel 
IJ, 1998). Taken together, these data suggest that bisphosphonates may have anti-tumour effects 
in addition to potently inhibiting osteoclast-mediated bone resorption. The work presented in 
chapters 3 and 4 supports the hypothesis that bisphosphonates can have direct effects on breast 
cancer cells at least in vitro. The important question is whether these effects are observed in 
patients with breast cancer-induced bone metastases who are receiving bisphosphonate treatment. 
To address this issue, it is important to identify the levels of apoptosis in tumour cells that are 
part of, or in contact with, secondary bone lesions and this can be done using bone marrow 
aspirate samples. 
The aim of the work presented in this chapter was to develop a technique that would allow the 
identification of apoptotic breast cancer cells in the mixed cell population present in the bone 
marrow. The assay was developed using MCF-7 breast cancer cells mixed with peripheral blood 
and, once established, was used to analyse paired bone marrow samples from patients with breast 
cancer before and after intravenous bisphosphonate treatment. Breast cancer cells are of 
epithelial origin and can therefore be recognised by epithelial cell markers. One such marker is 
the human epithelial antigen which is expressed on the surface and in the cytoplasm of epithelial 
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cells and we initially used an antibody raised against this antigen, the BerEP4 antibody (Latza U, 
1990) to identify tumour cells. Although this antibody performed well during the development of 
the technique, it did not identify any positive cells from the first set of bone marrow samples 
tested. It was therefore replaced with the MNF 116 antibody raised against a panel of cytokeratins 
which are expressed by cells of epithelial origin, both in normal and in malignant tissue (Goddard 
MJ, 1991). This was then combined with the fluorescence in situ nick translation assay for 
apoptosis to enable the detection of apoptotic breast cancer cells in the bone marrow of patients 
receiving bisphosphonate treatment. 
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5.3 MATERIALS AND METHODS 
5.3.1 Chemicals 
The FITe-conjugated antibodies, IgG 1 isotype control, BerEP4 and MNFl16, were purchased 
from DAKO Ltd (Cambridgeshire, UK) and stored at 4°C until use. Both antibodies were 
supplied at a concentration of 100mgIL and were used at the recommended dilution of 1: 1 O. 
Human AB serum was obtained from the Blood Transfusion Service, Northern General Hospital, 
Sheffield, UK. All other chemicals were purchased from Sigma Chemicals Co (Poole, Dorset, 
UK). 
5.3.2 Cell Culture 
The human breast carcinoma cell line MCF-7 was obtained from the European Collection of 
Animal Cell Cultures (Salisbury, UK). Cells were cultured in RPMI 1640 (Life Technologies, 
Inc., Paisley, UK) supplemented with 10% FCS, ImM glutamine, ImM sodium pyruvate and Ix 
MEM nonessential amino acids (Life Technologies Inc). Cells were harvested using trypsin! 
ETDA 0.5%/0.2% (Life Technologies). 
5.3.3 Bisphosphonate treatment of breast cancer cells 
In some studies, MCF-7 cells were seeded at a density of lx106 cells/ml in T25 flasks and 
allowed to grow to confluence. They were then incubated with fresh media containing PBS 
vehicle control or 50011M zoledronic acid for a further 72 hours before they were harvested. 
5.3.4 Patient Samples 
Pre- and post-treatment bone marrow aspirate samples were taken from 14 patients with breast 
cancer and bone metastases who were due to receive intravenous bisphosphonate treatment with 
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either pamidronate (90mg) or zoledronic acid (4mg or 8mg) for the first time at the Cancer 
Research Centre, Weston Park Hospital, Sheffield, UK. No concomitant chemotherapy treatment 
or treatment with agents that altered bone metabolism was allowed, although some patients were 
on long-term hormonal therapy for their breast cancer. A bone marrow aspirate sample was taken 
from the posterior iliac crest before and three days after bisphosphonate treatment. The first four 
patients had samples taken consecutively from the same iliac crest. Subsequent patients had 
samples taken from opposite sides before and after treatment to reduce the possibility of trauma-
related apoptosis in the samples. Ethics approval was obtained for the study from the South 
Sheffield Ethics Committee and full written informed consent was obtained from each patient 
before the samples were taken. Samples of peripheral blood for development of the assay were 
taken at the Outpatient Department, Royal Hallamshire Hospital, Sheffield, UK. 
5.3.5 Development ofthe dual labelling technique 
5.3.5.1 Breast cancer cell identification 
The FITC-conjugated antibody BerEP4 was used to identify breast cancer cells. This antibody is 
raised in the mouse against the Human Epithelial Antigen, a surface antigen present 
predominantly on the surface but also in the cytoplasm of cells of epithelial origin such as breast 
cancer cells [Latza U, 1990 #44]. MCF-7 cells were plated at lx106/ml in T25 tissue culture 
flasks (Costar), cultured until confluent, and were then harvested. Half the sample was fixed in 
4% formaldehyde (v/v) and half the sample was analysed whilst fresh. To confirm that this 
antibody binds to breast cancer cells, the MCF-7 cells were washed in ice-cold wash buffer 
consisting of PBS and 1 % FCS and resuspended in 100111 of wash buffer containing either 
10mg/L isotype control or 10mg/L BerEP4 for 30 minutes on ice in the dark. The cells were then 
washed again and resuspended in 300111 of PBS for FACSort analysis. The positively labelled 
tumour cells were detected using the FLl detector (530nm bandpass filter, 30nm bandwidth). The 
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isotype control was used to mark the background level of fluorescence in the sample and the 
positively labelled cells were detected above this gate. 
To confirm that MCF-7 cells stained positively with the BerEP4 antibody, cells were harvested, 
fixed with 4% (v/v) formaldehyde in PBS and cytospun onto glass slides. They were then stained 
with 4'-6-diamidino-2-phenyl-indole (DAPI) at 21lg/ml in PBS for 15 minutes, washed and 
stained with 10% (v/v) isotype control or 10% (v/v) BerEP4 in PBS containing 1 % FCS (v/v) for 
30 minutes. Cells were examined using a DMRB fluorescence microscope (Leica). 
5.3.5.2 Isolation of breast cancer cells from a mixed cell population 
MCF-7 cells were harvested, mixed with peripheral blood and subsequently processed according 
to the Erythrocyte Lysis Method described in Materials and Methods. The mononuclear cell 
population was then labelled with isotype control or BerEP4 as described in section 5.3.5.1 above 
and analysed for the presence of tumour cells by flow cytometry. The positively labelled tumour 
cells were detected using the FLl detector (530nm bandpass filter, 30nm bandwidth). The isotype 
control was used to mark the background level of fluorescence in the sample and positively 
labelled cells were detected above this gate. 
5.3.5.3 Identification of apoptotic tumour cells from a mixed cell population with the dual 
fluorescence labelling technique 
MCF-7 cells were seeded as above and incubated in the presence or absence of 500llM 
zoledronic acid for 72 hours. The cells were then harvested and mixed with peripheral blood, 
after which the samples were processed according to the Erythrocyte Lysis method (Materials 
and Methods). Cells were then fixed in 4% formaldehyde (v/v) and frozen in 100% ethanol and 
stored at -20°C until they were analysed. To allow simultaneous labelling for DNA strand breaks 
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associated with apoptosis and tumour cells, the samples were incubated at room temperature with 
a buffer containing 50mM tris, 2.5 mM magnesium chloride, 101lg/ml bovine serum albumen, 10 
mM l3-mercaptoethanol, O.2nM of un la be led dATP, dGTP and dCTP and O.2nM biotin-16-dUTP 
in the presence of 1 unit DNA polymerase for 4 hours with intermittent gentle agitation 
[Gorczyca W, 1993 #11]. The cells were then washed in sterile PBS and incubated with a second 
buffer containing 4x saline-sodium citrate buffer (SSC), 0.1 % Triton-X 100, 5% (w/v) fat free 
powdered milk,l % (v/v) phycoerythrin- conjugated streptavidin (DAKO) and either 10% (v/v) 
FITC-conjugated isotype control (DAKO) or 10% (v/v) FITC-conjugated BerEP4 antibody for 30 
minutes at room temperature in the dark. After washing with PBS, cells were analysed using flow 
cytometry. The R-PE-positive cells (apoptotic cells) were detected using the FL2 detector 
(585nm bandpass filter, 42nm bandwidth) and the FITC-positive cells (tumour cells) were 
detected using the FLl detector (530nm band pass filter, 30nm bandwidth). Results were 
expressed as log PE fluorescence against log FITC fluorescence. The FITC-conjugated isotype 
control was used as a negative control for each sample and signified the background level of 
fluorescence in each sample. Antibody positive cells (breast cancer cells) appeared above the 
marker for background FITC fluorescence. 
5.3.5.4 Dual fluorescence labelling of patient bone marrow 
Bone marrow aspirate samples were collected from breast cancer patients before and 72 hours 
after intravenous bisphosphonate treatment (pamidronate or zoledronic acid) into tubes 
containing EDT A. Samples were centrifuged at 1000rpm for 5minutes and the plasma removed 
and stored at -80°C for future analysis. The remaining cells were resuspended in erythrocyte lysis 
buffer and processed according to the Erythrocyte Lysis method described in Materials and 
Methods. The cells were then fixed in 4% (v/v) formaldehyde in PBS and stored in 100% ethanol 
at -20°C until analysed. To identify apoptotic tumour cells from the mi~ed mononuclear cell 
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population in the bone marrow, samples were processed according to the dual fluorescence 
labelling method described in section 5.3.5.3 above with the addition of 4% (v/v) human AB 
serum to the wash buffer. The cells were resuspended in 300~1 PBS and analysed on the F ACSort 
(Becton Dickinson). As before, the R-PE-positive cells (apoptotic cells) were detected using the 
FL2 detector (585nm bandpass filter, 42nm bandwidth) and the FITC-positive cells (tumour 
cells) were detected using the FLl detector (530nm bandpass filter, 30nm bandwidth). Results 
were expressed as log PE fluorescence against log FITC fluorescence. As before, the FITC-
conjugated isotype control was used as a negative control for each sample and signified the 
background level of fluorescence in each sample. 
5.3.5.5 Modifications to the fluorescence antibody labelling technique 
The dual fluorescence technique was used to analyse 5 sets of paired bone marrow samples from 
patients with breast cancer-induced bone metastases. No tumour cells were detected in any of 
these samples. The reasons for this were unclear but it was possible that the BerEP4 antibody was 
not sensitive enough to detect the presence oflow levels of tumour cells in the bone marrow. This 
antibody was therefore substituted with a FITC-conjugated antibody that had been raised against 
a panel of cytokeratins and could identify epithelial cells, the MNF116 antibody (Moll R, 1982; 
Goddard MJ, 1991). To confirm positive staining, MCF-7 cells were mixed with peripheral 
blood, the sample processed according to the Erythrocyte Lysis method (Materials and Methods), 
and the remaining cells prepared for antibody staining. The cells were washed in wash buffer 
consisting of 1 % (v/v) FCS in PBS and incubated with 1 00~1 of wash buffer containing either 
10% isotype control (v/v) or 10% MNFI16 (v/v) for 30 minutes on ice in the dark. The cells were 
then washed again and resuspended in 300~1 of PBS for F ACSort analysis. The positively 
labelled tumour cells were detected using the FLl detector (530nm bandpass filter, 30nm 
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bandwidth). The isotype control was used to mark the background level of fluorescence in the 
sample as before. 
5.3.5.6 Sensitivity of tumour cell detection with the modified assay 
To determine the sensitivity of tumour cell labelling with the MNFl16 antibody, MCF-7 cells 
were mixed with peripheral blood in increasing proportions (tumour cells to mononuclear cells) 
(0.5- 50%). The proportions were based on the assumption that peripheral blood contains 6x106-
lx107 mononuclear cells /ml. The samples were then prepared for flow cytometry analysis after 
undergoing erythrocyte lysis and fluorescence antibody staining as described in section 5.3.5.5 
above. The proportions of antibody positive cells detected by the technique were identified using 
the FLl detector on the F ACSort machine. 
5.3.5.7 Re-analysis of patient samples with MNF116 antibody 
The modified tumour cell labelling method described in section 5.3.5.5 appeared to be a sensitive 
method for identifying breast cancer cells in a mixed cell popUlation. We therefore re-analysed 
three of the previous patient samples using this technique (with the inclusion of 4% (v/v) human 
AB serum in the wash buffer). After labelling with the antibody, samples were analysed on the 
FACSort as in section 5.3.5.5. 
5.3.5.8 Analysis of apoptotic tumour cells in patient bone marrow using the modified dual 
fluorescence labelling technique 
The dual labelling technique described in section 5.3.5.4 was modified by substituting the 
BerEP4 antibody with the MNFl16 antibody in the second step of the assay. A further 9 paired 
patient samples were analysed using this assay for the presence of apoptotic tumour cells. 
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5.3.6 Statistical analysis 
The data was found to be non-parametric therefore the difference between pre- and post treatment 
levels of total cell apoptosis in the bone marrow samples was analysed using the Wi1coxon 
matched pairs test. Analysis of pre- and post-treatment apoptosis of breast cancer cells was not 
possible, as the number of patients with detectable tumour cells in both pre- and post-treatment 
samples was too small. 
124 
Chapter 5 Dualfluorescence labeling methodfor analysis of in vivo effects ofbisphosphonates 
5.4 RESULTS 
5.4.1 BerEP4 antibody positively identified breast cancer cells 
MCF-7 cells were labelled with FITC-conjugated isotype control and FITC-conjugated BerEP4 
(Figure 5.1). Visualisation using a Leica DMRB fluorescence microscope confirmed the presence 
of positive staining of MCF-7 cells with BerEP4 (Figure 5.1 B) compared with isotype control 
(Figure 5.1 B). 
A B 
Figure 5.1. MCF-7 staining with (A) isotype control and (B) BerEP4; original magnification 
x I 00. Cells were cytospun onto glass slides, stained with 10% (v/v) FITC-conjugated isotype 
control or FITC-conjugated BerEP4 antibody in wash buffer and counterstained with 4'-6-
diamidino-2-phenyl-indole (DAPt) at 2f.lg/ml in PBS. Cells were visualised using a Leica 
DMRB microscope. 
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Flow cytometry analysis of fresh MCF-7 cells revealed a shift in peak fluorescence in cells 
stained with BerEp4 to the right compared with those stained with isotype control (figure 5.2A 
and 5.2B). Similar levels of staining were achieved in MCF-7 cells that had been fixed in 4% 
(v/v) formaldehyde before the antibody labeling procedure (figure 5.2C and D). 
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Figure 5.2. Flow cytometric analysis ofMCF7 cells stained with isotype control and 
BerEP4 whilst fresh (A and B) and after fixation in 4% (v/v) formaldehyde (C and 
D). Results are expressed as Log FITC fluorescence against cell counts. 
126 
Chapter 5 Dualfluorescence labeling method/or analysis o/in vivo effects o/bisphosphonates 
5.4.2 Fluorescence antibody labeling method identified tumour cells in a mixed cell 
population 
MCF-7 cells were mixed with peripheral blood and labeled with either isotype control or BerEp4 
after undergoing erythrocyte lysis. Analysis of the isotype-Iabeled sample by flow cytometry 
identified the background level of binding and was marked with a marker just below the second 
log decade for FITC fluorescence (figure 5.3A). The analysis of the BerEp4 labeled sample 
revealed a population of positively-Iabeled cells above the second log decade for FITC 
fluorescence (figure 5.3B) indicating that this antibody can identify breast cancer cells in a mixed 
cell population. 
A. Isotype control VO~ ________________ -. ________________________ ~ B. BerEP4 VO~ ________________ -' ________________________ , 
10 1 
Log FITC Fluorescence 
Figure 5.3. Flow cytometry analysis of MCF-7 cells mixed with peripheral blood and 
labeled with isotype control (A) or BerEP4 (B) after erythrocyte lysis. Results are 
expressed as Log FITC fluorescence against side scatter. 
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5.4.3 Fluorescence dual labeling assay detected apoptotic breast cancer cells in a mixed cell 
population 
MCF-7 cells were treated with PBS control or 500).lM zoledronic acid for 72 hours after which 
they were loaded into peripheral blood. Dual labeling of the control samples as described in 
section 5.3.5.3 revealed an antibody positive population of cells around the second log decade for 
FITC fluorescence in the BerEp4 labeled samples compared to the isotype control labeled 
samples (Figure 5.4A). Cells that were positive for both FITC and PE conjugated markers, i.e. the 
apoptotic tumour cells, should appear in the right upper quadrant of the plots, RI. 0.2% of 
antibody-positive cells were detected in this region in sample A (PBS control). In contrast, 30% 
of BerEP4-positive cells (17.1% of total sample population) appeared in region RI after 
treatment with zoledronic acid (Figure 5.4B) indicating that apoptotic tumour cells can be 
identified by this technique. 
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Figure 5.4. Dual fluorescence labelling technique. MCF-7 cells were treated with PBS 
(A) or 500flM zoledronic acid (B) and loaded into peripheral blood. After erythrocyte 
lysis, samples were labelled with a dual fluorescence labelling assay (consisting of the 
BerEP4 tumour cell label combined with in situ nick translation assay) and analysed by 
flow cytometry. Results are expressed as Log PE fluorescence (apoptosis) against log 
FITC fluorescence (breast cancer cells). Cells positive for both labels (apoptotic tumour 
cells) fall in region RI. 
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5.4.4 Paired patient bone marrow samples were analysed using the fluorescence dual 
labelling technique. 
Five sets of paired patient bone marrow samples were analysed using the dual fluorescence 
labelling assay (Table 5.1). Of these, four patient samples showed an increase in apoptosis in all 
cell populations following intravenous bisphosphonate treatment (patients 1,2,3, and 5). Patient 
4 showed greater levels of apoptosis in the pre-treatment sample compared with post-treatment. 
No tumour cells were detected in any of these samples. 
Table 5.1. Analysis of patient bone marrow samples before and after bisphosphonate treatment 
using the dual fluorescence labelling assay. 
Patient Treatment Overall Apoptosis Antibody-positive 
(%) cells (%) 
Pre 0.08 X 
Post 11.44 X 
2 Pre 0.86 X 
Post 2.91 X 
3 Pre 2.57 X 
Post 8.01 X 
4 Pre 24.49 X 
Post 15.67 X 
5 Pre 6.90 X 
Post 12.92 X 
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5.4.5 The modified fluorescence antibody labelling technique sensitively detected tumour 
cells in a mixed cell population 
As the dual fluorescence labelling assay described above did not identify tumour cells in the five 
sets of samples analysed, the method was modified to incorporate a FITC-conjugated anti-
cytokeratin antibody (MNFI16) in place of the BerEP4 antibody. Tumour cell staining with this 
antibody was confirmed by labelling MCF-7 cells mixed with peripheral blood as described in 
section 5.3.5.5. The results are shown in figure 5.5 below. The background level of binding was 
determined with the isotype control (figure 5.5A). A marker was placed at the upper limit of the 
background population. On analysis of the MNFl16-labelled sample, a clearly positive 
population of cells appeared above the second log decade for FITC fluorescence (figure 5.5B). 
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Figure 5.5. Fluorescence antibody labelling of MCF-7 cells mixed with peripheral blood with 
isotype control (A) and MNF116 (B). Results are expressed as log FITC fluorescence against 
side scatter. 
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The sensitivity of the MNF 116 in detecting tumour cells was determined by mixing increasing 
proportions of MCF-7 cells into peripheral blood and then staining and analysing the samples 
after erythrocyte lysis. Flow cytometry analysis revealed that the antibody was able to detect 
breast cancer cells in a mixed cell population down to levels of around 1 % (Table 5.2). There was 
no statistically significant difference between the percentage of cells loaded and those recovered. 
Table 5.2 Sensitivity of MNFI16 antibody in detecting breast cancer cells in a mixed cell 
population. 
Breast cancer cells loaded (%) 
o 
0.5 
2.5 
5 
10 
20 
50 
Breast cancer cells recovered (%) 
0.07 
1.17 
1.63 
2.07 
5.94 
14.25 
22.12 
59.16 
Three of the previous five patient bone marrow samples (patients 2, 3 and 5) were re-analysed 
using the new antibody to determine whether breast cancer cells could be detected. Analysis of 
the sample from patient 3 revealed the presence of 5.08% MNF1l6-positive cells (breast cancer 
cells) in the pre-treat~ent sample and 18.99% tumour cells in the post-treatment sample 
compared with no positive staining with the previous antibody (figure 5.6). In addition, 3.22% 
and 20.08% antibody-positive tumour cells were detected in the pre-treatment and post-treatment 
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samples respectively of patient 5. Re-analysis of patient 2 did not demonstrate the presence of 
breast cancer cells. Unfortunately, there were insufficient numbers of cells remaining in these 
samples to stain with the full dual fluorescence labelling assay. 
0 A. Isotype 0 B. BerEP4 0 0 N RI N RI 
0 0 ~- oD 
.f!l:::3 0 §- N 
0 UO 0 co co 
0 ~ 0 v v 
0 
. ..:. vf'V..., ....... 
0 
100 101 102 103 104 104 
Log FITC Fluorescence 
o c. Iso e o~----------------~~~------------~ 
D.MNFU6 g~-----------r--------. 
o 
co 
.f!lo §oD 
o UO 
v 
o 
N 
RI 
o 
00 
o 
v 
o 
('.J 
O+......,;TTT1Im--,...,..,~....:::;;:cflr'l"l'!tt;w:-."'Aor'f"lf'l 
100 104 
Log FITC Fluorescence 
RI 
Figure 5.6. BerEP4 and MNFII6 antibody staining of patient 3's bone marrow cells. 
Patient bone marrow sample was stained with isotype control (A) and BerEP4 (B) and 
analysed by flow cytometry. The same sample was subsequently stained with isotype 
control (C) and MNFII6 (D). Results were expressed as Log FITC fluorescence against 
cell counts. The positively stained cells appeared above the marker in region I (RI). 
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5.4.6 The assessment of primary tumour cell apoptosis in the bone marrow of patients 
receiving bisphosphonate treatment 
Nine further paired patient samples were analysed using the modified dual labeling technique. 
The flow cytometry results of patient 8 are illustrated in figure 5.7 below. 
'IT 
0 
(') 
0 
1-0 
~ 
ro N () 
Cl.) 0 
{j 
en 
0 
A. 1.,,,,h7T'" control 
104 
Log FITC fluorescence 
B. MNF116 'lTo~ ______________ ~ ______ ~ 
(') 
o 
o 
Log FITC fluorescence 
v C. Dual fluorescence labelling 
O~------------~~~~~--~--~ 
RI 
o 
o -li=:::;=;::;::;;;;;;:::::;: ::::r:::;::;:;m;:;==;=;::::;::;:;:;m:;:::::.::..;:.:.,.....,. ......... ~ 
10 1 1 104 
Log PE Fluorescence (Apoptosis) 
Figure 5.7. Flow cytometry analysis of bone marrow cells from patient 8 (pre-treatment 
sample). Cells were labeled with isotype control (A) to identify background staining and 
MNFI16 (B) to identify tumour cells (evident above the second log decade for FITC 
fluorescence). The dual fluorescence labeling assay identified the proportion of cells that 
were positive for both labels, i.e., apoptotic tumour cells (region RI). Results are expressed 
as log PE fluorescence against log FITC fluorescence. 
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The levels of apoptosis in the whole sample population increased after bisphosphonate treatment 
in four out of nine patients (44.4%) (Table 5.3). The remaining five patient samples revealed a 
reduction in overall apoptosis. Antibody-positive breast cancer cells were detected in three out of 
nine new patients analysed (patients 8, 9 and 14). Of these, patients 8 and 14 demonstrated a 
reduction in tumour cell apoptosis in the post-treatment sample compared with pre-treatment 
whilst patient 9 showed no change. When the level of apoptosis within all cell populations was 
examined in all 14 patients, there was no significant difference between pre and post treatment 
total cell apoptosis (p=O.08). Overall, tumour cells were detected in 5 of 12 patients (41.6%) 
analysed with the MNFl16 antibody. The number of patients in the study was too small to draw 
any conclusions regarding the induction of breast cancer cell apoptosis after intravenous 
bisphosphonate treatment. 
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Table 5.3 Analysis of paired patient bone marrow samples with the modified dual fluorescence 
labelling technique. 
Patient Treatment Overall Tumour cells Apoptotic 
apoptosis (%) (%) tumour cells 
(%) 
Pre 0.08 NA 
Post 11.44 
2 Pre 0.86 NA 
Post 2.91 
3 Pre 2.57 5.0t! 
Post 8.01 JB.9c? 
4 Pre 24.49 X' 
Post 15.67 X' 
5 Pre 6.90 3.22u 
Post 12.92 20. Off 
6 Pre 1.4 X 
Post 0.55 X 
7 Pre 0.24 X 
Post 0.05 X 
8 Pre 19.13 31.64 11.47 
Post 6.78 52.01 2.96 
9 Pre 0.66 13.37 0 
Post 2.61 42.12 0 
10 Pre 1.31 X 
Post 0.16 X 
11 Pre 5.28 X 
Post 7.96 X 
12 Pre 0.82 X 
Post 1.79 2.69 9.15 
13 Pre 1.06 X 
Post 0.89 X 
14 Pre 0.3 X 
Post 0.99 X 
NA Not analysed with MNFl16 antibody 
a Analysed for presence of tumour cells using the MNF116 antibody subsequent to initial dual 
labelling with the BerEP4 antibody 
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5.5 DISCUSSION 
Recent clinical studies have suggested that the use of bisphosphonates in the management of 
patients with cancer-induced bone disease may confer a survival advantage (Berenson J, 1996; 
Diel 11, 1998) raising the possibility that these compounds may have direct anti-tumour effects in 
addition to inhibiting osteoclast-mediated bone resorption. The data presented in Chapters 3 and 
4 support the hypothesis that these compounds have anti-tumour effects on breast cancer cells in 
vitro. The important question is whether these effects are apparent in breast cancer cells present 
at or adjacent to the sites of bone metastasis. 
The first step in addressing this question was to develop a technique that would allow the 
identification of apoptotic breast cancer cells in a mixed cell population present in the bone 
marrow. Analysis by flow cytometry proved to be very useful as it allowed the simultaneous 
fluorescence labelling of samples for the presence of breast cancer cells and apoptotic cells. The 
long and detailed development of the dual fluorescence labelling assay was undertaken in order 
to optimise the detection of apoptotic breast cancer cells in the bone marrow. The tumour cell 
label initially used was the FITC-conjugated BerEP4 antibody. This antibody was raised against 
the human epithelial antigen, present on the surface and in the cytoplasm of epithelial cells, and 
has been shown to be useful in identifying cells of epithelial origin such as breast cancer cells 
(Latza U, 1990). This was combined with the in situ nick translation assay for apoptosis and cells 
positive for both fluorescent labels were identified as apoptotic breast cancer cells. The dual 
labelling method proved to be effective in identifying apoptotic MCF-7 cells loaded in to 
peripheral blood. Interestingly, when paired patient samples were analysed using this assay, no 
antibody-positive cells were identified. The assay did however demonstrate an overall increase in 
apoptosis after bisphosphonate treatment in all the bone marrow cell populations in 4 out of 5 
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patients. The reasons for the lack of detection of antibody positive cells were unclear. It is 
possible that the bone marrow aspirates were t~ken from sites that were not directly related to a 
site of metastasis and therefore no tumour cells were present in the sample. Alternatively, the 
BerEP4 antibody may not have been sensitive enough to identify very low numbers of breast 
cancer cells in the bone marrow. It is also possible that surface antigens may have been lost from 
the breast cancer cells during apoptosis and it was therefore not possible to identify apoptotic 
tumour cells with this antibody. 
To address the potential concerns about the labelling of tumour cells, the BerEP4 antibody was 
substituted in the antibody labelling protocol and the dual fluorescence labelling protocol with the 
FITC-conjugated MNF116 antibody. This antibody has been raised to a panel of cytokeratins (5, 
6, 8, 17, 19) (Moll R, 1982) and has been widely used in the identification of tumours cells of 
epithelial origin. The flow cytometric analysis of peripheral blood spiked with MCF-7 cells 
showed that this antibody was able to detect breast cancer cells in a mixed cell population. The 
assay was able to distinguish tumour cells from other cell populations with a sensitivity of 
approximately 1 %. When patient samples that had been examined with the previous assay were 
re-analysed using the MNF116 antibody, there were clear increases in the proportions of antibody 
positive cells in 2 out of 3 patients. This suggests that the BerEP4 antibody was not as effective at 
detecting tumour cells as the MNF116 antibody and that further samples should be analysed by a 
dual fluorescence labelling assay that incorporated the latter rather than the former antibody. 
The analysis of 9 further paired patient bone marrow samples with the modified dual labelling 
assay demonstrated that, firstly, antibody positive cells were identifiable in 33% of patient 
samples. Although all bone marrow aspirates were taken from the posterior iliac crests, the 
absolute proportions of tumour cells varied greatly between samples and between patients. This 
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observation possibly reflected the fact that the aspirate sites did not necessarily correspond to 
sites of bone lesions apparent on radiographs and may also be related to the varying degrees of 
metastatic tumour burden in the skeleton of individual patients. 
The results from the first five paired patient samples analysed with the dual labelling technique 
demonstrated an overall increase in apoptosis in all cell populations after intravenous 
bisphosphonate treatment in 80% of patients (4/5). Intriguingly, this observation was not 
supported by analysis of subsequent paired samples, which showed little or no change in 
apoptosis between pre-and post-treatment samples. The differences between these two sets of 
samples may be accounted for by the fact that, in the first five patients, bone marrow aspirates 
were taken from the same site both pre- and post-treatment. In subsequent patients, aspirates were 
taken from alternate iliac crests to avoid the influence oflocal trauma-related changes. Therefore, 
it is possible that the initial increases seen in apoptosis in the whole bone marrow cell population 
may have occurred as a result of a response to local trauma caused by the pre-treatment biopsy. 
The comparison of the proportions of apoptotic breast cancer cells in the bone marrow of breast 
cancer patients did not reveal an increase in tumour cell death following bisphosphonate 
treatment. There may be several reasons for this. Firstly, the timing of the post-treatment bone 
marrow aspirate at 72 hours after treatment may mean that any apoptotic breast cancer cells 
present in the bone marrow microenvironment may have already been phagocytosed and 
disposed of by local macrophages. Alternatively, as mentioned previously, the biopsy site may 
not coincide with a metastatic site and therefore sufficient numbers of tumour cells to be detected 
by the assay may not have been sampled. There are methods available to concentrate tumour cells 
into a smaller volume and hence aid detection, such as immunomagnetic techniques (Diel IJ & 
RJ., 2000). These generally involve the use of micro spheres coated with antibodies that recognise 
139 
Chapter 5 Dualfluorescence labeling method/or analysis o/in vivo effects o/bisphosphonates 
tumour cell antigens and bind to them. The tumour cell-microsphere complexes are then 
separated using a magnet. These techniques have been used in purging bone marrow stem cell 
grafts of tumour cells (Franklin W A et al., 1996; Ross AA, 1993) and have also proven effective 
in allowing the sensitive detection and characterisation of carcinoma cells in peripheral blood 
(Racila E, 1998). Other methods of tumour cell detection include immunhistochemistry and 
molecular biological techniques, such as DNA- and RT-PCR. The latter techniques have proven 
to be highly sensitive but can give false positive results due to factors such as contamination and 
detection of specific genes in non-specific cells (Ghossein RA, 1999). Quantitative PCR methods 
may allow for a 'background' level of expression to be identified and therefore may alleviate 
these problems somewhat (Slade MJ, 1999). Immunohistochemistry techniques can also very 
sensitively detect tumour cells using specific antibodies. Again, the problems of cross-reactivity 
and false positives remain. However these techniques have the added advantage of enabling 
morphological characterisation of antibody-positive cells. Indeed, new automated techniques, 
such as the Chromovision ACIS (automated cellular imaging system), are highly sensitive and 
can detect approximately 1 epithelial tumour cell per 1 million mononuclear cells (Osbome MP, 
1991). 
In any case, it is likely that the effects of bisphosphonate treatment on the bone marrow may be 
far more subtle than outright cell death. It is possible that the effects of bisphosphonates such as 
inhibition of breast cancer cell adhesion and invasion (Boissier, 1997; Magnetto S, 1999; Van der 
Pluijm G, 1996; (Boissier S, 2000) may be more prominent than the induction of tumour cell 
apoptosis. In addition, there may be subtle changes induced by bisphosphonates in the bone 
marrow microenvironment that may play a part in inhibiting breast cancer cell growth and 
proliferation. 
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In summary, the dual fluorescence labelling technique described in this chapter is a useful tool 
for the identification of apoptotic breast cancer cells in bone marrow aspirate samples. The 
analysis of bone marrow samples from patients with breast cancer-induced bone disease did not 
demonstrate a clear anti-tumour effect of bisphosphonate treatment in vivo, as sample numbers 
were very small. However, intravenous bisphosphonate therapy may have more subtle effects on 
the bone marrow micro environment and it would be pertinent to study these in vivo changes more 
closely. 
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CHAPTER 6 
THE EFFECTS OF INTRA VENOUS BISPHOSPHONATE 
TREATMENT ON CYTOKINES AND GROWTH FACTORS 
IN PATIENTS WITH BREAST CANCER AND BONE 
METASTASES. 
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6.1 SUMMARY 
The data presented so far in this thesis suggest that bisphosphonates may have direct anti-
tumour actions in vitro and possibly in vivo. However, as potent inhibitors of osteoclast-
mediated bone re sorption, bisphosphonates may also modulate the bone marrow 
microenvironment by inhibiting the release of growth factors from the cells of bone and 
also bone matrix. The aims of the study presented in this chapter were, firstly, to identify 
the differences in growth factor levels between patients with early breast cancer and those 
with bone metastases and, secondly, to investigate the effect of intravenous 
bisphosphonate treatment on cytokines and growth factors present in the local bone 
marrow microenvironment. 
19 patients with breast cancer and bone metastases were recruited to the study along with 
13 patients with primary breast cancer. Samples of serum, urine and bone marrow were 
taken from the advanced group before and three days after intravenous treatment with 
pamidronate (90mg) or zoledronic acid (4mg and 8mg) and from the primary breast 
cancer group on a single occasion. Serum and bone marrow samples were assayed for the 
presence of a panel of cytokines and growth factors that may be produced by the cells of 
bone or present in the bone matrix, including TGF~-l, IGF-1, FGF-2, VEGF, IL-6 and 
soluble IL-6 receptor (sIL-6R). Urine samples were assayed for the marker of bone 
resorption, N-telopeptide (NTX). 
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Samples of bone marrow plasma from patients with advanced breast cancer had 
significantly higher levels of TGF~-l, with higher serum levels of IL-6 and soluble IL-6 
receptor than those from patients with primary breast cancer (p<O.05). In the advanced 
breast cancer group, no changes were seen in IGF-1, IL-6 or TGF~-l levels 3 days after 
bisphosphonate treatment. However, treatment did result in significantly lowered levels 
of serum FGF-2 and bone marrow VEGF (p<O.05). 
There appear to be differences in certain cytokines and growth factors between patients 
with advanced and primary breast cancer. The beneficial effects of bisphosphonates 
experienced by patients with breast cancer and bone metastases may be due to alterations 
in cytokines and growth factors, such as FGF-2 and VEGF that are important in bone. 
144 
Chapter6 The effect of bisphosphonates on bone marrow and serum cytokines. 
6.2 INTRODUCTION 
Bone resorption by osteoclasts is a complex process that is influenced by many factors, 
including cytokines and cellular products, to maintain normal bone homeostasis (Mundy, 
1997, Guise T, 1998). The arrival of metastatic breast cancer cells in the bone appears to 
have profound effects on this process, ultimately resulting in highly accelerated bone 
breakdown. Complex interactions seem to occur between the tumour cells and the bone 
microenvironment. Breast cancer cells are known to express and produce soluble factors, 
such as PTHrP (Ogata, 2000; Powell G, 1991), (Birch MA, 1995; Carron J, 1997) which 
are potent stimulators of osteoclast maturation and activity (Guise T, 1996; Iezzoni J, 
1998). There may also be direct cell-cell interactions between the breast cancer cell and 
the osteoclast which augment bone resorption. A possible candidate for this is the 
RANK-RANKL-OPG system. In any case, the increased rate of bone breakdown in 
metastatic breast cancer may cause the release of bone matrix products, such as TGF-rJ, 
bFGF and IGF's, into the bone microenvironrnent. These factors have been shown in 
experimental studies to influence the growth and proliferation of breast cancer cells or to 
stimulate the production of further soluble mediators that enhance osteoclast activity 
(reviewed by (Guise T, 1998)). In this way, a loop forms between tumour-derived factors 
which stimulate increased osteoclast activity and the accelerated release of cytokines and 
growth factors from the bone matrix which serve to enhance tumour cell proliferation. 
Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption. The work 
presented so far in this thesis demonstrates that these compounds can have direct anti-
tumour effects on breast cancer cells in vitro although it is less clear whether this occurs 
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in vivo. Another potential consequence of bisphosphonate-induced inhibition of bone 
resorption is a reduction in bone-derived growth factors available to tumour cells and 
alterations in the bone marrow microenvironment that may inhibit tumour cell 
proliferation. The aim of the work presented in this chapter is to investigate the effects of 
a single treatment with intravenous bisphosphonate on cytokines and growth factors in 
the bone marrow microenvironment of patients with advanced breast cancer. In addition, 
the differences in these factors between patients with early breast cancer and those with 
advanced breast cancer and bone metastases were investigated. 
6.3 EXPERIMENTAL DESIGN 
6.3.1 Patients 
19 postmenopausal women with breast cancer-induced bone metastases attending the 
Outpatients Department at Weston Park Hospital, Sheffield, UK were recruited for this 
study. There was no significant difference in ages between the two groups. The only 
concurrent treatment allowed was long-term hormone therapy and these patients were 
bisphosphonate-naYve. A group of postmenopausal patients with primary breast cancer 
were recruited from the Department of Surgery, Royal Hallamshire Hospital, Sheffield. 
The characteristics of the patients in the study are shown in Table 6.1. Ethics approval 
was gained from the South Sheffield Ethics Committee and all patients provided written 
informed consent. 
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Mean Age± SD 
Previous 
Chemotherapy 
Previous endocrine 
therapy 
Bisphosphonate 
received: 
Pamidronate 
Zoledronic acid 
Baseline NTX 
(nM/mM of 
creatinine) 
The effect of bisphosphonates on bone marrow and serum cytokines. 
Group 1 
(primary breast cancer) 
n=13 
59.3 ± 13 years 
50.52 + 4.3 
Group 2 
(advanced breast cancer) 
n=19 
51.7 ± 8 years 
2119 (10.5%) 
12119 (63.1%) 
11119 (57.8%) 
8/19 (42.2%) 
164.44 ± 20.3 
Table 6.1 Baseline characteristics of patients entered into the study. 
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6.3.2 Study design 
Samples were taken from patients according to the following study design: 
ADVANCED BREAST CANCER PATIENTS 
I Pre-treatment I 
• Bone marrow 
aspirate (EDT A 
plasma) 
• Serum 
• Urine 
Bisphosphonate 
---t~~ treatment 
(pamidronate 
90mgor 
zoledronic acid 
4 or 8mg) 
PRIMARY BREAST CANCER PATIENTS 
72 Hours Post-
treatment 
• Bone marrow 
---I~~ aspirate (EDT A 
plasma) 
• Serum 
• Urine 
• Bone marrow aspirate (EDTA PlaSma)] 
• Serum On a single occasion 
• Urine 
6.3.3 Sample preparation 
Peripheral blood clotted samples were centrifuged at 2000 x g for 10 minutes, the serum 
collected and frozen at -80°C for later analysis. Bone marrow samples were processed as 
described in section 5.3.5.4. 
6.3.4 Analysis of cytokines/growth factors. 
Bone marrow plasma samples for 5 patients were sent for analysis of PTHrP levels (data 
not shown) and were therefore not available to be assayed for any other growth factors. In 
two further patients, bone marrow sampling yielded a dry aspirate in the pre-treatment 
sample hence a total of 12 patients were analysed for the presence of bone marrow factors 
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listed in table 6.2. Serum and bone marrow plasma samples were analysed by the 
enzyme-linked immunosorbant assay (ELISA) technique for a panel of cytokines and 
growth factors (Table 6.2). Urine was analysed using an automated chemi-Iuminescence 
assay (Vitros ECI analyser), at the Northern General Hospital, Sheffield, UK for the 
presence ofN-telopeptide molecules (NTX) as markers of bone resorption. 
Cytokine/ Assay Kit/ Assay Range Measured in Measured in 
Growth Factor Source (pg/ml) serum bone marrow 
J,!lasma 
TGF-~1 R&D Systems, 7-2000 / 7 Oxon, UK 
IGF-l Immunodiagnostic 10-1000 / / Systems (IDS), 
UK 
bFGF (FGF-2) R&D Systems, 0.2-64 / / Oxon, UK 
VEGF R&D Systems, 5-1000 / Oxon, UK 
IL-6 Amersham 0.1-20 / Pharmacia, UK 
sIL-6R Sigma Chemical 15-2000 / Co, UKa 
sgp130 Diac1one, Cedex, 15-1800 / France 
IFN-y Diac1one, Cedex, 5-400 / France 
Table 6.2 Sources and assay range of ELISA kits used for the analysis of patient serum 
and bone marrow samples. 
a Sandwich ELISA assay developed in house. 
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6.3.5 Statistical analysis 
Statistical analysis was performed using SPSS Version 10.00. As the patient numbers 
were relatively small, the data for each parameter were tested for normality. The data for 
IL-6 and b-FGF were found to be non-parametric. Therefore the differences between the 
primary and advanced breast cancer groups and the pre- and post-treatment levels were 
analysed using the Mann-Whitney-U and the Wilcoxon Matched Pairs tests, respectively. 
The data for all the other parameters were found to be normally distributed. In these 
cases, the differences in cytokine levels between advanced and primary breast cancer 
groups were analysed using the independent samples t-test and differences between pre-
and post-treatment cytokine levels in the advanced breast cancer group were analysed 
using paired samples t-test. 
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6.4 RESULTS 
6.4.1 Differences in serum levels of cytokines and growth factors between patients 
with primary and advanced breast cancer. 
The analysis of serum samples from patients with primary and advanced breast cancer 
revealed differences in levels of certain cytokines and growth factors (Table 6.3). Patients 
with bone metastases had higher levels ofTGFp-l (5.14 ± 0.9 pg/ml), and IGF-l (115.45 
± 12.12 pg/ml) compared with primary breast cancer patients (2.91 ± 0.9 pg/ml and 
110.50 ± 7.4 pg/ml respectively) although these differences did not achieve statistical 
significance. Similarly, in patients with advanced breast cancer, the levels ofb-FGF (7.83 
± 4.27 pg/ml), VEGF (165.63 + 39.81 pg/ml), and sgp-130 (219.70 ± 36.0 J.!g/ml) were 
elevated in comparison to the primary breast cancer group (3.80 ± 2.5 pg/ml, 184.91 + 
35.9 pg/ml, and 186.97 ± 19.5 J.!g/ml) although, again, these differences were not 
statistically significant. Importantly, however, there were significant differences in the 
levels of IL-6 and sIL-6R between the two groups. IL-6 levels were significantly higher 
in the advanced breast cancer group (4.72 ± 1.2 pg/ml) than in patients with primary 
breast cancer (1.31 ± 0.6 pg/ml) (p<0.05). There were also markedly higher levels of sIL-
6R in patients with bone metastases (260.61 ± 24.8 pg/ml) than in those with early breast 
cancer (153.08 ± 16.5 pg/ml) (p<0.005). No interferon gamma (lFN-y) was detected in 
these samples. 
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6.4.2 Differences in bone marrow levels of growth factors between patients with 
primary and advanced breast cancer. 
Patients with bone metastases had significantly higher levels of TGFI3-1 than those with 
primary breast cancer (6.85 ± 0.7 pg/ml and 3.56 ± 0.9 respectively) (p<0.05) (Table 6.3). 
They also had higher levels of IGF-l and b-FGF than the primary breast cancer group 
(82.88 ± 14.55 pg/ml and 126.49 ± 12.5 pg/ml compared with 56.19 ± 6.27 pg/ml and 
110.17 ± 4.4 pg/ml respectively) although these differences were not statistically 
significant. Furthermore, levels of VEGF in the advanced breast cancer group were 
significantly higher than those in patients with primary breast cancer (217.3 ± 10.62 vs. 
175.56 ± 38.4 pg/ml respectively) (p<O.O 1). 
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Group 1 Group 2 
(primary breast cancer) (advanced breast cancer) 
Serum Bone marrow Serum Bone marrow 
plasma plasma 
TGF-pl 2.91 ± 0.9 3.56 ± 0.9 5.14 ± 0.9 6.85 ± 0.7t 
IGF-l 110.50 ± 7.4 56.19 ± 6.27 115.45 ± 12.12 82.88 ± 14.55 
bFGF (FGF-2) 3.80 ± 2.5 110.17 ± 4.4 7.83 ± 4.27 126.49 ± 12.5 
VEGF 184.91 + 35.9 175.56 ± 38.4 165.63 ± 39.81 217.3 + 1O.62tt B 
IL-6 1.31 ± 0.6 X 4.72 ± 1.2* X 
sIL-6R 153.08 ± 16.5 X 260.61 ± 24.8** X 
sgp130 186.97 ± 19.5 X 219.70 ± 36.0 X 
(J.1g/ml) 
IFN-y X X X X 
Table 6.3 Serum and bone marrow cytokine and growth factor levels (pglml) in patients 
with primary (Group 1) and advanced (Group 2) breast cancer. 
* p<0.05 when group 1 compared with group 2 (serum) 
** p<0.005 when group 1 compared with group 2 (serum) 
t p<0.05 when group 1 compared with group 2 (bone marrow) 
tt p<0.005 when group 1 compared with group 2 (bone marrow) 
Bn=4 
X Not detected 
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6.4.3 Effect of intravenous bisphosphonate treatment on serum levels of cytokines 
and growth factors in patients with advanced breast cancer. 
Serum samples taken before and three days after intravenous bisphosphonate treatment 
were analysed for the presence of cytokines and growth factors (figure 6.1). 
Bisphosphonate treatment resulted in significantly lower levels of b-FGF in post-
treatment samples compared with pre- treatment (42.82 ± 14.4% of baseline) (p<0.05). 
Mean post-treatment serum levels of b-FGF were lower than those in the primary breast 
cancer group (1.59 + 0.3 vs. 3.8 + 2.5 pg/ml respectively). VEGF levels were also lower 
in post-treatment samples (95.04 ± 19.2 % of baseline), although not significantly. 
Levels oflGF-l and TGF13-1 appeared to increase with bisphosphonate treatment (114.74 
± 13.7 and 205.60 ± 80.57 % of baseline respectively) although statistical significance 
was not achieved. Bisphosphonate treatment did not result in significant changes in serum 
levels of IL-6 and sIL-6R, (116.45 ± 65.3% of baseline and 94.51 ± 6.0 % baseline 
respectively). In contrast, sgp-130 levels showed a tendency to increase after treatment 
(480.85 ± 344.17 % of baseline). 
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Figure 6.1 Levels of a panel of cytokines and growth factors in serum of patients with 
advanced breast cancer and bone metastases. Samples were taken before and three days after 
intravenous treatment with either pamidronate (90mg) or zoledronic acid (4mg or 8mg) and 
analysed using the ELISA technique. Results are expressed as percent of baseline (pre-
treatment level) for each parameter and are shown as the mean ± SEM. * p<O.05 
The values for b-FGF detected in the serum of individual patients are shown in figure 6.2 
below. 
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Figure 6.2 Serum levels of b-FGF (FGF-2) in individual patients 1-18 with breast cancer 
bone metastases before and 3 days after treatment with either pamidronate (90mg) or 
zoledronic acid (4mg or 8mg). Samples were analysed using the ELISA technique. 
Results are expressed as pg/ml ofb-FGF pre- and post-treatment. 
6.4.4 Changes in growth factor levels in bone marrow plasma from patients 
receiving intravenous bisphosphonate treatment. 
Samples of bone marrow plasma were taken from patients with advanced breast cancer 
before and three days after intravenous bisphosphonate treatment and analysed for the 
presence of growth factors (figure 6.3). Levels ofTGF-pl and IGF-l showed a tendency 
to increase after therapy with bisphosphonates (136.41 ± 43.4% and 114.73 + 14.8 % of 
baseline respectively). In contrast, b-FGF appeared to decrease following treatment with 
-
bisphosphonates (84.98 + 14.7 % of baseline) as did VEGF (71.77 + 23.2 % of baseline, 
(n=4, p<O.05). 
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Figure 6.3 Levels of a panel of cytokines and growth factors in bone marrow plasma of 
patients with advanced breast cancer and bone metastases. Samples were taken before and 
three days after intravenous treatment with either pamidronate (90mg) or zoledronic acid (4mg 
or 8mg) and analysed using the ELlSA technique. Results are expressed as percent of baseline 
(pre-treatment level) for each parameter and are shown as the mean ± SEM. 
* p<O.05 
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The values for VEGF detected in the bone marrow of individual patients (n=4) are shown 
in figure 6.4 below. 
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Figure 6.4 Bone marrow plasma levels of VEGF in individual patients 6, 10, 11 and 12 
with breast cancer bone metastases before and 3 days after treatment with either 
pamidronate (90mg) or zoledronic acid (4mg or 8mg). Samples were analysed using the 
ELlSA technique. Results are expressed as pg/ml ofVEGF pre- and post-treatment. 
6.4.5 Differences in clinical picture between patients with detectable tumour cells 
and those without. 
The work outlined in chapter 5 demonstrated that tumour cells were detectable in 33% of 
patients. The presence of breast cancer cells in the bone marrow as detected by the dual 
labelling method described in Chapter 5 appeared to relate to the clinical picture (Table 
6.5). 100% of patients in whom tumour cells were detectable experienced bone pain on 
presentation compared with 77.7% of patients (7/9) without detectable tumour cells. 
Approximately equal proportions of patients in each group experienced a symptomatic 
response to bisphosphonate treatment (60% vs 55.5%). Interestingly, a higher proportion 
158 
Chapter6 The effect of bisphosphonates on bone marrow and serum cytokines. 
of patients with detectable breast ca~cer cells experienced skeletal related events (40%) 
compared with those in whom breast cancer cells were not detected (22.2%). 
Breast cancer cells 
detected 
Yes (n=5) 
No (n=9) 
Bone pain at 
presentation 
100% 
77.7% 
Symptomatic 
response 
60% 
55.5% 
Skeletal related 
events 
40% 
22.2% 
Table 6.5 Relationship between the presence of breast cancer cells detectable by the dual 
labelling assay and clinical features. 
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6.5 DISCUSSION 
The present study set out to identify firstly whether there were differences in serum and 
bone marrow cytokines and growth factors between patients with breast cancer induced 
bone metastases and those with early breast cancer but no evidence of spread. Secondly, 
we investigated the effects of intravenous treatment with either pamidronate or zoledronic 
acid on cytokines and growth factors in the bone marrow microenvironment. 
There was no significant difference in age between patients with primary breast cancer 
and those with advanced breast cancer and bone metastases. Predictably, patients with 
bone metastases had much higher concentrations of urinary N-telopeptide than those with 
early breast cancer, indicating accelerated bone resorption due to the presence of bone 
secondaries. Of the advanced breast cancer group, 73.6% had received previous treatment 
for their breast cancer either in the form of chemotherapy or endocrine therapy. In this 
group, 57.8% received intravenous pamidronate (90mg) and 42.2% received zoledronic 
acid (4mg or 8mg). There was no significant difference in cytokine response between 
patients that had received pamidronate and those that had received zoledronic acid 
therefore the data from these two groups were pooled. 
The study demonstrated that all of the bone-derived factors were increased in the bone 
marrow plasma in patients with advanced breast cancer and bone metastases although the 
differences were only significant in the cases ofTGF13-1 and VEGF. TGF13-1, produced 
predominately by ~steoblasts, (Bonewald LF & GR, 1990) is present in abundance in the 
bone matrix and is released on osteoclast-mediated bone resorption (Hauschka P, 1986; 
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Pfeilschifter J, 1987). Recent studies suggest that tumour cells themselves may secrete 
TGFp (Pederson L, 1999) and this growth factor, along with related peptides, has been 
shown to influence a range of cellular processes including proliferation, differentiation, 
motility and death (reviewed by Massague) (Mass ague, 1998). Although there is evidence 
to suggest that TGFp-l inhibits growth of mammary carcinoma cells (Pierce DF, 1995; 
(Sun L, 1994) it has been postulated that TGFp may also stimulate breast cancer cell 
growth (Arteaga CL, 1996)and may even induce a more metastastic phenotype 
(Diudenvoorden W, 1999; Farina A, 1998; Yin J, 1999). Furthermore, in metastatic bone 
disease, the release of TGFp into the bone micro environment by the accelerated activity 
of osteoclasts may further enhance the evolution of the metastasis by promoting the 
production ofPTHrP by the carcinoma cells (Guise T, 1996; Guise T, 1993; Yin J, 1999). 
This in turn potently stimulates osteoclast maturation and activity (Guise T, 1996; Iezzoni 
J, 1998) and bone destruction is further enhanced. The findings from our study that bone 
marrow levels of TGFp are significantly elevated in patients with bone metastases, when 
compared to those without, supports the hypothesis that accelerated bone resorption 
influenced by breast cancer cells results in the release of bone matrix products into the 
microenvironment to perpetuate this cycle. Alternatively, TGFp may be produced by the 
tumour cells themselves in the bone microenvironment. 
Patients in this study with advanced breast cancer and bone metastases were found to 
have significantly higher serum levels of IL-6 and sIL-6R than those with early breast 
cancer. This supports previous observations of elevated serum levels of IL-6 and sIL-6R 
(Jablonska, 1998)in breast cancer patients compared with normal controls and the 
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correlation with more aggressive disease (Haverty A, 1997; Jiang X, 2000; Y okoe T, 
1997). IL-6 has been shown to be secreted by mammary carcinoma cells (Chiu J, 1996; 
Pederson L, 1999) as well as other tumour types, particularly multiple myeloma 
(reviewed by Guise and Mundy (Guise T, 1998) and Klein et al (Klein B, 1995) and 
normal bone marrow stromal cells (Boyce B, 1999; Mohan S, 1991). In multiple 
myeloma, this cytokine acts as important growth regulator in its ability to support 
myeloma cell proliferation (Kawano M, 1988) and indeed the stage of advancement of 
the disease has been shown to correlate with patient serum and bone marrow IL-6 
concentrations (Bataille R et al., 1992; Bataille R, 1989). In contrast, IL-6 has been 
shown to result in growth inhibition in mammary carcinoma cells (Novick D, 1992) and it 
has also been suggested that this cytokine may regulate the growth of normal and 
transformed human mammary epithelial cells differentially (Chiu J, 1996; Lai L, 1994). 
Interestingly, IL-6 has been implicated in the stimulation of osteoclast precursors, 
possibly through the activity of other factors such as PTHrP, which in turn would 
accelerate bone resorption (de la Mata J, 1995). The soluble form of the 11-6 receptor 
(sIL-6R) binds IL-6 and the complex interacts with the membrane-bound receptor, gp130, 
to stimulate signalling and enhance IL-6 effects. Bisphosphonate treatment did not 
significantly alter serum concentrations of either IL-6 or sIL-6R, suggesting that 
inhibition of bone resorption, or direct bisphosphonate action, did not affect release of 
these cytokines from cells such as monocytes, macrophages and granulocytes. 
Intriguingly, we demonstrated that serum concentrations of b-FGF were significantly 
reduced from baseline after bisphosphonate treatment. Serum VEGF levels showed a 
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similar change with treatment. Likewise, concentrations of VEGF and b-FGF in bone 
marrow plasma showed similar trends with a reduction after treatment with intravenous 
bisphosphonate. Both of these factors have been implicated in tumour dissemination and 
angiogenesis and VEGF is constitutively produced by many tumours, including breast 
cancer cells as well as osteoblasts (reviewed by Van Der Pluijm) (Van Der Pluijm G, 
2000). FGF-2 (b-FGF) is produced by osteoblastic cells, stored in the bone matrix, and 
released on bone resorption therefore the inhibition of bone resorption with 
bisphosphonate treatment may well result in a reduction in serum and bone marrow 
levels. In addition, there is evidence to suggest that b-FGF may dose-dependently induce 
the expression of VEGF by osteoblasts indicating that the activity of the two factors may 
be closely linked (Saadeh P, 2000). Also, the potent bisphosphonate zoledronic acid has 
been shown to inhibit endothelial cell proliferation in vitro and b-FGF-induced 
angiogenesis in vivo (Wood J, 2002), suggesting this as an alternative mechanism for the 
beneficial effects ofbisphosphonates in patients with solid tumour bone metastases. 
Overall, the data presented here suggests that there are differences in the bone marrow 
microenvironment between patients with early breast cancer and those with advanced 
breast cancer and bone metastases that relate to accelerated bone resorption stimulated by 
breast cancer cells. In patients with bone metastases, intravenous bisphosphonate 
treatment may modulate factors that are important in tumour cell migration and 
angiogenesis. These observations are made at a single point in time, 3 days after 
bisphosphonate treatment and further important information about the effects of these 
compounds on the bone microenvironment may be gained by repeating these studies at 
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later time points. However, these data may provide some insight into the mechanism via 
which bisphosphonates may exert effects in breast cancer-induced metastatic bone 
disease. 
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Bisphosphonates have become important agents in the management of bone metastases in 
breast cancer. The clear clinical benefits on skeletal morbidity have been highlighted by 
several studies and their use has become well established for breast cancer-induced 
metastatic bone disease as well as in multiple myeloma (Berenson JR et al., 1998; Diel IJ 
et al., 1998; Hortobagyi GN et al., 1996; McCloskey et al., 1998; Paterson AHG et al., 
1993; Theriault RL et al., 1999). Breast cancer cells are found in close proximity to sites 
of active bone resorption and may well be exposed to high concentrations of 
bisphosphonates. The inhibition of bone resorption by these compounds may result in 
indirect effects on breast cancer cells due to reduced release of growth factors into the 
bone microenvironment. However, the observation that bisphosphonate treatment may 
also confer a survival benefit in breast cancer patients, (Diel IJ et a!., 1998) as well as 
influencing skeletal events, raises the intriguing possibility that these compounds may 
have direct anti-tumour effects. This is further hinted at in studies using animal models of 
breast cancer in which apoptosis of mammary carcinoma cells occurs after administration 
of bisphosphonate treatment. The aim of this PhD was to determine whether 
bisphosphonates have direct anti-tumour effects on breast cancer cells. 
The initial aim of the work presented here was to determine whether zoledronic acid had 
anti-tumour effects on breast cancer cells in vitro. We demonstrated that treatment with 
zoledronic acid resulted in a time-dependent and concentration dependent reduction in 
cell number and induction of apoptosis in two mammary carcinoma cell lines (Chapter 3). 
These observations are supported by recent reports showing similar effects of nitrogen-
containing bisphosphonates on breast cancer cell proliferation and apoptosis (Fromigue 
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0, 2000; Hiraga T, 2001; Senaratne SG, 2000) as well as on multiple myeloma cells 
(Aparicio A et al., 1998; Shipman CM et al., 1997). Our studies showed that the effects 
on cell number and apoptosis were as marked after short term exposure (2-24 hours) to 
zoledronic acid as after longer term exposure up to 72 hours (Chapter 3). This is an 
important observation in view of the fact that bisphosphonates have a very high affinity 
for mineralised bone and localise to bone rapidly, thus in a clinical setting it is likely that 
primary breast cancer cells or those in visceral metastases may be exposed to these 
compounds for shorter periods. Indeed, peak serum concentrations are likely to be in the 
range of 1-31lM and maintained for only a few hours (Berenson JR et al., 2000). This is 
consistent with observations from a study in J774 macrophages which demonstrated a 
time-dependant increase in caspase-3-like enzyme activity, associated with apoptosis, 
when acutely exposed to nitrogen-containing bisphosphonates (Coxon FP et al., 1998) 
The mechanism of action of nitrogen-containing bisphosphonates has only recently been 
elucidated. Studies have shown that these compounds, in contrast to c1odronate, induce 
apoptosis by inhibiting enzymes of the mevalonate pathway in cells such as macrophages, 
(Luckman SP et al., 1998) osteoclasts (Fisher JE, 1999) and multiple myeloma cells 
(Shipman CM et al., 1998) and hence prevent protein prenylation. The exact target of 
amino-bisphosphonates has recently been identified as the enzyme, farnesyl 
pyrophosphate synthase (Van Beek E, 1999a). A further aim of the studies presented in 
Chapter 3 was to determine whether zoledronic acid acted on the same molecular target 
in breast cancer cells. We demonstrated that breast cancer cells could be rescued from 
zoledronic acid-induced apoptosis by the addition of GGOH, a precursor of GGPP, which 
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is an intermediate of the mevalonate pathway. This indicated that zoledronic acid did 
indeed interfere with this pathway in breast cancer cells. In contrast to observations in 
macrophages (Luckman SP et a!., 1998) and multiple myeloma cells, (Shipman CM et 
a!., 1998) the addition of FOH (a precursor of FPP) did not significantly rescue breast 
cancer cells from zoledronic acid-induced apoptosis. This may indicate that, in this 
particular cell type, farnesylated proteins may play a less important part in cellular 
function than geranyl geranylated proteins. Indeed, similar observations have been made 
in osteoclasts, where geranyl geranylated proteins such as Rac and Rho may be essential 
for functions such as maintenance of the cytoskeleton and integrity of the ruffled border 
(Fisher JE, 1999). 
Bisphosphonates are often used in combination with chemotherapy and endocrine 
treatment in everyday clinical practice. There are data suggesting that bisphosphonates 
may act synergistically with anti-neoplastic agents to affect tumour cells and survival, 
both in animal models (Yoneda T, 1999) and in clinical studies (Berenson JR et a!., 1998; 
Diel U et a!., 1998). The aim of the work presented in Chapter 4 was to investigate 
whether zoledronic acid and paclitaxel, a spindle toxin, had synergistic effects on breast 
cancer cells when combined. Our studies demonstrated that paclitaxel and zoledronic acid 
acted synergistically on breast cancer cells to induce apoptosis (Chapter 4). Previous 
studies have shown that bisphosphonates and taxanes have synergistic effects on breast 
cancer cells in other ways. Magnetto et al found that the combination of ibandronate with 
taxotere or taxol caused loss of breast cancer cell adhesion and invasion in an additive 
-
fashion (Magnetto S et a!., 1999). Interestingly, no additive effect was seen on apoptosis 
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at the low concentrations of bisphosphonates used in these studies. In contrast, studies by 
Yoneda et al in animal models of breast cancer have shown a greater reduction in both 
bony and visceral metastases when ibandronate was combined with a chemotherapy agent 
(Tegafur, an oral prodrug of 5-fluorouracil) than with either drug alone (Yoneda T, 
1999). 
The next aim of this PhD was to determine whether the anti-tumour effects observed in 
vitro could be translated to the in vivo patient setting. The first step in doing this was to 
develop an assay that could simultaneously detect breast cancer cells and measure 
apoptosis in these cells. This could then be used to identify the proportions of apoptotic 
cells in samples of bone marrow taken before and after intravenous bisphosphonate 
treatment from patient with breast cancer-induced bone metastases. We developed a flow 
cytometry-based assay, the dual fluorescence labelling assay, which combined the 
MNF116 antibody as a tumour cell label with the in situ nick translation assay to detect 
apoptosis (Chapter 5). Bone marrow samples taken before and three days after treatment 
with intravenous pamidronate or zoledronic acid were analysed using this technique. The 
assay positively identified breast cancer cells in 33% of patient samples. Interestingly, the 
patients in whom tumour cells were detected also appeared to have more clinically 
advanced disease and less alteration in serum and bone marrow cytokines and growth 
factors with bisphosphonate treatment. Unfortunately, the numbers of patients in whom 
breast cancer cells were detected in both pre- and post-treatment samples were too small 
to draw any conclusions about the effect of bisphosphonate treatment on in vivo tumour 
cell apoptosis. Similar studies in multiple myeloma patients have an increase in the 
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proportions of apoptotic myeloma cells in the bone marrow after intravenous pamidronate 
treatment (Gordon S, 2002). In contrast to haematological malignancies such as multiple 
myeloma, the proportions of breast cancer cells may in bone marrow samples may be 
very small unless a metastasis is directly sampled. The yield of positive tumour cells may 
be improved in several ways. One possibility would be to sample sites that are known 
radiographically to contain metastatic lesions. However, this approach raises ethical 
issues as these sites are often where the patient may experience pain. From a technical 
point of view, the method may be improved by using magnetic bead separation or similar 
techniques to isolate and concentrate breast cancer cells before labelling them. This has 
been used to good effect in previous studies looking at circulating or bone marrow solid 
tumour cells (Racila E, 1998). Other methods to allow detection of tumour cells include 
immunohistochemistry and PCR. 
Bisphosphonates have been shown unequivocally to inhibit osteoclast-mediated bone 
resorption. In so doing, they may inhibit the release of important factors from the bone 
matrix and even influence the production of tumour derived factors. The final aim of this 
PhD was to determine the effect of intravenous bisphosphonate treatment on the bone 
microenvironment and circulating growth factors and cytokines in vivo. We found that 
there were significant differences between patients with primary breast cancer and those 
with bone metastases (Chapter 6). Samples from patients with bone metastases had higher 
levels of IL-6 and sIL-6R. This may reflect tumour cell burden and activity (Jablonska, 
1998; Jiang X, 2000). In addition, patients with advanced disease had significantly higher 
concentrations of TGFp-l, which may be an indication of accelerated release of this 
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factor as a result of bone breakdown. Interestingly, VEGF levels in the bone marrow 
plasma of patients with bone disease were significantly higher than in patients with 
primary breast cancer. Clinical studies have reported elevated serum concentrations in 
both primary breast cancer patients and those with metastatic disease. The increase in 
IGF-l, b-FGF and VEGF may reflect bone-derived factor production. 
This clinical study also demonstrated that bisphosphonates appear to have selective 
effects on bone marrow and circulating factors (Chapter 6). We demonstrated that 
bisphosphonates result in a significant reduction in circulating bFGF and bone marrow 
VEGF levels (Chapter 6). Intriguingly, there has been recent evidence to suggest that 
aminobisphosphonates are potent inhibitors of angiogenesis both in vivo and in vitro 
(Wood J, 2002). It is possible therefore that these compounds may have a selective effect 
on the release of these factors in to the bone marrow microenvironment. 
The observations that bisphosphonate treatment results in a reduction in tumour burden in 
animal models (Hiraga T, 1998) and a possible survival benefit in patients with breast 
cancer (Diel IJ et al., 1998) raise the possibility that bisphosphonates have direct anti-
tumour effects in breast cancer. The work presented in this thesis demonstrates that 
zoledronic acid does have anti-tumour effects on breast cancer cells in vitro, an effect that 
is mediated via the same molecular target as in macrophages, osteoclasts and multiple 
myeloma cells. There are also synergistic anti-tumour effects when zoledronic acid is 
combined with pacIitaxel. The technique described in Chapter 5 is currently being used to 
evaluate the induction of tumour cell apoptosis in patient bone marrow samples before 
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and after intravenous bisphosphonate treatment. These continuing studies may provide 
valuable insight into whether bisphosphonates have direct anti-tumour effects on breast 
cancer cells in vivo. 
The observations of direct anti-tumour effects in vitro and possibly in vivo have clear 
implications for the clinical use of bisphosphonates, particularly aminobisphosphonates. 
At the moment these compounds are being used mainly in the palliative setting in breast 
cancer but they may also be of benefit in the adjuvant setting, particularly if a survival 
benefit can be confirmed. The studies conducted to date using adjuvant clodronate in 
patients with primary breast cancer and high risk of recurrence show conflicting results in 
terms of the clinical benefits (Diel IJ et al., 1998; Paterson AHG et al., 1993; Saarto T et 
al., 2001, Powles T et al 2002). Larger scale trials are needed to confirm the role of 
bisphosphonates in the adjuvant treatment of patients with primary breast cancer and are 
currently being planned. 
The benefits of bisphosphonate treatment observed in patients with metastatic bone 
disease may be due to the indirect effects on the bone microenvironment demonstrated in 
Chapter 6, as well as the inhibition of osteoclast-mediated bone destruction. These 
indirect effects are likely to make a significant contribution to the overall efficacy of 
bisphosphonate treatment and may even be more influential in halting bone disease 
progression than any direct anti-tumour effects. It is anticipated that the ongoing clinical 
studies in patients with breast cancer-associated bone metastases will provide valuable 
insight into the action and future use ofbisphosphonates in this disease. 
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APPENDIX 1 
Mathematical model used to determine synergy between paclitaxel and zoledronic acid. 
E(e) 
Emax 
Cp 
Cz 
EC50p 
EC50z 
a. 
y 
Effect at any given concentration of paclitaxel or zoledronic acid 
Maximum achievable effect 
Concentration of pacIitaxel 
Concentration ofzoledronic acid 
Concentration of paclitaxel that produces 50% of E max 
Concentration of zoledronic acid that produces 50% of E max 
Interaction term 
Sigmoidicity function 
The above model was used for analysis of synergy using the GraFit Version 3.00 software 
(Erithacus Software Ltd, Surrey, UK). This software allows 3-dimensional analysis so that the 
data for the zoledronic acid and paclitaxel effects can be analysed simultaneously according to 
the equation given above. This general model for non-additivity assumed an interaction term a.. If 
0.=0 then the effect of the combining the two drugs could be considered additive only. In contrast, 
negative values indicated antagonism and positive values demonstrated synergy. The 
sigmoidicity function y indicates the shape ofthe curve. 
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